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Abstract 
 
Colorectal cancer (CRC) is one of the most common cancers in Europe and the fourth 
most common in the UK, being influenced by environmental factors, genetic mutations and 
interactions with the host immune system. The Wnt pathway plays a key role in maintaining 
intestinal homeostasis. Constitutive activation of Wnt occur in more than 80% of CRC, 
primarily due to the loss of the Apc gene. This mutation occurs in the intestinal stem cells 
(ISC), the cell of origin for CRC. ISCs are identified by Lgr5 expression. The immune 
microenvironment of these tumours plays a key role in their progression. The local recruitment 
of immunosuppressive Foxp3+ regulatory T-cells (Tregs) has been demonstrated in CRC 
patients, however it is unclear whether they limit or promote the anti-tumour immune 
responses. Importantly most of the studies were done in patients with advanced disease, 
highlighting the need to understand the role of these cells in the early stages of 
tumourigenesis. 
To understand the influence of Tregs on an ISC following an oncogenic mutation, 
genetically modified mice were used. Using the Lgr5 transgene, to conditionally delete Apc in 
the intestinal stem cell (ISC), it is possible to model the initial stages of CRC. This mouse was 
crossed with the Foxp3DTR mouse, which expresses the human diphtheria toxin receptor under 
the control of the Foxp3 promotor (Lgr5CreERT2Apcfl/flFoxp3DTR). Selective depletion of Tregs 
can be achieved by injection of diphtheria toxin, enabling the investigation of the role that 
Tregs and conventional T-cells play during malignant transformation. To identify the role of 
other immune cell populations in the anti-tumoral immune response, CD4+ and CD8+ cells 
were depleted and IFNγ was neutralized in the Lgr5CreERT2Apcfl/flFoxp3DTR mouse model. 
 Here, it was shown that 15 days following Apc deletion, the number of Tregs increased 
in the small and large intestines, spleen and mesenteric lymph nodes (MLN). Treg depletion, 
in Apc deleted mice, resulted in a reduction of the intestinal tumour burden. The same was 
observed in mice where CD4+ and CD8+ cells were depleted. IFNγ neutralization had no 
effects. 
In this mouse model, data suggest that CD4+, CD8+ cells or IFNγ do not play a role in 
the anti-tumour immune responses. Overall these data indicate that Tregs inhibit the immune 
recognition of newly transformed ISCs suggesting that Tregs play a key role in the early stages 
of intestinal cancer by promoting tumourigenesis. This is particularly important as Tregs can 
be a possible target in the early stages of CRC and their modulation might prevent tumour 
progression, improving the outcome of CRC patients. 
 
1 
 
1 General Introduction 
 
1.1 Cancer 
 
Cancer is responsible for about 8.2 million deaths worldwide and is the leading cause 
of human mortality (Cancer Research UK). There are various factors implicated in the 
development of cancer, such as genetic mutations and environmental factors (e.g. poor diet, 
smoking, exposure to sunlight, obesity and others) (Whiteman and Wilson 2016). 
 
 
1.2 Colorectal Cancer 
 
Colorectal cancer (CRC) is the second most common cancer diagnosed in Europe and 
the fourth most common cancer in the UK accounting for 12% of all new cancer cases (Cancer 
Research UK). Since the early 1970s the mortality rates of CRC have decreased by 44% in 
the UK, however the five-year survival rate of people diagnosed with CRC remains at 59% 
(Cancer Research UK). 
The risk of developing CRC depends on several factors such as environmental (e.g. diet 
and microbiome), epigenetic, familiar history of CRC, inflammatory bowel disease (IBD) are 
also involved in the high incidence of CRC (Brenner et al. 2014).   More than 90% of the CRC 
are adenocarcinomas that arise from adenomatous polyps, also known as adenomas (Giuliani 
et al. 2006). To understand the oncogenic process in the intestine it is needed to understand 
the basic biology that will be described in the next sections.  
 
 
1.2.1 Intestinal anatomy and function 
 
The intestine is part of the digestive system, where the food passes through and the 
nutrients are absorbed. It is formed by the small and the large intestines, approximately 7.5 
metres long in humans (Drake et al. 2005) and 49 cm in mice (Fox et al. 2006). 
The small intestine is divided into three parts: the duodenum, the jejunum and the 
ileum. The luminal surface of the small intestinal is formed by a single layer of epithelial cells. 
These cells are polarised and organized into finger-like projections called villi, responsible for 
increasing the surface area to optimize the absorption, and invaginations called the crypts of 
Lieberkühn, generally known as crypts. Beneath the villi and the crypts lies the lamina propria 
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which is composed of mesenchymal stromal fibroblasts which encase the blood supply of the 
small intestine. Underneath the epithelial and stromal compartment  is located the smooth 
muscle layer which is responsible for the peristaltic movements of the food through the 
intestine (figure 1.1) (Williams et al. 1989). 
 The large intestine is divided into caecum, colon, rectum and anal canal. Most of the 
water that is ingested is absorbed in the large intestine. It is also where the faecal material is 
stored before it is egested (Williams et al. 1989). The large intestine is formed by a single layer 
of epithelial columnar cells, however only the crypts are present. Similar to the small intestine 
it also contains lamina propria, stromal fibroblasts and the sub and muscularis mucosae (figure 
1.1). The majority of the cells that form the large intestine are mucus secreting cells (Barker 
et al. 2008). 
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The small intestine is formed by villi and crypts. Bellow the crypts there are the mucosae and the smooth 
muscle layer. The large intestine is formed by a single epithelial layer, forming the crypts and, bellow 
them, there are the mucosae layer. Scale bars represent 50 µm. 
  
Figure 1.1 Histology of the murine small and large intestines.  
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1.2.2 Intestinal Epithelial Homeostasis  
 
The small intestinal epithelium is a highly dynamic and regulated tissue with 6-9 crypts 
feeding cells into each villus. The stem cells, which are located in bottom of the crypts, 
continuously proliferate, migrate and differentiate. The intestinal epithelium is renewed every 
5-6 days in humans and every 2-3 days in mice (Creamer 1967; Wright and Alison 1984) and 
there is a constant balance between proliferation and differentiation. There is a tight control of 
the genes that participate in these processes and this is done through various signalling 
pathways, such as Notch (Noah and Shroyer 2013; Kadur Lakshminarasimha Murthy et al. 
2018), TGF-β/BMP (Beck et al. 2003; Ihara et al. 2017), Hedgehog (Buller et al. 2012) and 
Wnt (Fevr et al. 2007; Krausova and Korinek 2014; Koch 2017). The Wnt signalling pathway 
will be discussed in more detail due to its relevance in this project. 
The intestinal stem cells are generally known as Crypt Base Columnar cells (CBC). 
CBC cells, can be identified by the expression of markers such as the leucine-rich repeat-
containing G-protein coupled receptor (Lgr5), olfactomedin 4 (Olfm4), achaete-scute family 
bHLH transcription factor 2 (Ascl2) and SRY-box 9 (Sox9) (figure 1.2). Due to the relevance 
in this project the Lgr5 marker will be discussed in more detail. CBC cells proliferate and 
originate the cell progenitors, the transit amplifying (TA) cells that divide 4-5 times while they 
migrate along the crypt. Depending on the specific signals that are received, TA differentiate 
into the 4 different cell types that are found in the intestine, namely the enterocytes, goblet 
cells, enteroendocrine cells and Paneth cells (Gerbe et al. 2011). This process of migration 
and differentiation is controlled by conserved signalling pathways such as Wnt and Notch 
signalling pathways (Gregorieff et al. 2005), as well as Eph/ephrin signalling (Poliakov et al. 
2004). 
Most of the differentiated cells located in the villi are enterocytes. These cells are 
responsible for the absorption of the nutrients as well as secretion of hydrolytic enzymes that 
participate in the digestion of the food. The enterocytes are tightly pack together by cell-to-cell 
adhesions and form the barrier that prevents the movement of the microbes to the bloodstream 
avoiding, in this way, immune reactions against them (Barker 2014).  
To assist the transit of luminal contents mucus is produced from the goblet cells, which 
produced a variety of mucin proteins. These mucins are responsible for the lubrication of the 
epithelium, protecting it from the mechanical stress caused by the food movement. In addition 
to mucins they produce trefoil proteins involved in tissue repair (Barker 2014). These cells are 
mainly located at the crypt-villus junction, particularly towards the distal end of the small 
intestine. Goblet cells are present in a higher frequency in the colon when compared to the 
small intestine (Mowat and Agace 2014) 
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Enteroendocrine cells, found throughout the crypt-villus axis, are present in a much 
lower number when compared to the other differentiated cell types. These cells secrete 
hormones, such as serotonin and secretin that control some of the intestinal functions 
including the regulation of glucose levels, modulation of food intake, gastrointestinal tract 
movement as well as mucosal immunity and repair (Schonhoff et al. 2004; Engelstoft et al. 
2008; Moran et al. 2008).  
Paneth cells, located exclusively in the bottom of the crypts (Barker et al. 2008), are 
long-lived (6-8 weeks) secretory cells that arise directly from the quiescent intestinal cells 
(Buczacki et al. 2013). In contrast to the other differentiated cells, Paneth cells migrate back 
down the crypt-villus axis, forming the intestinal stem cells (ISC) niche (Batlle et al. 2002). 
Paneth cells promote the immunity and protection of the ISC by secreting various 
antimicrobials such as cryptdins, lysozymes and other factors including TGF-α and Wnt3, 
being crucial in the intestinal homeostasis (Bevins and Salzman 2011). 
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A) The stem cells are located in the bottom of the crypts. These cells proliferate and originate the 
progenitor cells that will then migrate along the villi and differentiate into either absorptive or secretory 
cells depending on the signals that they receive. B) The cell populations present in the intestinal 
epithelia can be identified by the expression of different markers. The Wnt signalling pathway has a 
very important role in the control of the intestinal homeostasis, being particularly active in the bottom of 
the crypts (Carulli et al. 2014).
Figure 1.2 Organization of the intestinal epithelia and the markers for the different cell populations. 
A 
B 
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1.2.2.1 Intestinal Stem Cell Competition 
 
Intestinal stem cells (ISCs), located at the bottom of the crypts, are able to differentiate 
into all cell types within the intestine (Barker et al. 2007; Barker et al. 2008) during homeostasis 
or injury. This a highly regulated mechanism that is coordinated with cell death that occur in 
the villi, avoiding excessive loss of intestinal cells or, the opposite, abnormal accumulation of 
cells.  
Stem cells can divide in three different ways. Under normal circumstances the cells 
divide asymmetrically which results in the formation of a daughter stem cell and a daughter 
TA cell, allowing self-renewal of the stem cell compartment as well as expansion of the TA 
compartment (Figure 1.3) (Potten and Loeffler 1990). Following injury, stem cells undergo 
symmetrical division originating either two daughter stem cells or two daughter TA cells, which 
contributes to the maintenance of intestinal homeostasis. On the other hand, in the absence 
of sufficient numbers of stem cells, TA cells are also able to de-differentiate back to true-stem 
cells, maintaining the intestinal homeostasis (Figure 1.3) (Shahriyari and Komarova 2013; 
Barker 2014).  
During the differentiation process, cells move out of the crypt onto the villi, where they 
are shed. Contrary to the other differentiated lineages, Paneth cells move down to the crypt, 
where they assume position between the stem cells and form part of the stem cell niche (Sato 
et al. 2011). Buczacki and colleagues have demonstrated that in the mouse intestine, 
quiescent label retaining cells, the population that mature into enteroendocrine and Paneth 
cells during homeostasis can, in fact, upon injury, undergo rapid proliferation originating the 
main epithelial cell types. This research shows that established quiescent cells can function 
as a clonogenic reserve (Buczacki et al. 2013)  
The ISC clones compete to occupy the stem cell niche, resulting in the ongoing 
monoclonal conversion in all crypts and leading to the elimination of mutant cells (Lopez-
Garcia et al. 2010; Snippert et al. 2010; Ritsma et al. 2014). Snippert and colleagues 
generated a multi-colour Cre reporter and performed fate mapping of individual stem cells. 
The authors showed that Lgr5hi cells divide symmetrically giving rise to either two stem cells 
or two TA cells supporting the hypothesis that ISCs undergo neutral competition (Snippert et 
al. 2010), and contradicting the previously proposed model in which ISCs divide 
asymmetrically (Potten et al. 2002; Smith 2005). Further studies using computational and 
mouse models have confirmed the theory that stem cells located in the bottom of the crypts 
have a significant advantage to compete over the other cells located above (Mirams et al. 
2012; Ritsma et al. 2014). More recently, with the use of a 3D individual cell-based model to 
study clonal competition in the intestine, Thalheim and colleagues have shown that not only 
cell distribution, but also niche composition, can impact on clonal competition (Thalheim et al. 
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2016). The authors have studied the impact of Wnt and Notch signalling pathways on clonal 
competition due to their importance for stem cell self-renewal and lineage specification, and 
have shown that mutations in these pathways result in phenotypic changes; this demonstrates 
that fixation probability of mutations is dependent on mutation acquisition (Thalheim et al. 
2016). The model of ISC symmetric division predominates, however the mechanisms that 
drive fate choices regarding stem cell division are still unclear, being essential to test 
experimentally the mechanisms unveiled by multi-scale computational modelling.  
 
 
 
ISCs – Grey cells; TA – Orange cells 
 
 
1.2.3  Wnt Signalling Pathways  
 
There are various signalling pathways involved in intestinal epithelial homeostasis that 
maintain the balance between cell proliferation, migration and apoptosis. One of the most 
important pathways is the Wnt signalling pathway due to its importance in morphogenesis 
during both embryogenesis and in the adult tissue self-renewal homeostasis (Clevers 
2006).Three different Wnt pathways have been described: the canonical Wnt/β-catenin 
pathway, the non-canonical planar cell polarity pathway and the non-canonical Wnt/calcium 
pathway. 
 The canonical Wnt pathway is the major regulator of intestinal homeostasis and it will 
be described in more detail in the next section.  The best characterized non-canonical pathway 
Figure 1.3 Schematic representation of the potential outcomes of ISC division.  
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is the planar cell polarity pathway. As the name suggests, this pathway controls cell polarity 
in morphogenetic mechanisms in vertebrates, including neural tube closure and gastrulation, 
through cytoskeletal changes (Zallen 2007). The Wnt/calcium pathway controls the calcium 
levels, regulating the transcription of genes important for cell fate and cell migration (Kohn and 
Moon 2005). 
 
1.2.3.1 Canonical Wnt Signalling Pathway 
 
The canonical Wnt pathway, a conserved signalling pathway involved in development, 
regeneration, survival and cell proliferation, is crucial to the maintenance of homeostasis within 
the intestinal epithelia. Deregulation of this pathway occurs in 80% of human CRCs, leading 
to aberrant stem cell differentiation (Mazzoni and Fearon 2014).  
 In the absence of a Wnt ligand the pathway is in its “off state”. β-catenin is 
phosphorylate by the destruction complex formed by the scaffold protein Axin, Adenomatous 
Polyposis Coli (APC) tumour suppressor, glycogen synthase kinase-3β (GSK-3β) and casein 
kinase 1 α (CK1- α). After phosphorylation, β-catenin is recognized by the β-transducin repeat-
containing protein (β-TrCP) of the E3 ubiquitin ligase complex catalysing its ubiquitination. 
Following ubiquitination β-catenin is degraded in the proteasome. Low levels of free 
cytoplasmatic β-catenin allow the interaction of Groucho-related gene (GRO) repressors with 
T-cell factor (TCF) proteins, leading to the recruitment of histone deacetylases (HDACs) 
resulting in the inhibition of Wnt target genes (figure 1.4) (Clevers 2006; Clevers et al. 2014).  
Wnt activation occurs when the Wnt ligands bind to the Frizzled (FZD) and low-density 
lipoprotein-receptor related protein (LRP) co-receptor complex (Clevers 2006; Clevers et al. 
2014), leading to the phosphorylation of LRP receptors by CK1- α and GSK-3β. After this, DVL 
and Axin proteins are recruited to the plasma membrane where they become polymerized and 
activated. The destruction complex is inactivated by the DVL polymers, resulting in the 
accumulation of β-catenin in the cytoplasm, which translocate to the nucleus, binding to TCF 
proteins and activating the transcription of downstream target genes, including c-Myc, Cyclin 
D1 and others (figure 1.4). Mutation of the APC gene leads to the activation of the Wnt 
signalling, even if Wnt ligands are not present, by promoting the dissociation of the destruction 
complex. Similar to what happen in the presence of Wnt ligands, β-catenin accumulate in the 
cytoplasm and translocate to the nucleus activating the transcription of Wnt target genes 
(figure 1.4) and promoting uncontrolled cell growth (Mazzoni and Fearon 2014). These 
transformed cells do not differentiate, remaining located at the crypt bottoms, leading to the 
initiation of CRC. 
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In the absence of a Wnt ligand β-catenin binds to the destruction complex formed by APC, Axin, GSK-3β and CK1-α being phosphorylated and, after 
ubiquitination, degraded in the proteasome. In the presence of Wnt ligand, the destruction complex is inactivated and the β-catenin accumulate in the cytoplasm, 
translocate to the nucleus and promote the transcription of genes involved in proliferation and tumorigenesis. When the APC gene is mutated the destruction 
complex is not formed, leading to the translocation of β-catenin to the nucleus, promoting the transcription of Wnt target genes. 
 
 
Figure 1.4  Schematic representation of the canonical Wnt signalling pathway in normal colonic and cancer cells. 
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1.2.4 Cancer Stem Cells 
 
The concept of the existence of cancer stem cells (CSCs) was first proposed by 
Schofield a few decades ago (Schofield 1978) who suggested the tumour growth was 
sustained by a small population of cancer cells with the ability to self-renew. It has been shown 
that these cells reside in dedicated niches within the tumours, although their identification and 
elimination has been more challenging than what was expected (Batlle and Clevers 2017). 
The existence of this cell population explains the common recurrence of cancer in patients 
who have gone through initial successful chemotherapy and/or other treatments such as 
radiotherapy. 
After Schofield, other researchers have shown evidence supporting the existence of 
CSC population. Bonnet and Dick showed that transplanting immune-deficient mice with a 
population of human acute myeloid leukemic cells characterized by the expression of a 
combination of the surface markers CD34+CD38- was sufficient for these mice to develop 
leukaemia (Bonnet and Dick 1997). Similar studies were performed to further analyse the 
presence of CSCs and their function in CRC initiation (Zhou et al. 2018). Dalerba and 
colleagues collected CRC solid tissues from surgical specimens and xenografts developed in 
nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice, and performed flow 
cytometry to analyse surface markers (Dalerba et al. 2007); epithelial cancer cells expressing 
heterogeneous surface markers were cell sorted, and the capacity of different cell subsets to 
initiate tumours was tested by injecting them in NOD/SCID mice. The authors showed that the 
capacity to initiate tumours in the transplanted mice was restricted to a subpopulation of cells 
with enriched expression of epithelial cell adhesion molecule (EpCAMhigh) as well as 
expression of the surface marker CD44+ (Dalerba et al. 2007).  
Other studies have shown that a high density CD133+ cell population could initiate 
tumour formation when injected in immunodeficient mice, whereas injection of CD133- cells 
failed to initiate tumourigenesis (O'Brien et al. 2007; Ricci-Vitiani et al. 2007). However, a year 
later, another study contradicted these results by showing that both CD133+ and CD133- 
metastatic colon cells could initiate tumour formation (Shmelkov et al. 2008). More CSC 
markers have been identified in CRC such as aldehyde dehydrogenase 1 (ALDH1) (Hessman 
et al. 2012; Rassouli et al. 2016), octamer-binding transcription factor 4 (OCT 4) (Matsuoka et 
al. 2012; Wahab et al. 2017), SRY (sex determining region Y)-box 2 (SOX-2) (Neumann et al. 
2011; Talebi et al. 2015), Nanog Homeobox (NANOG) (Hadjimichael et al. 2015; Wahab et al. 
2017),  c-Myc (Takahashi and Yamanaka 2006; Markowitz and Bertagnolli 2009) and the 
leucine rich repeat containing G protein-coupled receptor 5 (LGR5) which will be discussed in 
more detail in the following section (Barker et al. 2009; Ricci-Vitiani et al. 2009; Shimokawa et 
al. 2017; Leng et al. 2018). 
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 Altogether, these studies agree with the cancer stem cell hypothesis, showing that 
this cell population can be identified by a variety of markers and can initiate tumourigenesis. 
 
 
1.2.5 Lgr5 stem cells as the origin of CRC 
 
The identification of a true stem cell population in the mouse intestine has been 
controversial. Several studies have suggested potential stem cell markers based on positional 
information of gene expression, which itself does not give enough evidence to define genes 
as ISCs markers (Barker et al. 2012). However, through lineage tracing (Barker and Clevers 
2007) and in situ hybridization (Gregorieff et al. 2005) several markers have been identified. 
Barker and colleagues have identified the Lgr5 as a marker of rapidly dividing stem cells in 
the small and large intestines (Barker et al. 2007). Lgr5 was selected from a panel of genes 
due to its restricted crypt expression; it was shown by lineage tracing that Lgr5+ CBC cells 
generated the epithelial lineages, suggesting that Lgr5 represents the stem cell of both small 
and large intestines (Barker et al. 2007).   
Lgr5 is a G-protein coupled receptor (GPCR) of the class A Rhodopsine-like family of 
GPCRs. These receptors control a variety of key functions by binding ligands such as 
hormones and neurotransmitters (Kumar et al. 2014). Leucine-rich repeat-containing GPCRs 
(LGRs) are distinct from the other GPCRs as they contain a large extracellular domain with, 
as the name suggests, multiple leucine-rich repeats. Apart from being a marker for intestinal 
stem cells, other studies have given insights into other functions of Lgr5, mainly from analysis 
of null or loss-of-function mutants. Disruption of Lgr5 resulted in total neonatal lethality, 
indicating the importance of Lgr5 in development. The Lgr5-null mice were characterized by 
gastrointestinal tract dilation and, interestingly, accelerated maturation of the Paneth cells, 
possibly indicating that during intestinal development Lgr5 negatively regulates Wnt signalling 
(Garcia et al. 2009). Lgr5 has been shown to modulate Wnt signalling pathway, upon biding 
to its ligand, R-spondin (RSPO). In the absence of RSPO, there is internalisation of two 
transmembrane E3 ligases (RNF43 and ZNRF3) and degradation of the Wnt receptors (FZD 
and LPR), keeping Wnt levels low. When RSPO binds to Lgr5, the E3 ligases are neutralised, 
and Wnt receptors are able to bind to the Wnt ligands as they are no longer degraded, leading 
to subsequent Wnt signalling activation (Carmon et al. 2011; de Lau et al. 2011; Glinka et al. 
2011). 
 Following the confirmation that Lgr5 is a marker for intestinal stem cells (Barker et al. 
2007), Barker and colleagues demonstrated that loss of the Apc gene in Lgr5 stem cells led 
to their transformation within days, resulting in adenoma development (Barker et al. 2009). 
The transformed stem cells remained located in the bottom of the crypts giving origin to 
13 
 
microadenomas that developed into adenomas within 3-5 weeks. When the Apc gene was 
deleted in the non-stem cell compartment small lesions formed in the intestinal epithelium, 
although they did not form tumours even 200 days post induction (Barker et al. 2009), 
indicating that only the stem cells located in the bottom of the crypt were responsible for 
adenoma formation.  
More recently, Shimokawa and colleagues have confirmed that human LGR5+ cells 
act as cancer stem cells giving new insights into their plasticity (Shimokawa et al. 2017). The 
authors performed lineage tracing experiments with a tamoxifen-inducible Cre knock in allele 
of LGR5 in patient-derived CRC organoids and showed the capacity of Lgr5+ tumour cells to 
self-renew and differentiate (Shimokawa et al. 2017). Following ablation of the Lgr5+ tumour 
cells in LGR5-iCaspase 9 knock in organoids, tumour regression was observed, however a 
few days later there was a re-emergence of the LGR5+ CSCs. Further experiments showed 
that LGR5- cells dynamically replenished LGR5+ after they were ablated and that the newly 
generated LGR5+ cells would be killed following consecutive ablation, demonstrating why 
targeting CSCs can be so challenging, considering the robust plasticity of non-targeted cancer 
cells (Shimokawa et al. 2017).  
 
 
1.2.6 Multi-step carcinogenesis of the intestine 
 
In 1990 Fearon and Vogelstein described a multistep genetic model for the initiation 
and progression of CRC (Fearon and Vogelstein 1990). This model was formulated following 
a mutational profile study in CRC samples collected from different stages of the disease. 
Fearon and Vogelstein proposed that various mutations, from inactivation of tumour 
suppressor genes to activation of oncogenes, in a preferential sequence, were essential in the 
process of colorectal tumourigenesis (Figure 1.4) (Fearon and Vogelstein 1990). Since then, 
other studies have supported this model (Pino and Chung 2010).  
The initiation of adenomas starts with intestinal crypt hyperplasia and the formation of 
aberrant crypts. A key and early event in intestinal tumourigenesis is the mutation of APC, a 
tumour suppressor gene (Kinzler and Vogelstein 1996). Dysfunction of the APC gene occurs 
in about 80% of CRCs (Rowan et al. 2000) leading to Wnt signalling activation and highlighting 
the importance of this gene in intestinal tumourigenesis (Morin et al. 1997; Zhang and Shay 
2017). Mutations or deletion of the APC gene leads to the development of familiar 
adenomatous polyposis (FAP), an autosomal dominant trait characterized by the development 
of colonic adenomatous polyps throughout life. These polyps are benign, however they can 
progress to adenocarcinomas if left untreated (Groden et al. 1991) 
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 Following APC mutation, there is a hyper-proliferation of the abnormal cells giving 
origin to tumour mass growth and alteration of the normal tissue anatomy. The process of 
tumour progression encompasses activation of the KRAS or BRAF oncogenes (Fearon and 
Vogelstein 1990; Boutin et al. 2017) and loss of the tumour suppressor gene TP53 (Li et al. 
2015) leading to the formation of carcinoma and, ultimately, invasion and metastasis (Figure 
1.5) (Fearon and Vogelstein 1990). Together with these changes there are other associated 
aberrations, including epigenetic changes such as DNA hypo-methylation and CpG island 
hyper-methylation. These changes in the DNA will directly influence the expression of 
oncogenes and silencing of tumour suppressor genes promoting tumour progression. 
Mismatch repair (MMR) gene mutations have also been implicated in CRC development (Li 
and Martin 2016)  
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Updated multi-step tumourigenesis model proposed by Fearon and Vogelstein (Fearon and Vogelstein 1990). Intestinal cancer initiation and progression occurs 
in a step-wise accumulation of mutations in various genes such as APC, KRAS/BRAF, DCC, TP53, 17p and PIK3CA/PTEN. DNA hypo-methylation, CpG island 
hyper-methylation and mutations in MMR genes can be present throughout tumour initiation and progression (adapted from (Hanahan and Weinberg 2011) 
 
Figure 1.5 Multi-step tumourigenesis of the intestinal epithelium 
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1.3 CRC and the Host Immune Environment 
 
1.3.1 Cancer Immunosurveillance 
 
In the early 1900’s Paul Ehrlich proposed that the immune system could recognize, 
target and eliminate cancer cells. Around 50 years later, Burnet and Thomas proposed that 
the immune system has an important role in the control of cancer progression and created the 
hypothesis of the “Cancer Immunosurveillance”. This hypothesis states that lymphocytes act 
as sentinels, recognizing and eliminating newly transformed cells (Burnet 1957). However, 
years later, this hypothesis was questioned by Stutman, who showed that there were no 
evidence that there was a difference in the number of tumours between immunodeficient and 
immunocompetent mice (Stutman 1974). Despite many studies performed in mice supporting 
this hypothesis of the transformed cells clearance, it is still difficult to show evidence in 
humans. People where immunosurveillance cleared any potential cancer, would not develop 
the disease and, as a consequence, would not be included in further studies. On the other 
hand, people diagnosed with cancer could be considered that their immune-mediated 
mechanisms of tumour control have failed (Gallimore and Godkin 2008). 
 
 
1.3.2 Cancer Immunoediting 
 
Immunosurveillance of the tumour cells is one part of the interaction between the 
immune system and the cancer. More recent studies have showed that the immune system, 
apart from eliminating cancer, is also able to initiate it, particularly during chronic inflammation  
(Grivennikov et al. 2010). The “Cancer Immunoediting” hypothesis, not only includes the 
capacity of the immune system to protect against cancer initiation, but also the fact that it can 
modify the immunogenicity of the developing tumour, allowing the escape of the tumour from 
the anti-tumour immune responses (Shankaran et al. 2001). 
The “Cancer Immunoediting” hypothesis is described as consisting in three distinct 
phases: Elimination, Equilibrium and Escape. “Elimination” refers to the previously described 
immunosurveillance, when both innate and adaptive immune responses eliminate newly 
transformed cells (Figure 1.6 A) (Schreiber et al. 2011).  
The “Equilibrium” phase occurs when not all the transformed cells are immediately 
destroyed by the immune system. Some of them are edited and sculpted by the adaptive 
immune system, leading to the dormancy of the tumour (Figure 1.6 B) (Schreiber et al. 2011).  
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Finally, “Escape” refers to the tumours that were previously edited by the immune 
system but escaped immune recognition. There are various mechanisms described by which 
escape can happen, such as loss of tumour antigen expression, an immunosuppressive 
microenvironment and resistance to cytotoxicity (Figure 1.6 C) (Schreiber et al. 2011).  
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A) “Elimination” involves both innate and adaptive immune responses to eliminate transformed cells. B) 
During “Equilibrium” the transformed cells that are not eliminated they can undergo immunogenicity 
editing and sculpting. C) During “Escape” the transformed cells lose their MHCs and/or antigen 
presentation capacity, they won’t be recognised by the immune system, escaping to the effector 
immune cells. 
  
Figure 1.6 Schematic representation of the three different phases of the concept of cancer 
immunoediting. 
A 
B 
C 
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1.3.3 Immune response 
 
In the presence of a foreign antigen the first response to its presence is given by the 
innate immune system, which recognize and destroys the antigen in a non-specific manner. 
There are various cell populations involved in this response, such as natural killer (NK) cells, 
macrophages, dendritic cells (DCs), neutrophils, eosinophils and basophils. These cells 
express pattern recognition receptors (PRRs) that recognize pathogen-associated molecular 
patterns (PAMPs) that usually are not present in the mammalian body, triggering an immune 
response to eliminate the foreign antigens (Parham 2015a). 
On the other hand, when the innate immune system is not able to control an infection, 
another immune response is built by the adaptive immune system which has a more 
specialized and long-lasting response against the antigens. The adaptive immune response 
is performed by lymphocytes which recognize the pathogens by using cell-surface receptors 
that are specifically of just one molecular type. Each cell-surface receptor can have a very 
high number of different versions that bind to different ligands building a very specific response 
(Parham 2015b).  
The adaptive immune response is mounted by B and T lymphocytes. B lymphocytes 
can act through two different ways: they can either recognize an antigen that binds to the B 
cell receptors promoting the proliferation of plasma cells and, as a consequence, there is the 
secretion of antibodies. The second mechanism relies on the fact that B cells can act like 
antigen-presenting cells (APCs), processing and presenting the antigens to the major 
histocompatibility complex (MHC) for recognition (Parham 2015c). T cells are distinguished 
from other lymphocytes be the expression on their surface of highly variable T cell receptors 
(TCRs) that recognize peptides presented by MHCs. The reactions that follow the binding of 
the peptides to the TCRs or MHCs depend on the T cell subpopulation that is participating. 
There are two different types of MHCs: MHC class I, which is responsible by presenting 
antigens from intracellular pathogens and MHC class II that presents antigens from 
extracellular pathogens (Parham 2015d).  
 
 
1.3.3.1  T-cells 
 
T-cells are lymphocytes that are produced in the bone marrow and mature in the 
thymus. During development, they express cell-surface glycoproteins which determine their 
function and can be used to identify them. T-cells can give rise to two different lineages that 
arise from a common thymocyte progenitor: α:β T-cells that are the majority of the T-cells and 
γ:δ T-cells. α:β T-cells share the expression of the surface marker CD3 and can be divided 
20 
 
into two different sub lineages depending on the expression of the co-receptors CD4 and CD8 
that are part of the immunoglobulin superfamily of proteins. These co-receptors help the T-cell 
receptors recognize the antigens and MHC molecules. The CD4 co-receptors binds 
specifically to MHC class II molecules and CD8 co-receptors bind to MHC class I molecules. 
CD4 and CD8 are functionally similar but their structures are different. CD4 is a single 
polypeptide formed by four extracellular immunoglobulin-like domains. CD8 is a heterodimer 
formed by an α and a β chain. Each of the chains are connected to the membrane-spanning 
region by immunoglobulin-like domains (Parham 2015d).   
 
 
1.3.3.1.1 CD8+ T-cells 
 
CD8+ T-cells, also known as cytotoxic T-cells (CTLs), participate in the immune 
response against intracellular pathogens, such as bacteria and viruses, but also in anti-tumour 
immune responses (Harty and Bevan 1999; Radziewicz et al. 2007; Hadrup et al. 2013). CD8+ 
T-cells can exert their cytotoxic activity by three different mechanisms. Firstly, via the secretion 
of the cytokines IFNγ and TNFα. These two cytokines have anti-viral and anti-tumour effects. 
Secondly CD8+ T-cells can release cytotoxic granules, such as perforin and granzymes, which 
are serine proteases. As the name suggests, perforins are proteins that able to form pores in 
the membrane of the targeted cell allowing the granzymes to enter the cell (Trapani and Smyth 
2002). In the 1990’s, an experiment showed that perforin-deficient mice developed more 
tumours, demonstrating the importance of CD8+ T-cells in cancer immunosurveillance (van 
den Broek et al. 1996). Granzymes will then cleave proteins inside the infected/malignant cell 
resulting in the apoptosis of the cell. Once this is done, CD8+ T-cells can then move to another 
infected cell, eliminating it.  
Finally, CD8+ T-cells induce a cell to undergo apoptosis via Fas/Fas-ligand 
interactions. Fas-ligands (or CD95) are expressed by activated CD8+ T-cells on their surface. 
Fas-ligand will then bind to Fas that are located on the surface of the target cell. After the 
binding, Fas, through trimerization, will activate signalling molecules and, as a consequence, 
the caspase cascade, resulting in the apoptosis of the infected cell (Waring and Mullbacher 
1999). Mice where Fas/Fas-ligand were mutated showed higher incidence of B-cell 
lymphomas. It has also been shown that cell death mediated by Fas/Fas-ligand interactions 
is fundamental for T-cell mediated immunosurveillance for B-cell lymphoma in mice (Davidson 
et al. 1998). 
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1.3.3.1.2 CD4+ T-cells 
 
Naïve CD4+ T-cells differentiate into functionally effector cells upon T-cell receptor 
(TCR) stimulation by peptide-MHC present in APCs, usually DCs. CD4+ T-cells are part of a 
very heterogeneous population and can be divided into different subpopulations that secrete 
cytokines that will either activate or suppress other immune cells, promoting various types of 
immune responses. The CD4+ T-cell subpopulations can be distinguished by the cytokines 
and transcription factors that induce and determine, respectively, their differentiation, the 
cytokines that they produce and the cells that are helped by them (figure 1.7) (Tripathi and 
Lahesmaa 2014).  
The first helper subsets that were described were the Th1 and Th2 (Mosmann et al. 
1986). With subsequent research identifying Th9, Th17, Th22, follicular T cells (Tfh) and Treg.  
The differentiation of Th1 cells is initiated by the cytokine IL-12 and their specific gene 
expression programme is regulated by the transcription factor T-bet (Szabo et al. 2000). Th 1 
cells produce cytokines such as IL-12, IFN-γ, TNFα and lymphotoxin (LT) that will help 
macrophages combat intracellular bacterial and viral infections (Szabo et al. 2003).  
Th2 cells help B-cells, mast cells, basophils and eosinophils control parasite infections 
by producing IL-4, IL-5, IL-6 and IL-13 cytokines (Zhu and Paul 2010). The transcription factor 
that define Th2 differentiation is GATA3 (Zheng and Flavell 1997) and their differentiation is 
initiated by IL-4.  
Th17 cells enhance neutrophils response against extracellular fungal and bacterial 
infections. The cytokines involve in their responses are IL-17, IL-22 and IL-23 (Zhu and Paul 
2010). The transcription factor that determine Th17 differentiation is RORγT but other 
transcription factors have been described as being part of the Th17 differentiation program. 
IL-6, IL-23 and TGF-β can initiate the differentiation of Th17 cells (Chen et al. 2007). 
Recently other T-cells were described, including Th9, Th22 and Tfh cells. Th9 
development depends on the transcription factors PU.1 and IRF4 and their differentiation is 
initiated by IL-4 and TGF-β (Tripathi and Lahesmaa 2014). These cells can have both 
beneficial and detrimental functions. Th9 cells promote immunity against helminth parasites 
and also participate in anti-tumour activity, particularly in melanoma by secreting IL-9 and IL-
21. On the other hand, Th9 cells can exacerbate the immune response in the case of asthma; 
they also contribute to inflammatory bowel disease (IBD), impairing tissue repair processes 
and increasing intestinal permeability (Kaplan et al. 2015).  
Th22 cells depend on the IL-6 and TNF to differentiate and aryl hydrocarbon receptor 
(AhR) for their transcriptional control (Duhen et al. 2009). These cells are characterized by a 
high production of IL-22, a cytokine that is secreted also by Th17 and NK cells. Although 
secretion of IL-22 is a common feature between these cell populations, Th22 cells are unique 
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in the secretion of IL-22 and absence of IL-17 and IFN-γ production (Duhen et al. 2009). This 
cell population is believed to have an important role in tissue repair, particularly damaged 
epithelial barriers as well as promoting responses against some pathogens. Other functions 
of Th22 cells include skin homeostasis by inhibition of keratinocytes differentiation as well as 
gastrointestinal and respiratory tract cells. Protective effects in models of inflammatory bowel 
disease, pancreatitis and hepatitis have also been associated to Th22 cells (Trifari et al. 2009; 
Sabat et al. 2014).   
Tfh cells participate in generation of B cell responses in germinal centres by secreting 
IL-21 and their differentiation depend on IL-6 and IL-21. Tfh cells are regulated by the 
transcription factor Bcl6 (Tripathi and Lahesmaa 2014).  
Tregs lineage and function is defined by the expression of the transcription factor 
Foxp3 and these cells are responsible for the suppression of effector immune responses. 
Tregs secret immunosuppressive molecules such as IL-10, TGF-β and IL-35 (Corthay 2009). 
Tregs will be described in more detail in the following section due to their relevance to this 
project. 
 
 
1.3.3.1.3 Interferon-gamma (IFN-γ) 
 
IFN-γ is produced by a variety of cells such as CD4+ T-cells, CD8+ T-cells, NK and 
NKT cells and it is a critical cytokine in the innate and adaptive immune system (Schoenborn 
and Wilson 2007). The receptor of IFN-γ is formed by two subunits: IFN-γR1 and IFN-γR2 
(Dunn et al. 2006). When IFN-γ binds to its receptor there is the recruitment and activation of 
the Janus kinase (JAK1 and JAK2), leading to the activation of STAT1 and interferon 
regulatory factor 1 (IRF1). Following STAT1 and IRF1 phosphorylation, and translocation to 
the nucleus, IFN-γ-regulated genes are transcribed (Horvath 2004).  
Various studies have shown the importance of IFN-γ in the anti-tumour immune 
responses in CRC (Wang et al. 2015a; Katlinski et al. 2017; Liu et al. 2017). Wang and 
colleagues have shown in a mouse model of Apc-mediated intestinal cancer (ApcMin/+), that 
mice deficient in IFN-γ or IFN-γ receptor subunit 1 (IFN-γR1) had an increased number and 
size of adenomas, with about 41% of the mice developing adenocarcinomas. The authors 
have also shown that heterozygous deletion of IFN-γ promoted activation of the EGFR/Erk1/2 
and Wnt signalling pathways (Wang et al. 2015a). More recent studies have shown that 
downregulation of IFN-γR1 occurs in human CRC as well as mouse models of CRC. 
Downregulation of IFN-γR1, apart from causing tumour development, promoted the formation 
of an immune-privileged niche and was associated with a poor prognosis. On the other side, 
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stabilization of IFN-γR1 improved response to anti-PDL1 therapy and survival, indicating the 
importance of IFN-γR1 in the efficacy of immunotherapies (Katlinski et al. 2017).  
IFN-γ has been shown to promote apoptosis in malignant cells (Liu et al. 2011; 
Kotredes and Gamero 2013; Ni and Lu 2018). Liu and colleagues have shown that metastatic 
colon carcinoma cell lines treated with TNFα and IFN-γ reduced resistance to TNF-related 
apoptosis-inducing ligand (TRAIL), a protein that induces cell death by apoptosis, being very 
important in the anti-tumour responses. The authors treated a mouse model of metastatic 
CRC with TRAIL together with TNFα and IFN-γ, and observed a reduced expression of the 
antiapoptotic protein Bcl-xL. This resulted in increased apoptosis through TRAIL-induced 
caspase 8 activation, leading to the suppression of the metastasis (Liu et al. 2011). Taken 
together, these studies and others show the importance of IFN-γ in the anti-tumour immune 
responses.  
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Figure 1.7 Differentiation of Naive CD4+ T-cells. 
 
Upon activation by DCs, and in the presence of specific cytokines, naïve CD4+ T-cells differentiate into 
different T helper (Th) or Foxp3+ regulatory T-cells (Treg) subsets. Each subset is defined by the 
expression of lineage specific transcription factors, and by the production of effector or 
immunosuppressive cytokines. 
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1.3.3.1.4 Foxp3+ Regulatory T cells (Tregs) 
 
1.3.3.1.4.1 Tregs – an introduction to their discovery and function 
 
Several studies showed evidence of the presence of a T-cell subpopulation 
responsible for suppression of active immune cells. The first marker identified for these cells 
was CD25 and its depletion would cause a series of autoimmune diseases.  These mice could 
be rescued by reintroducing CD4+CD25+ but not CD4+CD25- cells (Sakaguchi et al. 1995). 
Subsequent studies identified a subpopulation of CD25+ cells which expressed the Forkhead 
box protein 3 (Foxp3).  Foxp3 is a transcription factor encoded on the X chromosome which 
belongs to the member of the forkhead/winged-helix family. Studies performed in mice that 
had uncontrolled CD4+/CD8+ T-cell proliferation showed that Foxp3 was not functional due to 
a mutation (Brunkow et al. 2001). It was demonstrated that CD4+CD25+ T-cells had higher 
expression levels of Foxp3 when compared to CD4+CD25- T-cells. Furthers experiments 
demonstrated that CD4+CD25+Foxp3+ T-cells could suppress the proliferation of 
CD4+CD25- T-cells (Fontenot et al. 2003).  
Bennett and colleagues demonstrated that, in humans, a mutation in the Foxp3 gene 
affected Treg cells development and function. This was the cause of Immune dysregulation 
Polyendocrinopathy Enteropathy, X-linked (IPEX) syndrome, a fatal, early-onset, autoimmune 
disorder. The same was observed in the scurfy mice, where a spontaneous Foxp3 mutation 
occurs, leading to the development of a lymphoproliferative disease with multiple organ 
inflammation (Godfrey et al. 1991; Bennett et al. 2001). All these evidences showed that Treg 
cells had a very important role in the regulation of the immune responses. 
Further experiments were possible due to the creation of a mouse model that allowed 
the depletion of Foxp3+ cells after injection of the diphtheria toxin. These mice expressed the 
human diphtheria toxin receptor under the control of the Foxp3 promotor. Deletion of Foxp3+ 
cells caused a similar phenotype presented by the mice that were Foxp3 deficient, developing 
autoimmunity (Kim et al. 2007; Lahl et al. 2007). 
Tregs can have different origins. Most of them derive from the thymus (tTregs), also 
known as natural Treg cells (nTregs), develop during the negative and positive selection. 
Tregs can also be induced in the periphery (pTregs) after antigen stimulation of the CD4+ T-
cells.  
One of the main functions of the Tregs is to maintain self-tolerance and the prevention 
of autoimmunity by controlling the expansion of T-lymphocytes that react against self-
antigens. By promoting self-tolerance, Tregs prevent the occurrence of autoimmune diseases, 
promote feto-maternal tolerance and suppress allergies. They are also important in the 
prevention of chronic inflammatory diseases (Maloy and Powrie 2001). 
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1.3.3.1.4.2 Immunosuppressive mechanisms of Tregs 
 
There are several mechanisms by which Tregs can exert their immunosuppressive 
activity have been demonstrated. Immunosuppression by Tregs can be achieved by the 
modulation of the APCs activity by contact-dependent interactions (Schmidt et al. 2012). It 
was shown that this activity was dependent on CTLA-4, a surface marker that is expressed 
on Tregs (Takahashi et al. 2000) and LAG-3 (lymphocyte-activation gene 3), a transmembrane 
protein. Gene expression studies performed by several groups allowed the identification of 
molecules with suppressive activity, such as: galectin-1 and galectin-10, TGF-β, IL-10 and IL-
35, a member of the IL-12 heterodimeric cytokine family (Shevach 2009). Tregs are also able 
to promote direct cytolysis as they express perforins and granzymes. This was observed in 
both humans and mice (Shevach 2009; Hoves et al. 2010). 
 
 
1.3.3.1.4.3 Tregs in Cancer 
 
It is well known that Tregs are essential in maintaining peripheral tolerance and that 
they do it by preventing self-reactivity. In the 1970s and 1980s several studies started to 
establish a connection between a population of suppressive cells and anti-tumour immune 
responses (Zou 2006). After the identification of the CD25 as a Treg marker (Sakaguchi et al. 
1995) other studies showed that the depletion of cells expressing this marker induced CD8+ 
T-cell responses and controlled the tumour growth (Onizuka et al. 1999; Shimizu et al. 1999). 
The opposite was observed after adoptive transfer of CD4+CD25+ T-cells to tumour-bearing 
mice, where the anti-tumour immunity was suppressed (Turk et al. 2004; Antony et al. 2005). 
Other experiments that were done after the discovery of the Foxp3 marker demonstrated that 
depletion of Foxp3+ cells would prevent the tumour initiation and development (Klages et al. 
2010; Teng et al. 2010; Hindley et al. 2012).  
Several studies showed increased numbers of Tregs in the tumour microenvironment in 
a variety of different cancers, such as: melanoma, lymphoma, pancreatic, breast, lung, gastric 
and others, when compared to tissue from healthy donors (Nishikawa and Sakaguchi 2010; 
Quezada et al. 2011; Scurr et al. 2012; Whiteside 2012). However, it is controversial whether 
this increased number of Tregs indicates a good or a bad prognosis, having different studies 
reporting opposite conclusions (Curiel et al. 2004; Alvaro et al. 2005; Sato et al. 2005; Bates 
et al. 2006; Mantovani et al. 2008; Perrone et al. 2008; Ladoire et al. 2011). This highlights 
the importance of studying the types of cancer and their origin, as Tregs may play different 
roles depending on that. In the case of inflammation-driven tumours, Tregs may have anti-
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tumour effects by suppressing the inflammation that promoted the cancer initiation and 
development (Erdman et al. 2005; Grivennikov et al. 2010; Ruffell et al. 2010). 
 
 
1.3.4 T-cells and CRC  
 
Cancer patients with increased tumour immune infiltrate correlates with an improved 
clinical outcome, when compared to patients with lower immune infiltrates in different types of 
cancers such as melanoma (Mihm and Mulé 2015), ovarian (James et al. 2017), head and 
neck (Schneider et al. 2018), breast (Ingold Heppner et al. 2016) and CRC (Braha et al. 2016). 
An extensive study from Pagès and colleagues has shown that the absence of 
metastasis in human CRC samples was associated with increased infiltration of effector 
memory T-cells in the primary tumour (Pages et al. 2005). It was also reported that patients 
without metastasis and that remained disease-free had increased levels of granzyme B, T-
bet, interferon regulatory factor 1 (IRF-1) and IFNγ when compared with patients that relapsed 
(Pages et al. 2005). T-cell markers, such as CD3+, CD4+ and CD8+ were also significantly 
increased in patients with a better outcome (Pages et al. 2005). Following this study, the same 
group showed that, in three different cohorts of CRC patients, there was a high density of 
CD3+ and CD8+ T-cells, alongside with granzyme B and CD45RO, within the tumour centre 
and invasive margin (Galon et al. 2006). The high levels of these markers were associated 
with a longer disease-free survival for the three groups when compared to groups that showed 
a lower infiltration of these immune markers (Galon et al. 2006). A number of studies have 
associated lymphocytes infiltration in CRC with a better prognosis (Ropponen et al. 1997; 
Pages et al. 2005; Galon et al. 2006; Pages et al. 2009; Mei et al. 2014; Jakubowska et al. 
2017), however it has becoming evident that disease outcome does not depend only in the 
quantity of the lymphocytes that are present, but also their type can have a distinct impact in 
the prognosis. A study by Tosolini and colleagues showed that CRC patients with increased 
expression of Th1 related-genes had a better survival when compared to patients with a lower 
gene expression. The opposite was observed with Th17 associated-genes. CRC patients with 
significantly higher expression of Th17 associated-genes had a earlier relapse, even in the 
presence of higher expression of Th1 associated-genes, indicating that Th17 responses were 
stronger in the tumour progression comparing to the anti-tumour responses by Th1 cells 
(Tosolini et al. 2011). Later, it was shown that CRC patients had increased levels of Th17 cells 
in their blood, particularly in more advanced stages of the disease, suggesting a key role of 
the Th17 cells in CRC progression (Wang et al. 2014). 
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1.3.4.1 Tregs and CRC development 
 
As previously described, there is a number of different malignancies where it is 
observed an increased frequency of Tregs, however it is still controversial whether this T-cell 
sub-population promotes or limits tumour progression. This is also applied in the case of CRC. 
Studies have demonstrated in the blood of CRC patients there was a higher frequency of 
Tregs (Wolf et al. 2003; Clarke et al. 2006). In vitro experiments showed that removal of these 
cells would increase T-cell responses against tumour antigens (Clarke et al. 2006). The 
increased frequency of Tregs in CRC patients was also observed in their intestines, when 
compared to healthy intestines (Ling et al. 2007). A study from our group analysed the CD4+ 
T-cells responses against the tumour antigens 5T4 and carcinoembryonic antigen (CEA) in 
CRC patients before and at multiple time-points following surgery (Betts et al. 2012). It was 
demonstrated that CRC patients had significantly increased levels of Foxp3+ when compared 
to healthy age-matched controls. The levels of Foxp3+ decreased to normal following the 
surgery, suggesting that CRC drives the activity of Tregs. Patients that relapsed had a 
significantly lower activity of 5T4 and CEA T-cell responses that was suppressed by Tregs, 
suggesting that Tregs contribute to tumour progression (Betts et al. 2012). A further study from 
our group supported this finding. It was shown that 5T4-specific T-cell responses were 
decreased in CRC patients, when compared to healthy controls, and they were further 
diminished with disease progression (Scurr 2013). 
On the other side, several studies have associated increased frequencies of Tregs in 
CRC patients with a better outcome and improved survival. Both Salama et al. and Vlad et al. 
showed independently that a higher density of Tregs in the tumour was associated with a 
better outcome and improved survival (Salama et al. 2009; Vlad et al. 2015).  In another study 
it was shown that lower frequencies of Tregs were associated with shorter CRC patient 
survival time (Sinicrope et al. 2009).  
 
 
1.3.4.2 The intestinal immune system 
 
The intestine represents the biggest compartment of the immune system, containing 
many more immune cells than any other tissue in the body. The intestine is continually 
exposed to antigens and dietary immunomodulatory agents. The majority of the immune 
processes occurs in the mucosa, also referred as intestinal barrier. This barrier separates the 
inner and the outer environments blocking the passage of potentially harmful substances, but 
allowing the passage of nutrients and electrolytes, preserving the epithelial barrier, the 
immune responses, as well as allowing the tolerance against the intestinal microbiota. The 
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mucosal immune system is formed by three lymphoid areas: the lamina propria, the 
intraepithelial compartment and the Peyer’s patches (PPs). The PPs are secondary lymphoid 
tissues, located in between the submucosa layer of the ileum and mucosa layer. They are 
covered by follicle-associated epithelium (FAE) that are formed by specialized microfold (M) 
epithelial cells that are responsible by the capture of the antigens that are in the intestinal 
lumen and their transport to the associated subepithelial dome (SED) (Reboldi and Cyster 
2016). 
In mice, both lamina propria and PPs contain a large number of B lymphocytes. The 
intraepithelial compartment contains more CD8+ T cells (Lefrancois and Lycke 2001; Jung et 
al. 2010). The PPs contain a higher number of CD4+ cells, (~45% of the CD3+ T-cells), when 
compared to CD8+ T-cells (~34%) and Tregs (~5%). They also contain other immune cell 
populations such as memory T-cells, naïve T-cells and dendritic cells (DCs) (Jung et al. 2010). 
All these lymphoid areas participate actively to respond to immunological insults in the 
intestine, as it is constantly exposed to various antigens from pathogens and the commensal 
bacteria. 
 
 
1.4 Mouse Models of CRC 
 
The use of mouse models has allowed many important breakthroughs in the 
understanding of tumorigenesis. Mice are relatively easy to genetically modify and this allows 
deeper studies from the early stages of cancer to long term studies. Here the Apcmin mouse 
model and the Lgr5CreERT2Apcfl/flFoxp3DTR will be described in more detail due to their 
relevance in this project. 
 
 
1.4.1 Apcmin mouse model  
 
In the 1990’s Moser and colleagues performed experiments where mice were treated 
with a germline mutagen called ethyl nitrosourea. Via the random mutagenesis approach, they 
identified predispose mice to develop spontaneous intestinal cancer, subsequent analysis 
demonstrated they carried a mutation in the Apc gene. The mutant gene was named Multiple 
Intestinal Neoplasia (Min) and the mouse model Apcmin. This mouse model mimicked what 
happen in FAP patients, the development of multiple polyps in the intestine.(Moser et al. 
1990), being very useful to study intestinal tumorigenesis. 
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It was well known that the loss of function of both APC alleles occurs in the earlier 
stages of about 80% of CRCs (Gryfe et al. 1997), however the requirement of a second “hit” 
to remove the WT allele limits the study of tumour initiation in this mouse model. 
 
 
1.4.2 Cre-lox technology  
 
The Cre-lox system is a tool used for the deletion, insertion, translocation and inversion 
of DNA at specific sites. This system has been extensively used in the generation of mouse 
models for disease (Sauer 1998). This system consists of two major components: the Cre 
recombinase and its targets, known as loxP sites. The Cre recombinase is an enzyme derived 
from the Bacteriophage I and it has the ability, after activation, to recognise the loxP sites in 
the same orientation and excise the DNA sequence located between them. The Cre-
expression can be linked to tissue-specific promoter allowing the control gene expression in 
specific tissues (Sauer 1998). 
 Using genetically modified mice with the Cre-lox technology it is possible to 
conditionally delete both Apc alleles within the intestinal epithelium. It was observed that, after 
Apc deletion, there was an activation of the Wnt signalling, with nuclear accumulation of β-
catenin. Apc deletion also affected the dynamics of the intestinal epithelium by perturbing cell 
proliferation, migration, differentiation and apoptosis. The Apc mutant cells maintained what 
the authors called a “crypt progenitor-like phenotype” (Sansom et al. 2004).  
 
 
1.4.3 Lgr5CreERT2 Apcfl/fl Foxp3DTR mouse model 
 
The mouse model used in this project allows the deletion of the Apc gene specifically in 
the intestinal stem cells (ISC). The Ce-recombinase is linked to a modified estrogen receptor 
(ER), forming a transgene. This transgene remains inactive until an injection of tamoxifen. The 
tamoxifen will bind to the ER and the Cre-recombinase will be activated and able to recombine 
the loxP sites and delete the Apc gene. In this particular model, the Cre-recombinase is linked 
to the Lgr5 promoter, meaning that the recombination will specifically occur in the cells that 
express Lgr5 (Barker et al. 2007). Barker and colleagues have shown that activation of Cre 
was possible with a single IP injection of tamoxifen. The authors observed accumulation of 
nuclear β-catenin in the bottom of about 6% of the crypts within 3 days after Cre induction 
(Barker et al. 2009). Overtime the number of transformed stem cells increased and 8 days 
later it was possible to observe the presence of microadenomas within the associated villus 
stroma. At day 14 the authors observed a similar number of larger adenomas (around 8 %) 
31 
 
and the mice had to be sacrificed at day 36 (Barker et al. 2009). These lesions were observed 
in the mice small intestine, however Lgr5 gene is also a marker of stem cells in the large 
intestine. Barker and colleagues detected the presence of transformed cells in the bottom of 
the colonic crypts within 8 days after Cre induction and the formation of microadenomas 3 
weeks after induction. This showed that, in this model, the formation of microadenomas occur 
more frequently in the small intestine, however colonic stem cells are also transformed but in 
a lower frequency (Barker et al. 2009). Lgr5 is not only expressed in the ISCs, but also foetal 
mammary stem cells (Trejo et al. 2017) and hair follicle stem cells (Jaks et al. 2008).  
This mouse model was crossed with the Foxp3DTR mouse model that expresses the 
human diphtheria toxin receptor (DTR) under the control of the Foxp3 promotor, allowing the 
depletion of the Tregs after diphtheria toxin injection (Kim et al. 2007). 
 
 
Hypothesis and Aims 
 
Previous studies have demonstrated that CRC patients with an increase number of 
Tregs have a poorer prognosis. These studies were done mainly in patients with advanced 
disease, however it is still unclear the role of Tregs in the early stages of CRC. In this project 
I aimed to clarify the role of Tregs in the early stages of intestinal cancer. To do this, the 
following hypothesis were tested: 
 
 Hypothesis 1: Treg numbers and frequency increase following deletion of the Apc 
gene in the ISCs.   
 
Aim: To investigate the response of Tregs upon Apc deletion in the ISCs of the 
genetically modified Lgr5CreERT2Apcfl/flFoxp3DTR mouse model. 
 
 Hypothesis 2: Treg depletion in an Apc deleted mice reduce the intestinal tumour 
burden. 
 
Aim: To assess tumour burden and immune changes following Treg depletion 
in Lgr5CreERT2Apcfl/flFoxp3DTR mouse model.  
 
 Hypothesis 3: Depletion of CD4+ and CD8+ T-cells, and IFNγ neutralization increase 
the intestinal tumour burden. 
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Aim: Identification of immune cell populations and cytokines that participate in 
the anti-tumour immune response in the Lgr5CreERT2Apcfl/flFoxp3DTR mouse 
model.  
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2 Material and Methods 
 
2.1 Experimental Animals and Husbandry 
 
All animal procedures were conducted according to the UK Animal (Scientific 
Procedures) Act 1986, under the authority of UK Home Office personal and project 
licences in accordance with the ARRIVE guidelines. 
 
2.1.1 Colony Maintenance and Breeding 
 
All animals were maintained on an outbred background. Mice of known genotype 
and, at least, 6 weeks old were bred. The breeding was done in trios (one male and two 
females) and pups were weaned and ear clipped at approximately 4 weeks old for 
identification purposes and genotyping.  
 
2.2 Transgenic Mouse Models 
 
The mouse models used within this project were Apcmin  (Moser et al. 1990) and 
Lgr5CreERT2Apcfl/flFoxp3DTR (Barker et al. 2007; Kim et al. 2007) (discussed in sections 
1.4.1 and 1.4.3). 
 
2.3 Experimental Procedures 
 
All animal procedures were carried out in designated procedure rooms. The 
animals used in these procedures were at least 10 weeks old. Administration of the 
different treatments was done via intraperitoneal injection (IP). 
 
2.3.1 Animal Identification and Genotyping 
 
The identification of the animals was done based on ear biopsies that were taken 
using a 2 mm ear punch (Harvard apparatus). The ear biopsies were kindly done by the 
staff in the animal unit (Elaine Taylor, Mike Quirk, Paul Chapman and Sarah Davies). 
 
2.3.1.1 Polymerase Chain Reaction (PCR)   
 
Genotyping was performed by PCR using genomic DNA (gDNA) allowed the 
correct choice of the experimental cohorts. Part of the genotyping was kindly performed 
by Matthew Zverev. 
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2.3.1.1.1 DNA Extraction 
 
The ear biopsies were collected by the time the mice were weaned and stored at 
-20 ºC in order to prevent degradation. Tissues were digested using 250 µl of lysis buffer 
(VWR) containing 0.4 mg/ml proteinase K (Sigma), overnight (O/N) at 42 ºC with 
agitation. After the overnight incubation, 100 µl of protein precipitation solution (VWR) 
was added and mixed by inversion to the digested tissue. Following centrifugation at 
13000 rpm for 10 min the protein and insoluble debris were pelleted. The supernatant 
was transferred to a 1.5 ml Eppendorf tube containing 250 µl of isopropanol (Thermo 
Fisher Scientific). The solution was mixed by inverting the tubes and centrifuged at 13000 
rpm for 15 min to pellet the DNA. The supernatant was discarded, the pellet was left to 
dry for an hour at 32 ºC and the DNA was resuspend in 250 µl Milli-Q water. The DNA 
was left at room temperature (RT) for short-term storage or at 4 ºC for longer-term 
storage. 
 
2.3.1.1.2 Generic PCR Protocol 
 
PCR reactions were done in 96 well semi skirted straight side plates (Alpha 
Laboratories). In each well, 3 µl of gDNA was mixed with 47 µl of PCR master-mix (see 
Table 2.1). A blank control was included, were the gDNA was replaced by dH2O. The 96 
well-plates were covered with aluminium foil seals (StarLab) and air bubbles were 
removed by spinning the plates for 5 seconds in a PCR plate spinner (VWR). The 
reactions were run in a GS4 (G-Storm) thermocycler using the conditions shown in Table 
2.1. Primer sequences are shown in Table 2.2. 
 
2.3.1.1.3 Visualization of the PCR Products 
 
PCR products were separated by agarose gel electrophoresis. The agarose gel 
was prepared by mixing 2% of agarose (Eurogentech) in 1X Tris Borate EDTA (TBE) 
buffer (National Diagnostic). The mixture was heated in a microwave until boiling. After 
cooling the solution under running tap water, 14 µl of Safe View fluorescent nucleic acid 
stain (NBS biological) was added per 400 ml. The solution was poured into moulds (Bio-
Rad) and combs were added to create the wells. Bubbles were removed using a tip. The 
gel was left to set for an hour and the combs were carefully removed. The gel was placed 
into an electrophoresis tank containing 1X TBE buffer with Safe View (10 µl Safe View 
per 100 ml 1X TBE). For the PCR products containing clear buffer, 5 µl of loading dye 
(50% glycerol (Sigma-Aldrich), 50% dH2O, 0.1% bromophenol blue (Sigma-Aldrich)) 
were added and gently mixed. 20 µl of the samples were loaded into the gel wells and 
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run at 120 V for approximately 30 min or until the loading dye had run more than half 
way across the gel. The gel was visualised under UV light using a GelDoc UV 
Transilluminator (Bio-Rad) and the images were captured using the GelDoc software 
(Bio-Rad). 
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Table 2.1 Genotyping PCR reaction mixture and conditions 
 Lgr5CreERT2 Apcfl/fl Foxp3DTR Cre Apcmin 
PCR mix      
DNA 3 µl  3 µl 3 µl 3 µl 3 
Milli-Q water 31.1 µl 31.2 µl 31.2 µl 31.2 µl 31.1 µl 
Taq PCR buffer 10 µl 10 µl 10 µl 10 µl 10 µl 
PCR buffer (type) Green Green Clear/Green (2:1) Clear Clear 
MgCl2 (5 mM) 5 µl 5 µl 5 µl 5 µl 5 µl 
dNTPs (25 mM) 0.4 µl 0.4 µl 0.4 µl 0.4 µl 0.4 µl 
Forward Primer (100 mM) 0.1 µl 0.1 µl 0.1 µl 0.1 µl 0.2 µl 
Reverse Primer (100 mM) 0.1 µl 0.1 µl 0.1 µl 0.1 µl 0.2 µl 
Taq Polymerase 0.2 µl 0.2 µl 0.2 µl 0.2 µl 0.2 µl 
Taq Polymerase Brand GoTaq GoTaq GoTaq GoTaq G2 Taq 
PCR thermal cycler conditions      
Initial denaturation 3 min, 95 ºC 3 min, 95 ºC 3 min, 95 ºC 3 min, 95 ºC 2.5 min, 94ºC 
Cycler number 40 40 40 30 35 
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Step 1: denaturation 30 sec, 94 ºC 30 sec, 95 ºC 30 sec, 94 ºC 30 sec, 94 ºC 30 sec, 94 ºC 
Step 2: annealing 30 sec, 58ºC 30 sec, 60ºC 30 sec, 58ºC 30 sec, 55ºC 30 sec, 54ºC 
Step 3: extension 30 sec, 72ºC 1 min, 72ºC 30 sec, 72ºC 1 min, 72ºC 1 min, 72ºC 
Final extension 5 min, 72ºC 5 min, 72ºC 5 min, 72ºC 5 min, 72ºC 10 min, 72ºC 
 Hold at 10ºC Hold at 10ºC Hold at 10ºC Hold at 10ºC Hold at 10ºC 
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Table 2.2 Primer sequences and band sizes 
 
 
2.4 Experimental Cohorts 
 
After the genotyping was done and ascertained by PCR, mice of appropriate age 
were selected into control and experimental groups. Whenever possible, mice were 
housed in cages with other mice. Once animals were induced, they were monitored 
closely for signs of illness such as hunched body, pale feet, piloerection or any other 
signs of loss of condition.  
 
2.4.1 Administration of Tamoxifen  
 
Powdered tamoxifen (Sigma-Aldrich) was mixed in corn oil (Sigma-Aldrich) at a 
concentration of 10 mg/ml in a 70 ºC water bath, while being stirred at intervals, until 
completely dissolved. Aliquots were stored at -20 ºC, thawed before each procedure at 
70 ºC and kept warm until administration into the mice. Each aliquot was used only for 4 
days. Mice were injected with 80 mg/Kg of tamoxifen via intraperitoneal (IP) injection for 
Gene Forward primer sequence  Reverse primer sequence  Product size 
 
Lgr5CreERT2 
 
CTG CTC TCT GCT CCC 
AGT CT 
Wildtype (WT): ATA CCC CAT 
CCC TTT TGA GC 
 
WT=298 bp;  
Mutant=174 bp 
Mutant: GAA CTT CAG GGT CAG 
CTT GC 
 
Apcfl/fl 
GTT CTG TAT CAT GGA 
AAG ATA GGT GGT C 
CAC TCA AAA CGC TTT TGA 
GGG TTG ATT C 
WT=266 bp;  
Targeted=315 bp 
 
 
Foxp3DTR 
WT: TGG ACC GTA GAT 
GAA TTT GAG TT 
WT: CCA GAT GTT GTG GGT 
GAG TG 
 
WT= 500 bp; 
HOM= 650 bp 
HOM: GGG ACC ATG AAG 
CTG CTG GCC G 
HOM: TCA GTG GGA ATT AGT 
CAT GCC 
 
Cre 
TGA CCG TAC ACC AAA 
ATT TG 
ATT GCC CCT GTT TCA CTA TC  
1000 bp 
 
 
Apcmin 
 
TTC TGA GAA AGA CAG 
AAG TTA 
WT: GCC ATC CCT TCA CGT 
TAG 
 
WT=450 bp 
Apcmin = 200 bp 
APCmin: TTC CAC TTT GGC ATA 
AGG C 
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4 consecutive days and sacrificed 15 days after the beginning of the treatment. Injections 
were done using a 1 ml syringe (BD Plastik) and a 25 G needle (BD Microlance3). 
Tamoxifen injection allowed the activation of the Cre-recombinase and deletion of the 
Apc gene in the ISCs. 
 
2.4.2 Depletion of Immune Cells or Neutralization of Cytokines 
 
2.4.2.1 Administration of Diphtheria Toxin (DT)  
 
For in vivo depletion of Foxp3+ Treg cells 15 µg/Kg DT (Sigma), diluted in sterile 
phosphate buffered saline (PBS, ThermoFisher Scientific) was IP injected every other 
day for 15 days. Injections were done using a 1 ml syringe and a 26 ½ G needle (BD 
Microlance3).  
 
2.4.2.2 Administration of CD4 Depleting Antibody 
 
The CD4 depleting antibodies (clones YTS-191 & YTS-3) were gratefully received 
from Professor Awen Gallimore. These clones were grown and purified in Professor 
Awen Gallimore lab as previously described (Jones 2002). Mice were injected with 2 mg 
of each clone at day -1 and again one week later. Injections were done using a 1 ml 
syringe and a 26 ½ G needle (BD Microlance3). 
 
2.4.2.3 Administration of CD8 Depleting Antibody 
 
CD8+ depletion was achieved by IP injection of a depleting anti-CD8 monoclonal 
antibody (InVivoMab, clone YTS-169) (Bioxcell). The antibody was diluted in the 
InVivoPure pH 7.0 Dilution Buffer (Bioxcell) and 250 µg were injected at day -1 and 100 
µg one week later. Injections were done using a 1 ml syringe and a 26 ½ G needle (BD 
Microlance3). 
 
2.4.2.4 Administration of Interferon-gamma (IFNγ) Neutralising Antibody 
 
IFNγ neutralisation was achieved by injecting the mice with 2 mg of a neutralising 
IFNγ antibody (clone XMG1.2) at day -1 and with 1mg one week later. Injections were 
done using a 1 ml syringe and a 26 ½ G needle (BD Microlance3). Similar to the CD4 
depleting antibody, the XMG1.2 clone was grown and purified in Professor Awen 
Gallimore lab as previously described (Jones 2002). 
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2.5 Tissue Harvesting and Processing 
 
All experimental animals were culled by cervical dislocation according to the Home 
Office Licence procedures (schedule 1 of Animals (Scientific Procedures) Act 1986). The 
tissues were dissected immediately after the animal sacrifice in order to avoid 
degradation of RNA (Ribonucleic Acid) and proteins. 
 
2.5.1 Dissection of Organs 
 
Mice were dissected in a designated area using a dissection kit. The abdomen 
was sprayed with 70% ethanol and it was opened longitudinally through the skin and 
smooth muscle wall. Spleen, a part of the liver and kidney were collected and fixed 
immediately as described in section 2.5.3. For flow cytometry experiments the whole 
spleen and mesenteric lymph nodes (MLN) were collected and placed in tubes 
containing RPMI 1649 medium supplemented with GlutaMAX (Life Technologies), 
penicillin/streptomycin (Thermo Fisher Scientific) and 5% Foetal Bovine Serum (FBS) 
(Thermo Fisher Scientific).   
 
2.5.2 Dissection of Intestines 
 
The stomach and caecum were dissected out and discarded. The small intestine 
and the large intestine were flushed with HBSS (phenol red, calcium and magnesium 
free (Thermo Fisher Scientific) containing HEPES buffer (Gibco) (1:100). Depending on 
the purpose, the intestines were processed in different ways that will be described below. 
For tissue fixation, the small intestine was opened longitudinally and sections with 
different sizes were rolled into a “Swiss roll-like” structures using dissection tweezers, 
pinned with a needle and fixed in 10% formalin (Sigma-Aldrich) (section 2.5.3). The 
whole large intestine was rolled into “Swiss-like rolls” and fixed (section 2.5.3). 
For gene expression analysis, a section of the small intestine (between the 5th cm 
of the small intestine and the 12th cm) was opened longitudinally and cut into small 
fragments. The intestinal fragments were brought to the main laboratory in a 50 ml tube 
with HBSS containing HEPES buffer. 
For flow cytometry analysis the whole small and large intestines were open 
longitudinally and cut into small fragments that were placed into in a 50 ml tube with 
HBSS containing HEPES buffer. 
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2.5.3 Tissue Fixation 
 
All tissues were quick-fixed in 10% neutral buffered formalin (Sigma-Aldrich) for 
24 hours at 4 ºC. After that, the formalin was replaced by 70% ethanol (EtOH) and kept 
at 4 ºC until paraffin embedding. 
 
2.5.4 Paraffin Embedding  
 
After the fixation, the tissues were transferred to an embedding cassette 
(ThermoFisher Scientific) and processed using an automated processor (Leica TP1050). 
The tissues were dehydrated by immersion into increasing alcohol gradients (70% EtOH 
for 1 h, 95% EtOH for 1 h, 2x 100% EtOH for 1.5 h and 100% EtOH for 2 h) and 2x xylene 
for 2 h. Following the dehydration, the tissues were placed in liquid paraffin 3x for 1h 
each. The samples were then removed from the cassette and embedded in paraffin wax 
by hand and allowed to harden. 
 
2.5.5 Sectioning of Paraffin Embedded Tissue  
 
In order to prepare the tissue for Haematoxylin and Eosin staining (H&E, section 
2.6.2) and immunohistochemistry (IHC, section 2.6.3), the paraffin embedded tissue was 
cut by a microtome (Leica RM2135) to 5 µm sections. The sections were placed on Poly-
L-Lysine (PLL) coated slides and baked at 58 ºC for 24 h. 
Paraffin embedding, sectioning and H&E staining were performed by Derek 
Scarborough and Mark Isaac. 
 
2.6 Histological Analysis 
 
2.6.1 Preparation of Sections for H&E and IHC 
 
Paraffin embedded tissue sections on PLL slides were dewaxed by immersion in 
xylene (Fisher Scientific) 2x for 5 min. The PLL slides were then rehydrated through 
incubations in a gradient of decreasing EtOH (VWR) (2x 3min in 100% EtOH, 1x 3min in 
95% EtOH, 1x 3min 75% EtOH). The slides were removed and placed in dH2O in 
preparation for IHC staining. 
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2.6.2 Haematoxylin and Eosin (H&E) Staining 
 
H&E was performed to allow the visualization of tissue morphology. Haematoxylin 
stains the cell nuclei, whereas Eosin marks the cytoplasm. 
PLL slides were dewaxed and rehydrated as previously described (section 2.6.1) 
and immersed in Mayer´s Haemalum (R.A. Lamb) for 45 secs, removed and briefly 
washed in running tap water. Slides were then stained with 1% Eosin (R.A. Lamb) 
solution for 5 min and washed again in running tap water to remove excess stain. Slides 
were dehydrated and mounted as described in section 2.6.3.7. 
 
2.6.3 Immunohistochemistry (IHC) 
 
IHC enabled the visualization of presence and location of specific proteins in the 
tissue PLL samples. The generic protocol will be described below, whereas the specific 
conditions for each target are described in Table 2.3. 
 
2.6.3.1 Blocking of Endogenous Peroxidise Activity 
 
The visualization of the antibodies involves an enzymatic reaction catalysed by 
horse radish peroxidase (HRP), so it is essential to block endogenous peroxidase 
activity. The slides were placed for 35 min in a peroxidase block solution (832 mg Citric 
Acid (Sigma-Aldrich), 2.2 g Sodium Dihydrogen Phosphate Dihydrate (H₂NaO₄P * 2 H₂O, 
Fluka), 10 ml of 30% Hydrogen Peroxide (H2O2, Sigma-Aldrich) in 200 ml dH2O). 
 
2.6.3.2 Antigen Retrieval 
 
During fixation of the tissue it is possible that cross-linking bonds of amino-acids 
could form, altering the biochemistry of the proteins and masking the epitope of interest. 
When this happens, the epitope is no longer able to bind to the primary antibody having 
a negative impact on the IHC. Performing antigen retrieval allowed the unmasking of the 
antigen, restoring the epitope-antibody binding. 
Slides were boiled in a pre-warmed solution of Tris Buffered EDTA (stock solution: 
12.1 g of Tris Base (Fisher Scientific) and 0.93 g of EDTA (Sigma-Aldrich) in 50 ml dH2O; 
working solution: 20 ml of the stock solution in 1 L dH2O, pH 8.0) for 50 min in a 1.5L 
beaker at approximately 225 ºC. Following the antigen retrieval, the slides were left (in 
Tris EDTA buffer) at RT for 30 min to cool down. After that, they were washed 3x for 3 
min in 1x PBS (Fisher Scientific). 
A circle around each section was draw using an ImmEdge PAP pen (Vector Labs), 
and slides were placed in a humidified chamber. 
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2.6.3.3 Blocking of Non-specific Antibody Binding 
 
Tissue sections were incubated for 30 min with normal serum that was derived 
from a different species that the primary antibody was raised in. Details of the serum for 
each antibody are indicated in Table 2.3.  
 
2.6.3.4 Primary Antibody Treatment 
 
After blocking non-specific binding of the antibody, the serum was removed and 
the primary antibody, previously diluted in 1% Bovine Serum Albumin (BSA, Sigma-
Aldrich), was applied and incubated. Slides were washed 3x 3 min in PBS. Slides were 
covered with parafilm (Sigma-Aldrich) in order to guarantee the hydration of the tissue 
and equal distribution of the antibody. Slides were washed 3x 3 min in PBS.  The 
conditions for each antibody can be found in the Table 2.3. 
 
2.6.3.5 Secondary Antibody Treatment 
 
The secondary antibody was chosen to recognise specifically the primary 
antibody species and isotype. The tissue sections were incubated with the secondary 
antibody for 30 min at RT. Slides were washed 3x 3 min in PBS.  Details of the secondary 
antibodies are in Table 2.3. 
 
2.6.3.6 Visualization of Antibody Binding 
 
To visualize the target protein antigen, its location and relative levels in the tissue 
sections an enzyme-specific, chromogenic colour development was used according to 
manufacturer’s recommendations. Slides were incubated with the appropriate 
chromogen for 3 min at RT and washed 1x 3 min in dH2O and 3x 3 min in PBS.  The 
chromogens utilised for each antibody are shown in Table 2.3. 
 
2.6.3.7 Dehydration and Mounting of Slides 
 
Slides were placed for 50 secs in Mayer’s medium for counterstain and briefly 
washed in running water until becoming clear. Sections were dehydrated in ascending 
alcohol concentrations (1x 2 min 70%, 1x 2 min 95%, and 2x 2min 100%) and 2x 5min 
in xylene. Slides were mounted using DPEX (ThermoFisher Scientific) and appropriate 
coverslips (ThermoFisher Scientific) and left to dry overnight. 
Slides were scanned in the Axio Scan.Z1 Zeiss, using a 20x magnification. 
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Table 2.3 Antibody-specific conditions used for IHC 
 
Primary 
antibody 
 
Manufacturer 
 
Serum 
Block 
Primary 
antibody 
conditions  
 
Secondary 
antibody 
 
Chromogen 
 
 
Anti-
Mouse/Rat 
Foxp3 
 
 
 
eBioscience 
 
2.5% Normal 
goat serum 
(Vector 
Labs) 
 
 
1:500, 
O/N at 4 ºC 
 
Anti-Rat 
(Mouse 
adsorbed) 
(ImmPRESS 
HPR, Vector 
Labs) 
 
DAB 
(Peroxidase 
substrate kit, 
Vector Labs) 
 
 
Rat Anti-
Mouse CD8 
 
 
 
eBioscience 
 
2.5% Normal 
goat serum 
(Vector 
Labs) 
 
 
1:200, 
O/N at 4 ºC 
 
Anti-Rat 
(Mouse 
adsorbed) 
(ImmPRESS 
HPR, Vector 
Labs) 
 
DAB 
(Peroxidase 
substrate kit, 
Vector Labs) 
 
 
Rat Anti-
Mouse CD4 
 
 
 
 
eBioscience 
 
2.5% Normal 
goat serum 
(Vector 
Labs) 
 
 
1:100, 
O/N at 4 ºC 
 
Anti-Rat 
(Mouse 
adsorbed) 
(ImmPRESS 
HPR, Vector 
Labs) 
 
DAB 
(Peroxidase 
substrate kit, 
Vector Labs) 
 
Rabbit Anti-
Human CD3 
(Polyclonal) 
 
 
 
DAKO 
 
2.5% Normal 
horse serum 
(Vector 
Labs) 
 
 
1:300, 
O/N at 4 ºC 
 
 
Anti-Rabbit 
(ImmPRESS 
HPR, Vector 
Labs) 
 
VIP 
(Peroxidase 
substrate kit, 
Vector Labs) 
 
 
Anti-Mouse 
Beta-catenin 
 
 
 
BD 
Biosciences 
 
 
1% BSA 
 
 
1:100, 
1h30 at RT 
 
Anti-Mouse 
(ImmPRESS 
HPR, Vector 
Labs) 
 
SG 
(Peroxidase 
substrate kit, 
Vector Labs) 
45 
 
2.7 Cell Counting 
 
 To quantify histological sections the images that were acquired in the Zeiss Axio 
Scan.Z1 slide scanner were analysed using the ZEN image analysis software. Analysis 
was done from areas that were not crosscut and without staining artifacts. At least four 
biological replicates per cohort were analysed. Statistical analysis was conducted as 
explained in section 2.13. 
 
2.7.1 Total Tumour Burden 
 
To analyse the total tumour burden, the whole crypts touching the basement 
membrane with positive nuclear B-catenin staining (aberrant crypts), from both small and 
large intestines, were counted. The paraffin embedded tissues were cut into three serial 
sections separated by 120 µm distance to avoid the quantification of the same aberrant 
crypts. Data was normalised by counting the total number of whole crypts touching the 
intestinal basement membrane. 
 
2.7.2 Partial Tumour Burden 
 
Partial tumour burden was analysed by assessing the number of whole crypts with 
positive nuclear B-catenin in 100 crypts of the first 5 cm of the small intestine. The 
average number of aberrant crypts was calculated and the mean across the cohorts was 
determined. 
 
2.7.3 Apoptotic Index 
 
Apoptotic index was determined from H&E sections. Apoptotic bodies were 
identified based on their appearance and their number was scored per crypt from 25 
whole crypts. The average number of mitotic cells was calculated and the mean across 
the cohorts was determined. 
 
2.7.4 Scoring of Immune Cell Types 
 
The number of Tregs was determined by Foxp3 IHC staining. Cells were quantified 
in both small and large intestines in the Lgr5CreERT2 Apcfl/fl mouse model in the 
surrounding tissue of normal and aberrant crypts of at a minimum number of 5 fields of 
view of at least 50μm2. Foxp3 scoring was performed by Dr. Lee Parry prior the start of 
my project.  
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For the Apcmin mouse model, the number of Tregs was quantified in polyps and in 
a similar area of the surrounding normal tissue of the small intestine. The area was 
determined using the ZEN image analysis. Data were normalised by the number of Tregs 
per 1000μm2. 
The number of CD4 and CD8+ T-cells was determined by CD4 and CD8 
respectively IHC staining. Cells were counted from 25 normal and 25 aberrant whole 
crypts. The average number of positive cells was calculated and the mean across the 
cohorts was determined. 
 
2.8 Intestinal Epithelial Cells Extraction for Gene Expression Analysis  
 
After dissecting the tissue (section 2.5.2), the fragments were washed gently 3x 
with HBSS containing HEPES (1:100). The supernatant was discarded, 10ml 8mM EDTA 
(Sigma-Aldrich) were added to the intestinal fragments and left incubating on ice for 30 
min. After that, falcon tubes containing the fragments were shaken vigorously, before 
being allowed to settle. Supernatant was collected into a fresh 50ml tube containing 10ml 
complete RPMI 1649 medium supplemented with GlutaMAX (Life Technologies), 
penicillin/streptomycin (Thermo Fisher Scientific) and 10% Foetal Bovine Serum (FBS) 
(Thermo Fisher Scientific). Further 10ml complete RPMI media were added to the 
fragments and re-shaken. Fragments were filtered through a 70 µm cell strainer (MACS) 
and supernatant collected. The 50ml tubes containing the supernatant were spun down 
at 1000rpm for 5 minutes. Supernatant was discarded and pellet was re-suspended in 
1ml RNA later (Sigma-Aldrich). 
 
2.9 RNA extraction 
 
The intestinal epithelial cells extracted (section 2.7) were disrupted with 500 µl RLT 
buffer (QIAGEN) and the RNA was purified with RNeasy mini kits (QIAGEN) according 
to manufacturer’s recommendations. RNA was quantified using a NanoDrop 2000 
spectrophotometer (ThermoFisher Scientific) and stored at -80 ºC. 
 
2.10 Gene Expression Analysis: Quantitative Real-Time PCR (qRT-PCR) 
 
RNA extracted (section 2.8) was reverse transcribed to generate complementary 
DNA (cDNA) using Superscript III Reverse Transcriptase (Invitrogen) according to the 
manufacturer’s instructions. Quantitative real-time PCR was performed using either 
TaqMan® (table 2.4) or SYBR® Green (Table 2.5) assays.  
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For the TaqMan® assays the reaction was performed in a final volume of 10 µl 
containing 2 µl of diluted (1:5) cDNA sample (200ng), 5µl of 2x Gene Expression 
TaqMan® Master Mix (Applied Biosystems) and 0.5µl of 20x TaqMan® Gene Expression 
Assay probes (Applied Biosystems).  
The SYBR® Green assays were performed in a final volume of 20 µl containing 1 
µl of cDNA sample (1000 ng), 10 µl of Fast SYBR® Green Master Mix (Applied 
Biosystems) and 0.5 of 10µM forward and reverse primers (Applied Biosystems). All 
samples were prepared in triplicate, including a blank for each target gene. 
Reactions were performed on an Applied Biosystems QuantStudio 7 Flex Real 
Time Machine. Relative expression of mRNA was calculated using the ΔΔCt method and 
ACT B was used as an internal control. Statistical analysis was conducted as explained 
in section 2.13.
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Table 2.4 TaqMan® qRT-PCR primers/probes 
 
 
Table 2.5 SYBR® Green qRT-PCR primers 
 
 
 
2.11 Flow Cytometry 
 
2.11.1 Preparation of Single Cells Suspensions from Tissues 
 
2.11.1.1 Spleen and Mesenteric Lymph Node (MLN) Lymphocyte Extraction 
 
Mice were harvested and spleen, MLN, small intestine (SI) and large intestine 
(LI) were collected as explained in section 1.5.1.  
Gene Identification Species Source 
ACTB (DQ) Mix 20x  Mus musculus Applied Biosystems 
Lgr5 Mm00438890_m1 Mus musculus Applied Biosystems 
Olfm4 Mm01320260_m1 Mus musculus Applied Biosystems 
Ascl2 Mm01268891_g1 Mus musculus Applied Biosystems 
Ifng Mm01168134_m1 Mus musculus Applied Biosystems 
Foxp3 Mm00475162_m1 Mus musculus Applied Biosystems 
Gene Forward sequence Reverse sequence Species Source 
ACTB TGT TAC CAA CTG 
GGA CGA CA 
GGG GTG TTG AAG 
GTC TCA AA 
Mus musculus Applied 
Biosystems 
Axin2 GCA GCT CAG CAA 
AAA GGG AAA T 
TAC ATG GGG AGC 
ACT GTC TCG T 
Mus musculus Applied 
Biosystems 
cMyc CTA GTG CTG CAT 
GAG GAG ACA C 
GTA GTT GTG CTG 
GTG AGT GGA G 
Mus musculus Applied 
Biosystems 
CIITA ACC CCC TAC ATC 
TCT ACC ACC T 
TCG CAG TTG ATG 
GTA TCT GTG T 
Mus musculus Applied 
Biosystems 
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Spleen and MLN were homogenized using the back of a 1ml syringe plunger 
through a 70 µm cell strainer (MACS) and rinsed through with 4ml complete RPMI. The 
single cell suspensions were centrifuged at 1500 rpm for 5 minutes, supernatant was 
aspirated. MLN pellet was resuspend in 0.5 ml. Spleen pellet was resuspend with 2 ml 
red blood cells lysis buffer (Sigma) for 2 min at 37°C. 10 ml of complete RPMI was then 
added in order to stop the reaction and cells were centrifuged at 1500 rpm for 5 minutes. 
Supernatant was discarded and the pellet was resuspend in 5 ml complete RPMI media.  
 
2.11.1.2 Small and Large Intestine Lymphocyte Extraction 
 
Both SI and LI were dissected and collected as explained in section 2.5.2. 
 
2.11.1.2.1 Intra epithelial lymphocyte (IEL) fraction. 
 
15 ml of pre-warmed complete RPMI media with 5mM EDTA were added to the 
tubes containing the tissue and they were placed in a thermomixer (Eppendorf) at 300 
rpm at 37°C for 20 minutes. Supernatant was collected, through a cell strainer, and 
placed to a fresh tube containing 5 ml complete RPMI media with 10 mM HEPES (Gibco). 
Another 15 ml of pre-warmed complete RPMI media with EDTA were added to the tissue 
and incubation was repeated in the thermomixer. Supernatant was collected and placed 
in the collection tube. 10 ml of complete RPMI media with HEPES were added to the 
tissue and incubation was repeated. Supernatant was collected and placed in the 
collection tube.  
 
2.11.1.2.2 Lamina propria lymphocyte (LPL) fraction 
 
In order to obtain the LPL fraction, the tissue was incubated in the thermomixer 
for 45 minutes with 10 ml complete RPMI media containing 1mg/ml collagenase VIII 
(Sigma) and 200U/ml DNAse II (Sigma). Whilst tissue was digesting, Percoll (GE Health 
Life Sciences) density gradients were prepared. Percoll solutions were prepared the day 
before using sterile PBS or RPMI in the tissue culture hood and kept overnight at 4°C.  
100% Percoll was prepared using 10X PBS (Fisher Scientific) (1:10), 75% and 30% 
Percoll were diluted in 1x PBS and the 40% Percoll in RPMI. A 15 ml tube was laid flat 
against the bench, with the head of the tube resting on its lid. Using a pipette pump, the 
40% Percoll solution (pink) was slowly layered on top of the 70% Percoll solution (clear), 
then the tube was carefully turned upright. The tubes were stored at 4°C for later use. 
Following digestion, 200 µl EDTA was added to the LPL fraction to inhibit collagenase 
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activity and the tissue was further disrupted in a gentleMACS dissociator (MACS). Cells 
from the LPL fraction were collected through a cell strainer and placed into a fresh tube.  
Tubes containing cells from SI (IEL & LPL) and LI (IEL & LPL) were centrifuged 
for 5 minutes at 1500 rpm. Supernatant was aspirated and resuspend in 3 ml 30% Percoll 
solution (clear). Carefully, it was added to the pre-prepared Percoll gradients as 
previously described. Tubes were centrifuged at 1800 rpm for 20 minutes with the brake 
off. Supernatant was aspirated until half of the 40% Percoll solution remained. 
Lymphocytes were collected and placed into a 15 ml tube containing 12 ml complete 
RPMI media, then centrifuged at 1500 rpm for 5 minutes. 
 
2.11.2 Cell Surface Staining 
 
0.2 – 1 x 106 lymphocytes from the different compartments (i.e. spleen, MLN, SI 
IEL, SI LPL, LI IEL and LI LPL) were plated out in a 96 round-bottomed well plate. Cells 
were washed twice in 200 µl PBS 1x. Dead cells were stained by adding and mixing well 
3 µl of aqua amine-reactive viability dye (LIVE/DEAD Aqua, Invitrogen), previously 
diluted in PBS 1x (1:10), to the cell pellet and incubated for 15 minutes in the dark at 
room temperature. Cold FACS buffer (PBS containing 2% FBS and 5mM EDTA) was 
used to wash twice the cells prior the incubation with 50 µl per well of Fc Receptor block 
(eBioscience) diluted (1:200) in FACS buffer. Cells were incubated at 4°C in the dark for 
10 minutes. After washing the cells twice with FACS buffer, they were stained with a 
surface stain panel (Table 2.3). A master mix of the antibodies, diluted in FACS buffer, 
was prepared and 25 µl of the mix was added to each well. Cells were incubated with 
the antibodies for 15 minutes at 4°C in the dark and washed twice in FACS buffer.  
 
2.11.3 Intracellular Antigen and Cytokine Staining 
 
To analyse intracellular cytokines, 0.2 – 1 x 106 cells were stimulated for 3 hours 
with complete RPMI media containing 50 ng/ml phorbol myristate acetate (PMA; Sigma 
– Aldrich), 1 µl/ml ionomycin (Sigma – Aldrich) and 5 µg/ml brefeldin A (Sigma – Aldrich). 
After the stimulation was completed, cells were fixed and permeabilized with 200 
µl of fixation / permeabilization solution (Foxp3 staining kit, eBioscience) overnight 
(maximum 16 hours) at 4°C in the dark. Cells were washed twice with 1x 
permeabilization buffer (eBioscience) and a master mix of the antibodies to stain 
intracellular markers/cytokines (Table 2.6) was prepared. The antibodies were diluted in 
1x permeabilization buffer and 25 µl of the master mix was added to each well. Cells 
were incubated for 30 minutes at 4°C in the dark and washed twice in 1x permeabilization 
buffer. Finally, the pellets were resuspend in 200 µl FACS/fix buffer (FACS buffer with  
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2% formaldehyde (Fisher Scientific)). Single staining and Fluorescent Minus One (FMO) 
controls were included in the analysis. FMO’s correspond to a sample that is incubated 
with the antibodies minus a specific one, helping in the choice of the correct position of 
gates during the analysis. Samples were run in a NovoCyte ® 3000 cytometer. 
 
Table 2.6 Flow Cytometry Antibodies 
 
 
Antibody 
 
 
Fluorochrome 
(Conjugate) 
 
Clone 
 
Isotype 
 
Dilution 
 
Company 
Surface Antibodies      
 
Anti-Mouse CD3 
 
 
AF488  
 
145-2C11 
Armenian 
hamster 
IgG 
 
1 in 50 
 
eBioscience 
 
Anti-Mouse CD4 
 
 
BV421  
 
GK1.5 
Lewis 
IgG2b, κ 
 
1 in 80 
 
 
BD Biosciences 
 
Rat Anti-Mouse 
CD8 
 
 
APC-H7  
 
53-6.7 
 
LOU/M 
IgG2a, κ 
 
1 in 100 
 
BD Biosciences 
Intracellular 
Antibodies 
     
 
Anti-Mouse/Rat 
Foxp3 
 
 
PeCy7 
 
FJK-16s 
 
IgG2a, 
kappa 
 
1 in 50 
 
eBioscience 
 
Anti-Human/Mouse  
Granzyme B 
 
 
APC 
 
 
QA16A02 
 
 
Mouse 
IgG1, κ 
 
1 in 50 
 
Biolegend 
 
Rat Anti-Mouse 
 IL-17A 
 
 
PE 
 
TC11-
18H10 
 
Lewis 
IgG1, κ 
 
1:100 
 
BD Pharmingen 
 
Rat Anti-Mouse 
IFN- 
 
 
PerCP-
Cy™5.5 
 
XMG1.2 
 
Rat IgG1, 
κ 
 
1 in 50 
 
BD Pharmingen 
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2.11.4 Flow Cytometry Analysis 
 
Flow cytometric data were analysed using the FlowJo version 10 and NovoExpress 
software. Gating strategy is represented in Figures 2.1 – 2.5. 
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Lymphocytes were identified based on forward (FSC) and side scatter (SSC) characteristics. Then, live cells were gated based on negative Amcyan staining. 
Single cells were gated based of forward scatter area (FSC-A) and height (FSC-H) characteristics. CD3+ cells were gated from singles cells and both CD4+ 
and CD8+ cells were gated from CD3+ cells. Fluorescence Minus One (FMO) controls were used to help the gating correctly the populations of interest. The 
same gating strategy was applied to all the markers analysed in each cell compartment. 
  
Figure 2.1  Representative flow cytometry plots showing gating strategy and examples of FMO’s in the spleen. 
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Figure 2.2 Gating strategy for flow cytometry analysis of the indicated markers in each cell 
compartment analysed (spleen, MLN, SI IEL, SI LPL, LI IEL and LI LPL). 
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Figure 2.3 (Continuation) Gating strategy for flow cytometry analysis of the indicated markers in 
each cell compartment analysed (spleen, MLN, SI IEL, SI LPL, LI IEL and LI LPL). 
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Figure 2.4 (Continuation) Gating 
strategy for flow cytometry analysis 
of the indicated markers in each cell 
compartment analysed (spleen, 
MLN, SI IEL, SI LPL, LI IEL and LI 
LPL). 
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Figure 2.5 (Continuation) Gating 
strategy for flow cytometry 
analysis of the indicated markers 
in each cell compartment 
analysed (spleen, MLN, SI IEL, 
SI LPL, LI IEL and LI LPL). 
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2.12 Lgr5 RNAscope® 
 
RNAscope allows the detection of RNA single molecules and their quantification 
in single cells. 
 
2.12.1 Preparation of Sections for RNAscope 
 
Prior to RNAscope, the PLL slides were baked in a dry oven for 1 h at 60°C. After 
that slides were dewaxed by immersion in fresh xylene 2x for 5 min and in 100% EtOH 
2x for 1 min. The slides were left to air dry for 5 min at RT. A circle around the tissue 
section was drawn using an ImmEdge PAP pen. 
 
2.12.2  Pre-treatment  
 
The pre-treatment of the tissue allows an improved accessibility to the target 
RNA. 
 
2.12.2.1 Blocking of Endogenous Peroxide Activity 
 
To block the activity of endogenous peroxides, the tissue was covered with H2O2 
(ACD Bio, pre-treatment 1) for 10 min at RT. After that, the H2O2 was removed and the 
slides were washed 2x for 5 min in dH2O. 
 
2.12.2.2 Antigen Retrieval 
 
Slides were boiled in a pre-warmed Target Retrieval (ACD Bio, pre-treatment 2) 
solution for 15 min in a 1.5 L beaker at approximately 100°C. Slides were carefully 
removed and washed 2x for 5 min in dH2O.  
 
Slides were washed briefly with 5 dips in EtOH and left to dry at RT either for 5 
min or overnight. 
 
2.12.2.3 Protease plus Treatment  
 
Together with the antigen retrieval, the protease plus treatment allow the 
RNAscope probes to access RNA by breaking cross links that could have occurred 
during the tissue fixation. 
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Slides were covered with protease plus (ACD Bio, pre-treatment 3) and incubated 
in a HybEZ oven at 40°C for 15 min. Slides were removed and washed 2x for 1 min in 
dH2O. 
 
2.12.3  Probe Hybridization 
 
The Lgr5 probe (mmLgr5, ACD Bio) was applied to the slides and placed in the 
HybEZ oven at 40°C for 2 h. A negative (dapB, ACD Bio) and a positive (mmPpib, ACD 
Bio) control were also included. Slides were removed and washed in 1x wash buffer 
(ACD Bio) 2x for 2 min.  
 
2.12.4  Probe Hybridization and Amplification 
 
The probe hybridization and amplification occur as a cascade of events. The 
probe amplification was done using the RNAscope® 2.5 HD Reagent Kit-BROWN (ACD 
Bio) kit. The conditions for the amplification steps are detailed in Table 2.7. Between 
each amplification step the slides were washed 2x for 2 min in wash buffer. 
 
Table 2.7 Amplification steps conditions 
Amplification Step Time (min) Temperature (°C) 
 #1 30  40 
 #2 15 40 
#3 30 40 
 #4 15 40 
 #5 30  RT 
 #6 15  RT 
 
2.12.5  Signal Detection 
 
To detect the signal the RNAscope® 2.5 HD Reagent Kit-BROWN (ACD Bio) kit 
was used. Equal volumes of DAB-A and DAB-B were mixed into an appropriate sized 
tube, dispensed on the tissue samples and incubated for 10 min at RT. The excess was 
disposed and the slides were washed 2x for 2 min in dH2O. 
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2.12.6  Counterstain and Slides Mounting 
 
Slides were placed in 50% haematoxylin diluted in Milli-Q H2O for 30 seconds at 
RT and briefly washed in running water until becoming clear. Slides were dehydrated in 
ascending alcohol concentrations (1x 2min 70% EtOH and 2x 2min 100% EtOH) and for 
5 min in xylene. Slides were mounted using DPEX and appropriated coverslips and left 
to dry overnight. 
 
2.12.7 RNAscope Analysis 
 
To analyse the RNAscope data, the number of punctate dots from 25 crypts and 
25 villi from the first 5 cm of the SI and LI were counted for each experimental group. 
 
 
2.13 Statistical Analysis 
 
Data presented were analysed using Graph Pad Prism 7 software. The Mann-
Whitney U test, unpaired and two-tailed was used and p values less than 0.05 were 
accepted as statistically significant different. For analysis of qRT-PCR gene expression 
Whitney U test, unpaired and one-tailed was used due to a small n number (number of 
mice per cohort) of some groups.
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3 Investigating the immune effects of Apc deficiency in the 
early stages of CRC 
3.1 Introduction 
 
The canonical Wnt pathway, a conserved signalling pathway involved in 
development, regeneration, survival and cell proliferation, is crucial to the maintenance 
of homeostasis within the intestinal epithelia. Deregulation of this pathway occurs in 80% 
of human CRCs, including the loss of function of the tumour suppressor gene APC, 
leading to aberrant stem cell differentiation (Mazzoni and Fearon 2014).  
The intestinal epithelium is a dynamic tissue where stem cells continuously 
proliferate, migrate and differentiate. Intestinal stem cells are found in the crypts and are 
generally known as Crypt Base Columnar (CBC) cells (Gerbe et al. 2011). CBC cells 
proliferate and originate the cell progenitors that migrate along the villi. Depending on 
the specific signals that are received, cell progenitors differentiate into the different cell 
types that are found in the intestine (e.g. Goblet cells, Paneth cells, and others) (Gerbe 
et al. 2011). This process of migration and differentiation is controlled by conserved 
signalling pathways such as Wnt signalling and Notch pathways. CBC cells, which are 
maintained by the Paneth cells, can be identified by the expression of markers such as 
Lgr5, Sox9 and Olfm4. It was demonstrated that, when the Apc gene is deleted, stem 
cells are transformed, do not differentiate and lead to the development of adenomas 
(Barker et al. 2009). 
Previous studies have demonstrated that CRC progression depends on the 
interaction between the tumour and the host immune environment, comprising diverse 
cell types. Some of these cells include the CD4+ T cell population, which comprises 
regulatory T (Treg) cells and conventional T helper (Th) cells. Several CD4+T cell 
subsets are found within these two broad categories (Szabo et al. 2003; Corthay 2009; 
Zhu and Paul 2010; Tripathi and Lahesmaa 2014; Kaplan et al. 2015; Vlad et al. 2015). 
Th cells activate other effector immune cells, controlling the adaptive immune 
response against foreign agents and cancer. On the other hand, Tregs are responsible 
for suppressing the activity of Th cells. Some of the specific functions of Tregs include: 
limiting inflammatory responses, the maintenance of tolerance to self-antigens tolerance 
thereby preventing the occurrence of autoimmune diseases, feto-maternal tolerance, 
suppression of allergy, and others (Corthay 2009). It is essential that a balance exist 
between the activities of these two cell populations. 
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The best Treg marker is Foxp3, a transcription factor that has an important role in 
the development, phenotype and functional maintenance of Tregs (Bennett et al. 2001; 
Fontenot et al. 2003). 
It has been demonstrated that evaluating the density of CD3+ T-cells may have a 
higher prognostic value when compared to the routinely used TMN stage (Galon et al. 
2006). While an increased tumour infiltration by some cell populations (e.g. CD8+ and 
CD45RO+) has been associated with favourable prognosis in CRC (Pages et al. 2005; 
Koch et al. 2006), the role of Tregs in this pathology is still unclear (Fontenot et al. 2003; 
Maeda et al. 2011). 
Previous studies have shown that CRC patients have an increased number of 
Tregs (Betts et al. 2012; Syed Khaja et al. 2017). As Tregs suppress the activity of 
cytotoxic T cells, they are considered to have an inhibitory effect on the anti-tumour 
immune response being associated with disease progression, thus CRC patients with 
increased levels of Tregs have a poor prognosis (Betts et al. 2012; Liu et al. 2014), 
however there are some contradictory studies which suggest that Tregs may limit 
disease progression, possibly through suppressing the activity of tumour-promoting 
inflammatory cells (Erdman et al. 2005).  
Considering that the majority of the previous studies were done in patients with 
advanced disease, I aimed to clarify the role of Tregs in the early stages of intestinal 
cancer, by analysing the immune changes in the murine intestines upon conditional Apc 
deletion in the intestinal stem cells (ISCs). 
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3.2 Results 
 
3.2.1 Characterisation of Treg cells during tumourigenesis in the Apcmin/+ 
mouse 
 
 Apcmin/+ mice develop multiple polyps that can progress to adenocarcinoma, 
mimicking what happens to patients with FAP disease (see section 1.4.1). Previous 
studies have demonstrated that Tregs accumulate in intestinal adenomas of Apcmin/+ mice 
(Akeus et al. 2014; Chae and Bothwell 2015). Akeus and colleagues have shown, in 
mice between 70 and 154 days old (d.o.), increased frequencies of Tregs in adenomas 
of Apcmin/+ mice when compared to surrounding normal tissue. 
 Here the number of Tregs in polyps present in the small intestine of Apcmin/+ mice 
and normal adjacent tissue from mice at 60 d.o. and 180 d.o was quantified. Data were 
normalised by the number of Tregs per 1000μm2. The minimum number of polyps 
present in a mouse was one and the maximum 13. 
 Intestinal sections were stained using IHC against B-catenin (grey) and Foxp3 
(brown). The polyps were identified by their aberrant position in the tissue or by the 
positive B-catenin nuclear staining in the small intestinal crypts.  
In accordance with previous reports (Akeus et al. 2014; Chae and Bothwell 2015) 
I found an increased number of Tregs in the polyps of 60 & 180 d.o. mice in comparison 
to normal surrounding tissue of the small intestine (Figure 3.1 Ai, Aii and 3.1 B). Despite 
comparable increases in total numbers of Tregs at both time points in polyps, when 
compared to normal adjacent tissue, the density and number of Tregs is reduced in the 
larger 180 d.o. polyps (Figure 3.1 B&C) when compared to 60 d.o. mice (Figure 3.1 B & 
C), indicating that Tregs accumulate in the polyps and may play a role in the early stages 
of the disease. 
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(A)Representative images of B-catenin (grey) and Foxp3 (brown) IHC staining of 60 d.o. and 180 
d.o. age matched mice in normal tissue and polyps. Tregs are identified with black arrows. (B) 
Scoring of the Foxp3 IHC stained cells revealed an increased number of Tregs in polyps (A ii) 
compared to normal tissue in 60 d.o. mice (A i). There is no significant different in the number of 
Tregs between normal tissue (A iii) and polyps (A iv) in 180 d.o. mice. (C) Quantification of the 
polyps area in 60 and 180 d.o. mice. Polyps have an increased area in older mice. (*) P value ˂ 
0.05, (****) P value ≤ 0.0001. Data represent the quantification of at least one polyp and 
surrounding normal tissue. The maximum number of polyps identified in a mouse was 13, n ≥ 4 
Figure 3.1 Tregs quantification in the small intestine of an Apcmin/+ mouse model. 
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mice. Two-tailed Mann Whitney U test. Error bars represent Standard Deviation (SD). Scale bars 
represent 50 µm.  
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3.2.2 Characterising Treg cells during initiation of intestinal tumourigenesis by 
conditional deletion of the Apc gene in the intestinal stem cells (ISCs) 
 
The Apcmin/+ mouse model is an important model for the study of intestinal 
tumorigenesis, but the requirement for a “second hit” to remove the WT allele limits 
studies of tumour initiation.   
To overcome the limitations of the Apcmin/+ model, we used the Lgr5CreERT2Apcfl/fl 
mouse model which allows temporal and conditional deletion of the tumour suppressor 
gene Apc and activation of the Wnt pathway in the Lgr5 ISCs. Detailed description of the 
mouse model can be found in section 1.4.3. Here, Treg numbers were characterized in 
the intestines by IHC, gene expression of Foxp3 in the small intestine and frequency of 
Foxp3 by flow cytometry in mice 15 days after ISC deletion of Apc. 
 
3.2.2.1 Apc deletion in ISCs increases the number and frequency of Tregs  
 
Paraffin sections of both non-induced and induced mice were stained with B-
catenin (grey), Foxp3 (brown) and CD3 (purple) antibodies. Tregs were quantified in both 
small (SI) and large (LI) intestines in at least 5 random fields of view of at least 50μm2. 
The IHC data demonstrates a significant increase in the number of Tregs, after Apc 
deletion, in both SI and LI when compared to non-induced mice (Figure 3.2).  
Relative gene expression was performed in RNA extracted from epithelial cells 
from the small intestine. Relative expression of mRNA was calculated using the ΔΔCt 
method and ACT B was used as an internal control. Relative gene expression analysis 
confirmed an increased expression of Foxp3 following Apc deletion (Figure 3.3). 
Analysis by flow cytometry demonstrated the expansion of Tregs in the small 
intestine intraepithelial lymphocytes (SI IEL), small intestine lamina propria lymphocytes 
(SI LPL) and large intestine intraepithelial lymphocytes (LI IEL) (Figure 3.4). Expansion 
of Treg cells was also demonstrated in the spleen and mesenteric lymph nodes (MLN) 
(Figure S 9.1), 
Taken together, these data show that Tregs start accumulating in the intestines 
and also other compartments (spleen and MLN), soon after the loss of function of the 
tumour suppressor Apc gene suggesting that Tregs play an important role from the early 
stages of intestinal cancer. 
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Representative images of β-catenin (grey) and Tregs (brown) IHC staining of SI (A) and LI (B) 
from non-induced mice; SI (C) and LI (D) from Apc deleted mice. Tregs are identified with yellow 
arrows. (E) Scoring of Tregs revealed an increased number of Treg. (****) P value ≤ 0.0001. Data 
represents the quantification of Tregs in at least 5 random fields of view of at least 50μm2, n ≥ 3 
mice. Two-tailed Mann Whitney U test. Scale bars represent 20 µm. This analysis was performed 
by Dr Lee Parry.
Figure 3.2 Tregs quantification in the Lgr5CreERT2Apcfl/fl mouse in small (SI) and large intestines 
(LI).   
 
E) 
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Apc deletion significantly upregulates the expression of Foxp3. Data represent a single 
experiment, n ≥ 3 mice per group.  (*) P value ˂ 0.05, One-tailed Mann Whitney U test. 
 
  
Figure 3.3 Relative gene expression of Foxp3 in the small intestinal epithelium.  
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Representative flow cytometry plots of the frequency of Tregs in the small and large intestines of 
non-induced and Lgr5CreERT2Apcfl/fl mice (A). Apc deletion increases significantly the frequency 
of Foxp3+ cells in SI IEL, SI LPL (B) and LI IEL (C). Data represent a single experiment, n ≥ 5 
mice per group. (*) P value ˂ 0.05, (**) P value ≤ 0.01, (***) P value ≤ 0.001, two-tailed Mann 
Whitney U test.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Frequency of CD4+ cells expressing Foxp3 in the specified compartments of the small 
and large intestines.  
B C 
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3.2.2.2 Examining the effects of Apc deletion in T-cell populations  
 
Previous data showed for the first time that in the Lgr5CreERT2Apcfl/fl mouse model 
there is an increased number and frequency of Tregs following Apc deletion in the ISCs. 
To analyse further other immune changes caused by Apc deletion, it was performed flow 
cytometry for T-cell activation markers. Cells collected from the spleen, MLN, SI IEL, SI 
LPL, LI IEL and LI LPL were stained with CD3, CD4, CD8, Granzyme B, Foxp3, IL-17A 
and IFNγ antibodies.   
The gating strategy was based in the CD3, a T-cell marker, from which we further 
analysed the CD4+ and CD8+ T-cell sub-populations.  
The frequency of CD3+ cells, was not altered in the compartment examined 15 
days after ISC Apc deletion; SI (Figure 3.5 A), LI (Figure 3.5 B); spleen or MLN (Figure 
S 9.2), suggesting that Apc deletion does not impact in the total frequency of the T-cell 
population, however it might be different for each sub-population.  
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Apc deletion does not alter the frequency of CD3+ cells in any of the intestinal compartments (A, 
B). Data represent a single experiment, n ≥ 6 mice per group. Two-tailed Mann Whitney U test. 
 
 
 
 
  
Figure 3.5 Frequency of CD3+ T-cells in the specified compartments of the small and large 
intestines. 
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I next analysed the frequency of CD4+ and CD8+ cells. CD3+CD4+ cells were 
significantly increased in the SI IEL (Figure 3.6 A) and with no alterations in the SI LPL 
(Figure 3.6 A) or LI (Figure 3.6 B). There were no significant changes in the spleen 
(Figure S 9.3), but a decreased CD3+CD4+ cell frequency was observed in the MLN 
(Figure S 9.3)   
For the CD3+CD8+ cells, flow cytometry indicated no significant changes in this 
population in the SI (Figure 3.6 C), LI (Figure 3.6 D) or spleen (Figure S 9.4).  However, 
in contrast to the CD3+CD4+ cells, they were significantly increased in the MLN (Figure 
S 9.4). These data imply that ISC Apc deletion resulted in induction of a CD4+ cells 
immune response in the small intestine within 15 days. 
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Apc deletion resulted in a significantly increased frequency of CD4+ cells, but only in the SI IEL 
(A). There were no changes in the LI (B). Apc deletion didn’t alter the frequency of CD8+ cells in 
both SI and LI (C, D). Data represent a single experiment, n ≥ 5 mice per group.  (*) P value ˂ 
0.05, two-tailed Mann Whitney U test. 
 
Figure 3.6 Frequency of CD3+ T-cells expressing CD4 and CD8 in the specified compartments 
of the small and large intestines. 
D C 
B A 
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To further characterise this response, I analysed the expression of effector 
molecules Granzyme B, IL-17A and IFNγ which can be expressed by both CD3+CD4+ 
and CD3+CD8+ cell populations.   
The percentage of CD4+ cells producing Granzyme B is not affected in SI (Figure 
3.7 A), LI LPL (Figure 3.7 B) or spleen (Figure S 9.5) but significant increases are 
observed in LI IEL (Figure 3.7 B) and MLN (Figure S 9.5) as a result of Apc deletion. 
The frequency of Granzyme B produced by CD8+ T-cells is not affected in any of 
the cell compartments analysed after Apc deletion (Figure 3.7 C, D; Figure S 9.6). 
 These data suggest that Granzyme B does not have an impact in the early stages 
of intestinal cancer.   
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Apc deletion did not alter the frequency of CD4+ cells expressing Granzyme B in the SI (A) but 
increases significantly in the LI IEL (B). There are no changes in the LI LPL compartment (B). The 
frequency of CD8+ cells expressing Granzyme B is not affected after Apc deletion in both SI (C) 
and LI (D). Data represent a single experiment, n ≥ 4 mice per group. (***) P value ˂ 0.001, two-
tailed Mann Whitney U test. 
Figure 3.7 Frequency of T-cells expressing Granzyme B in the specified compartments of the 
small and large intestines. 
A B 
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IL-17A is an inflammatory cytokine that can be produced by either CD4+ or CD8+ 
cells, however the phenotype and function of CD8+ cells that are capable of producing 
IL-17A is poorly understood. There are studies showing that this cytokine plays a key 
role in the pathogenesis of autoimmune diseases and allergies, but it has been also 
demonstrated that it can have a protective role in the immunity against pathogens, 
indicating its controversial roles (Song and Qian 2013).  
Here, I show that, following Apc deletion, there are no alterations in the frequency 
of CD4+IL-17A+ cells in SI (Figure 3.8 A), LI (Figure 3.8 B) and MLN (Figure S 9.7), 
being only increased in the spleen (Figure S 9.7). It is important to note that there is a 
high variability in the frequencies of IL-17A in both SI and LI.  
The frequency of CD8+IL-17A+ cells is not altered in the SI following ISC Apc 
deletion (Figure 3.8 C), LI (Figure 3.8 D), spleen or MLN (Figure S 9.8). These data 
suggest that IL-17A does not participate the tumourigenesis in the early stages of 
intestinal cancer. 
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Apc deletion did not alter the frequency of CD4+ cells expressing IL-17A in the SI (A) and LI (B). 
The frequency of CD8+ cells expressing IL-17A is not affected in SI (C) or LI (D). Data represent 
a single experiment, n ≥ 5 mice per group. (**) P value ˂ 0.01, two-tailed Mann Whitney U test. 
Figure 3.8 Frequency of T-cells expressing IL-17A in the specified compartments of the small and 
large intestines. 
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Interferon gamma (IFNγ) is produced by a variability of immune cells including 
CD4+ T-cells (Th1), CD8+ T-cells, NK and NKT cells (Schoenborn and Wilson 2007).  
 The frequency of CD4+IFNγ+ cells is not altered in SI (Figure 3.9 A), LI (Figure 
3.9 B) and MLN (Figure S 9.9), being only increased in the spleen (Figure S 9.9) following 
Apc deletion. Again, it is observed a high variability in the frequencies of IFNγ in both SI 
and LI.  
Regarding to CD8+ IFNγ+ cells frequency, there are no significant changes in the 
SI (Figure 3.9 C), LI (3.9 D), spleen (Figure S 9.10) or MLN (Figure S 9.10). 
Similar to IL-17A, these data suggest that there are no alterations in the secretion 
of IFNγ+ following Apc deletion, indicating that it does not participate in the early stages 
tumourigenesis.   
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Apc deletion did not alter the frequency of CD4+ IFNγ+ cells (A, B) as well as CD8+ IFNγ+ cells 
(C, D) in both SI and LI. Data represent a single experiment, n ≥ 4 mice per group. Two-tailed 
Mann Whitney U test. 
  
Figure 3.9 Frequency of T-cells expressing IFNγ in the specified compartments small and large 
intestines. 
A B 
C D 
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3.3 Discussion 
 
CRC can arise by various genetic alterations, including the deletion of the Apc 
gene, which is part of the Wnt signalling pathway (Barker et al. 2009). It has been 
demonstrated that CRC progression also depends on the interaction between the tumour 
and the immune system (Corthay 2009). 
Previous studies have shown that CRC patients have an increased number of Treg 
cells (Syed Khaja et al. 2017). Some of these studies, including from our group (Clarke 
et al. 2006; Betts et al. 2012), indicate that an increased number of Tregs is associated 
with a bad prognosis. However, other studies have suggested the opposite; patients with 
increased levels of Tregs have a better prognosis (Sinicrope et al. 2009). Importantly, 
most of these studies were done in patients with advanced disease, however 
Rubinkiewicz and colleagues have demonstrated that Tregs increased in lymphocytic 
infiltrate of large intestinal polyps (Rubinkiewicz et al. 2016). Despite the fact that it is 
known that Tregs play a role in the pathology of intestinal cancer, there is still a need for 
clarification as to how Tregs actually promote malignant transformation.  
In this chapter I aimed to further study how the Tregs were affected in the early 
stages of intestinal cancer. To do this I started by analysing the number of Tregs in the 
small intestine of Apcmin/+ mice in two groups of age matched mice (60 and 180 d.o.). The 
Apcmin/+ mouse model develop multiple polyps in the intestine that can progress to 
adenocarcinoma. Mice of different ages gave information about the numbers of Tregs in 
the early (60 d.o.) and later (180 d.o.) stages of disease progression. I hypothesized that 
the number of Tregs would be higher in polyps compared to the normal surrounding 
tissue in both groups of mice. Data showed that, as expected, the number of Tregs is 
increased in the polyps of 60 d.o. mice relatively to the normal adjacent tissue. 
Surprisingly, the older mice (180 d.o.) did not have a significant increased number of 
Tregs in the polyps when compared to the normal adjacent tissue, despite the fact that 
the area of the polyps in these mice was bigger than those from the 60 d.o. mice. It is 
possible that the recruitment of Tregs occur primarily in the early stages of the disease 
and that in later stages there is a stabilization in the number of Tregs recruited. The data 
obtained is similar to those previously published by other groups, where it was reported 
an increased number of Tregs in the polyps when compared to normal adjacent tissue 
(Akeus et al. 2014; Chae and Bothwell 2015); however the data described here show 
that the significant increase in the number of Tregs occurs only in younger mice, 
indicating that Tregs may play an important role in very early stages of the disease. As 
previously described, the Apcmin/+ mouse model is a very useful tool to study early stages 
of intestinal cancer, however the requirement of a second “hit” to remove the WT allele 
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limits the study of tumour initiation. To overcome this issue, I used a genetically modified 
mouse model, the Lgr5CreERT2Apcfl/fl mouse model, where it is possible to conditionally 
delete the Apc gene in the ISCs in a temporal manner.  
It was demonstrated by IHC that, when the intestinal stem cell becomes malignant, 
there is an increased number of Tregs in both small and large intestines. This was also 
shown by an increase in the relative gene expression of Foxp3. The expression of 
Foxp3+ was examined by flow cytometry in different cell compartments including 
lymphocytes extracted from the spleen, MLN, epithelium and lamina propria from the 
whole small and large intestines (SI IEL, SI LPL, LI IEL and LI LPL respectively). Spleen 
and MLN were included in the flow cytometry analysis as they provide information about 
how the systemic response is affected in the different experimental groups. Apart from 
the LI LPL all the other cell compartments showed an increased frequency of CD4+ cells 
expressing Foxp3, confirming again the increased levels of Tregs following Apc deletion 
in the ISCs. 
To better understand the immune changes following Apc deletion, flow cytometry 
was performed in the previously indicated cell compartments for a panel of T-cell 
activation markers such as CD3, CD4, CD8, Granzyme B, IL-17A and IFNγ.  
Apc deletion did not alter the frequency of CD3+ cells in any of the compartments 
studied, suggesting that the total frequency T-cells was not altered, however changes in 
the frequencies of the CD4+ and CD8+ cells might have occurred. To further analyse 
this, I then looked at specifically CD4+ and CD8+ cells. These cells are associated with 
a good prognosis in patients with CRC (Diederichsen et al. 2003; Galon et al. 2006; 
Deschoolmeester et al. 2011; Shibutani et al. 2017). CD4+ T-cells include a range of 
different sub-populations that participate in the adaptive immune response by enhancing 
or suppressing the immune response. There were no significant changes in the 
frequency of CD3+CD4+ cells after Apc deletion in the spleen, however there was a 
significant decrease of CD4+ cells frequency in MLN. In the small intestine there was an 
increased frequency of CD4+ cells but only in the IEL compartment. There were no 
significant changes in the frequency of CD4+ cells in the large intestine. The frequency 
of CD3+CD8+ cells was not altered in most of the cell compartments as a consequence 
of Apc deletion in the ISCs.  
Salama and colleagues demonstrated that low expression of Granzyme B in CRC 
is associated with early metastatic invasion (Salama et al. 2011). Other studies have 
shown that high expression is associated with improved survival (Prizment et al. 2017) 
not only in CRC but other types of cancers such as lung and breast (Kontani et al. 2001).  
In this study, the frequency of CD4+ cells expressing Granzyme B was increased in the 
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MLN and LI IEL. There were no changes in the other cellular compartments. CD8+ cells 
expressing Granzyme B had no significant changes following Apc deletion.  
The proinflammatory IL-17A cytokine has been associated with various immune 
responses, not only in the pathogenesis of autoimmune diseases, allergic responses, 
but also tumorigenesis (Song and Qian 2013). Several studies have shown that IL-17A 
can either promote cancer or have an antitumor role in different cancer models including 
CRC (Murugaiyan and Saha 2009; Yang et al. 2016). In general, data do not show 
significant changes in the frequency of IL-17A expressed by either CD4+ or CD8+ cells. 
The only alteration observed, after Apc deletion, is in the CD4+ cells expressing IL-17A 
in the spleen, showing an increased frequency of IL-17A. It was observed a big variability 
in the frequencies of the mice that were studied making difficult the interpretation of the 
data. 
IFNγ is a critical cytokine in innate and adaptive immunity. Various studies have 
demonstrated that IFNγ plays an important antitumor role in CRC (Wang et al. 2015a; 
Katlinski et al. 2017; Liu et al. 2017). The frequency of CD4+ cells expressing IFNγ is 
only increased in the spleen. It was not observed any alteration in the frequency of 
CD8+IFNγ+ cells in any of the cell compartments. 
The numbers of Foxp3+ cells were significantly altered in the intestinal 
compartment 15 days after the initiation of tumorigenesis, implying an important role in 
the initiation of intestinal cancer. In general, however, our data show very little alterations 
in the expression of the T-cell activation markers analysed at the same time-point. It is 
possible that at this early time point, large scale changes in immune activation are not 
detectable. It is important to note that it was used the whole intestines in the flow 
cytometry analysis and thus alterations which may occur in distinct locations within the 
intestine may be missed. Performing other types of analyses, such as IHC and looking 
at the localization of the immune cells in normal tissue and lesions would most likely give 
more accurate information regarding the frequency and role of these cells in the early 
stages of intestinal cancer. The exact mechanism by which Tregs are attracted to the 
early lesions is still not clarified. Previous research showed that in the early stages of 
CRC there is the loss of the epithelial barrier, leading to the infiltration of bacteria and 
microbial products. This infiltration promotes the activation of immune cells that produce 
the cytokines IL-23 and IL-17, leading to tumour progression (Brenchley and Douek 
2012; Goldszmid and Trinchieri 2012) (Yang and Karin 2014). The integrity of the 
epithelial barrier was not accessed, however future experiments should include this 
analysis as this could explain the accumulation of Tregs in the early lesions. More 
recently, Biton and colleagues have shown that ISCs enriched with MHC-II can act as 
non-conventional antigen-presenting cells. Upon stimulation of these cells with antigens, 
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they were able to interact with Th cells. Possibly Apc deletion in ISCs would promote 
their antigen-presenting function, being able to attract Tregs to the site of the early lesion 
(Biton et al. 2018). In the future, ISCs Apc deleted cells could be sorted by Fluorescent 
–activated cell sorting (FACS) and their MHC-II expression analysed. Next, the capacity 
of ISCs Apc deleted cells to activate Tregs could be tested in vitro.  
In summary, in this chapter, it was shown that Tregs increase in number and 
frequency, following Apc deletion in the ISCs, in different cells compartments, particularly 
in the intestines, indicating a possible impact on cancer development in the intestine. To 
investigate whether Tregs play a pro- or anti-tumoral role in our mouse model, I 
considered it important to examine the consequences of their depletion on tumour 
development. This is detailed in the next chapter. 
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4 Investigating the effects of Treg depletion after loss of Apc 
gene in the ISCs 
4.1 Introduction 
 
Tregs have been associated with disease progression (Clarke et al. 2006; Betts et 
al. 2012; Syed Khaja et al. 2017). Previous studies have shown an increased frequency 
of Tregs in both CRC patients and mouse models of intestinal cancer (Akeus et al. 2014; 
Chae and Bothwell 2015), however the role of these immune cell population in the early 
stages of intestinal cancer remains unclear. In the previous chapter I showed that Tregs 
accumulate as soon as 15 days after Apc deletion. It was also showed increased 
frequency of Foxp3+ cells in the spleen, MLN, SI IEL, SI LPL and LI IEL. This correlated 
with a significant increase in the relative gene expression of Foxp3 in the epithelial cell 
compartment of the small intestine. 
Other studies have shown that depletion of Tregs in combination with other 
therapies improved the survival of patients with metastatic CRC (Scurr et al. 2017a; Scurr 
et al. 2017b). Studies performed in other mouse models have also shown reduction in 
the tumour progression by depleting Tregs (Akeus et al. 2015; Colbeck et al. 2017).  
In this chapter I sought to establish the impact of Treg depletion on the pro-
tumorigenic aberrant crypts produced by Apc deficient ISCs, by characterising the ISCs, 
target genes of the Wnt pathway and changes to the immune profiles in the early stages 
of intestinal cancer.    
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4.2 Results 
 
4.2.1 Treg cell depletion reduces tumorigenic potential in the 
Lgr5CreERT2Apcfl/flFoxp3DTR mouse model  
 
4.2.1.1 Total tumour burden 
 
I started by quantifying the number of aberrant crypts in the whole small and large 
intestines of mice with ISC Apc deletion alone or with Treg depletion as well. Mice were 
either injected with tamoxifen to delete the Apc gene (Lgr5CreERT2Apcfl/fl) or with both 
tamoxifen and diphtheria toxin (DT) to achieve Apc deletion and Treg depletion 
respectively (Lgr5CreERT2Apcfl/flFoxp3DTR). Based on previous experiments, the standard 
Cre induction regime of a single i.p. dose of tamoxifen for four consecutive days results 
in extensive Apc ISC deletion preventing analysis of single aberrant crypts. To overcome 
this, I reduced the induction regime to tamoxifen administration for two consecutive days. 
For experiments requiring concurrent depletion of Tregs, mice were administered DT the 
day before the first tamoxifen injection and then every other day for the duration of the 
experiment. Mice were dissected 15 days after the first treatment. For analysis, paraffin 
embedded tissues were cut into three serial sections of 5 µm separated by 120 µm. 
Slides were stained with a -catenin antibody (section 2.6.3) and entire crypts from both 
small and large intestines which stained positive for nuclear β-catenin staining (aberrant 
crypts), were counted (section 2.7.1). 
The number of aberrant crypts in the small intestine (SI) were reduced, although 
not significantly, in Apc deleted/Treg depleted mice (Figure 4.1 Aii; B) when compared 
to Apc deleted mice (Figure 4.1 Ai; B). In the large intestine (LI) the number of aberrant 
crypts were significantly reduced in Apc deleted/Treg depleted mice (Figure 4.1 Aiii, iv; 
C). Overall, these data suggest that Tregs may play a pro-tumoral role in the early stages 
of intestinal cancer, particularly in the LI. 
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Representative images of B-catenin (grey) IHC staining of SI (i) and LI (ii) from Apc deleted mice 
(Lgr5CreERT2Apcfl/fl), SI (iii) and LI (iv) from Apc deleted/Treg depleted mice 
(Lgr5CreERT2Apcfl/flFoxp3DTR). Black arrows indicate aberrant crypts. (B) There is a trend for a 
reduced number of aberrant crypts with Apc deletion/Treg cells depletion in the SI. (C) The 
Figure 4.1 Tumour burden analysis in the SI and LI. 
B C 
A 
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number of aberrant crypts is significantly reduced in the LI in Apc deleted/Treg depleted mice. 
Data represent a single experiment, n=5 mice per group. (**) P value ≤ 0.01, two-tailed Mann 
Whitney U test. Error bars represent Standard Deviation (SD). Scale bars represent 50 µm. 
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4.2.1.2 Evaluating the apoptotic index following Apc deletion and Treg depletion 
 
To understand why Treg depletion in an Apc deleted mouse decreased the 
number of aberrant crypts, I analysed the apoptotic index within the crypts. Slides from 
the groups that were previously described in the tumour burden analysis were stained 
with H&E and apoptotic bodies were identified in small intestinal crypts by their 
morphology such as cell shrinkage, chromatin condensation and the presence of a 
border and their number was scored per crypt from 25 whole crypts. The average number 
of mitotic cells was calculated and the mean across the cohorts was determined. Mice 
with Apc deletion/Treg depletion had a significantly increased apoptotic index when 
compared to non-induced or Apc deleted mice. Treg depletion alone had a similar 
apoptotic index to Apc deleted/Treg depleted mice. Interestingly, Apc deleted/Treg 
depleted mice had an increased average number of apoptotic bodies in aberrant crypts 
when compared to normal crypts, indicating that Treg depletion affected aberrant but not 
normal crypts (Figure 4.2).  
90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A) 
91 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A)Representative images of H&E from crypts of non-induced, Treg depleted, Apc deleted and 
Apc deleted/Treg depleted mice. (B) The average number of apoptotic bodies is significantly 
increased with Apc deletion. As a result of Treg depletion there was an increased number of 
apoptotic bodies. Aberrant crypts in both Apc deleted and Apc deleted/Treg depleted mice had a 
significant higher number of apoptotic bodies when compared to normal adjacent crypts. Data 
represent a single experiment, n=5 mice per group. (**) P value ≤ 0.01, two-tailed Mann Whitney 
U test. Scale bars represent 10 µm.  
  
Figure 4.2 Apoptotic index in the small intestinal crypts. 
B) 
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4.2.1.3 Evaluating the gene expression of Wnt and ISC markers following Apc deletion 
and Treg depletion 
 
Deletion of Apc leads to constitutive activation of the canonical Wnt signalling 
pathway perturbing homeostatic control of intestinal epithelia (Sansom et al. 2004). 
Previous data have shown that Treg depletion in Apc deleted mice significantly reduced 
the intestinal tumour burden. To verify whether this reduction was reflected in a reduced 
activation of the Wnt signalling, gene expression of Wnt markers was analysed in RNA 
extracted from small intestinal epithelial cells by qRT-PCR (see section 2.8). Relative 
expression of mRNA was calculated using the ΔΔCt method and ACT B was used as an 
internal control. 
As expected, deletion of the Apc gene in the mouse ISCs (Lgr5CreERT2Apcfl/fl) 
caused a significant upregulation of the Wnt markers when compared to mice that were 
not induced with tamoxifen (non-induced) (Figure 4.3). I hypothesised that depleting 
Tregs in an Apc deleted mouse would decrease the expression of Wnt and ISC markers. 
In this analysis I have included, apart from the previously described groups (Non-induced 
and Lgr5CreERT2Apcfl/fl), two more experimental groups. Foxp3DTR corresponds to the 
group of mice that were injected only with DT, every other day for 15 days to deplete 
Tregs. Looking at the effects of Treg depletion alone would clarify what responses were 
mainly due to this immune alteration and independent of Apc deletion. The other 
experimental group was the Lgr5CreERT2Apcfl/fl Foxp3DTR mice that was injected for four 
consecutive days with tamoxifen, to delete the Apc gene as well as with DT every other 
day for 15 days to deplete Tregs, allowing the analysis of the effects of Treg depletion in 
the early stages of intestinal cancer. It was observed that Treg depletion alone 
(Foxp3DTR) did not alter the expression of Wnt target gene Axin2 but significantly 
upregulated c-Myc (Figure 4.3). However, the increase in Wnt target gene expression 
associated with ISC deletion of Apc is attenuated, significantly for Axin2, in the absence 
of Treg cells (Figure 4.3).  This finding is in keeping with the reduction in the number of 
aberrant crypts observed in this model.   
The aberrant crypts are supported by ISCs. The expression of the ISCs markers 
Lgr5, Olfm4 and Ascl2 was analysed to verify whether the reduction of aberrant crypts in 
Apc deleted/Treg depleted mice was reflected in a downregulation of these markers. 
Both Lgr5 and Ascl2 have an increased gene expression after following Apc deletion 
(Figure 4.4). There is a trend for the upregulation of Olfm4 although it is not significant 
(Figure 4.4). Treg depletion alone or in combination with ISC Apc loss significantly 
decreased the expression of Lgr5, itself a Wnt target, compared to non-induced and Apc 
deleted mice.  (Figure 4.4). For the Apc deleted/Treg depleted group these changes were 
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mirrored by the other ISC markers Olfm4 and Ascl2 indicating that Tregs play a role in 
ISC numbers or activity (Figure 4.4). 
  
 
 
 
 
 
 
 
Apc deletion significantly upregulates the expression of both c-Myc and Axin2 genes. Treg 
depletion alone did not alter the expression of Axin2. The expression of Axin2 has a trend to 
decrease, however not significant, with Apc deletion and Treg depletion. Treg depletion alone, 
and together with Apc deletion, significantly increases the expression of c-Myc. Data represent a 
single experiment, n ≥ 3 mice per group. (*) P value ˂ 0.05, one-tailed Mann Whitney U test. 
 
 
 
 
 
 
 
 
 
 
Apc deletion significantly upregulates the expression of Lgr5 and Ascl2 genes. Treg depletion 
alone resulted in decreased the expression of Lgr5 when compared to non-induced and Apc 
Figure 4.3 Relative gene expression of the Wnt signalling markers Axin2 and c-Myc in the small 
intestinal epithelium. 
Figure 4.4 Relative gene expression of the ISCs markers Lgr5, Olfm4 and Ascl2 in the small 
intestinal epithelium. 
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deleted mice. The expression of Olfm4 was decreased with Treg depletion, but not Ascl2. Apc 
deletion and Treg depletion resulted in decreased the expression of the three ISC markers. Data 
represent a single experiment, n ≥ 3 mice per group. (*) P value ˂ 0.05, (**) P value ≤ 0.01, one-
tailed Mann Whitney U test. 
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4.2.1.4 Evaluating the gene expression of Foxp3 and IFNγ 
 
To begin to understand the role of the immune system cells in this phenotype I 
analysed the expression of Foxp3, a transcriptional factor expressed by Tregs, and IFNγ 
by qRT-PCR as previously explained. It was shown in the previous chapter that Apc 
deletion resulted in a significant increased gene expression of Foxp3. Contrary to what 
was expected, Treg depletion alone did not result in a downregulation of Foxp3 (Figure 
4.5). Treg depletion in Apc deleted mice, as expected, resulted in a significant 
downregulation of Foxp3 (Figure 4.5). In keeping with the ability of Tregs to prevent an 
anti-tumour immune response, the significant increase in expression IFNγ observed in 
Apc deficient mice was further up regulated in the absence of Tregs, suggesting another 
beneficial effect of Treg depletion in the early stages of intestinal cancer (Figure 4.5). 
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Apc deletion significantly upregulates the expression of Foxp3 and IFNγ. Treatment with DT alone 
did not alter significantly the expression of Foxp3, however Apc deleted/Treg depleted mice had 
a significantly reduced expression of Foxp3. Relative gene expression of IFNγ increased 
significantly after Treg depletion, alone and in combination with Apc deletion.  Foxp3 gene 
expression data for the non-induced and Lgr5CreERT2Apcfl/fl groups is repeated in figure 3.3. Data 
represent a single experiment, n ≥ 3 mice per group. (*) P value ˂ 0.05, (**) P value ≤ 0.01, one-
tailed Mann Whitney U test. 
  
Figure 4.5 Relative gene expression of Foxp3 and IFNγ in the small intestinal epithelium. 
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4.2.2 Examining the effects of Treg depletion on T-cell populations in the early 
stages of intestinal cancer 
 
In the previous chapter I have analysed the effects of ISCs Apc deletion in T-cell 
populations and cytokine markers. To understand whether the reduction in the intestinal 
tumour burden, following Treg depletion, was a result of an unleashed immune response, 
the previously described T-cell activation markers were analysed once again. 
The frequency of CD3+ cells was significantly increased in the SI IEL (Figure 4.6 
A), LI IEL (Figure 4.6 B) and spleen (Figure S 9.2) following Apc deletion/Treg cells 
depletion. There were no significant changes in the LPL compartment of both SI (Figure 
4.6 A) and LI (Figure 4.6 B) as well as MLN (Figure S 9.2). 
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In the SI IEL only Apc deletion/Treg depletion increased the frequency of CD3+ cells. There were 
no significant changes in the SI LPL (A). In the LI IEL both Treg depletion and Apc deletion/Treg 
depletion resulted in an increased frequency of CD3+ cells. A trend for an increased frequency of 
CD3+ cells in the LI LPL was observed following Treg depletion and Apc deletion/Treg depletion 
(B). Data represent a single experiment, n ≥ 4 mice per group. Data for the non-induced and 
Lgr5CreERT2Apcfl/fl groups are repeated in figure 3.5. (*) P value ˂ 0.0.5, (**) P value ≤ 0.01, (***) 
P value ≤ 0.001, (****) P value ≤ 0.0001, two-tailed Mann Whitney U test. 
  
Figure 4.6 Frequency of CD3+ T-cells in the specified compartments of SI and LI following Treg 
cells depletion. 
B A 
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Treg depletion alone or in combination with Apc deletion resulted in a significantly 
increased frequency of CD4+ cells in the SI IEL and LI (Figure 4.7). In the SI LPL, only 
Treg depletion resulted in a significantly increased frequency of CD4+ cells (Figure 4.7).  
The effect of Treg depletion on the CD4+ T-cells is lost in the Apc deleted/Treg 
depleted mice, indicating that in the presence of Apc deleted intestinal cells activation of 
CD4+ naive cells, or their accumulation within the SI LPL, due to Treg depletion, is 
inhibited (Figure 4.7 A). Within the spleen and MLN there is a significant decreased in 
the frequency of CD4+ cells in the absence of Treg cells (Figure S 9.3). These data 
suggest that only in the intestines, Treg depletion allow the expansion of other sub-
populations of CD4+ T-cells, such as Th1 cells, that may participate in the anti-tumour 
immune response. 
The frequency of CD8+ cells is not altered in the SI IEL compartment; however, 
it is significantly decreased in the SI LPL, following Treg depletion (Figure 4.7 C). In 
contrast to SI, the frequency of CD3+CD8+ is significantly increased in the LI (Figure 4.7 
D) and MLN (Figure S 9.4) in the absence of Treg cells as well as Apc deleted/Treg 
depleted mice. In the spleen the frequency of CD8+ cells is only significantly increased 
as a result of Apc deletion/Treg cells depletion (Figure S 9.4). These data suggest that 
Treg depletion unleashed an immune response by CD8+ cells, particularly in the LI 
compartment, possibly explaining the significantly reduced tumour burden observed in 
the LI.  
Treg depletion was confirmed in SI (Figure 4.8 A), LI (Figure 4.8 B), spleen and 
MLN (Figure S 9.1) by the significant decreased frequency of CD4+ cells expressing 
Foxp3. 
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(A)The frequency of CD3 expressing CD4+ cells is significantly increased with both Treg depletion 
and Apc deletion/Treg depletion in the SI IEL. In the SI LPL only Treg depletion results in an 
increase in the frequency of CD4+ cells. (B) In the LI, both Treg depletion and Apc deletion/Treg 
Figure 4.7 Frequency of CD3+ T-cells expressing CD4+ and CD8+ in the specified compartments 
of SI and LI following Treg cells depletion. 
D 
A B 
C 
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cells depletion results in an increase in the frequency of CD4+ cells. (C) The frequency of CD3+ 
cells expressing CD8 is only altered in the SI LPL where it is decreased following Treg depletion. 
(D) In the LI Treg depletion and Apc deletion/Treg depletion result in a significant increase in the 
frequency of CD8+ cells. Data represent a single experiment, n ≥ 4 mice per group. Data for the 
non-induced and Lgr5CreERT2Apcfl/fl groups are repeated in figure 3.6. (*) P value ˂ 0.0.5, (**) P 
value ≤ 0.01, (***) P value ≤ 0.001, (****) P value ≤ 0.0001, two-tailed Mann Whitney U test.
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(A) The frequency of CD4+ cells expressing Foxp3, as expected, is significantly reduced in the SI 
following DT treatment. (B) The same is observed in the LI where a reduced frequency of Foxp3+ 
cells is observed. Data represent a single experiment, n ≥ 4 mice per group. Data for the non-
induced and Lgr5CreERT2Apcfl/fl groups are repeated in figure 3.4. (*) P value ˂ 0.0.5, (**) P value 
≤ 0.01, (***) P value ≤ 0.001, (****) P value ≤ 0.0001, two-tailed Mann Whitney U test. 
  
Figure 4.8 Frequency of CD4+ cells expressing Foxp3 in the specified compartments of SI and LI 
following Treg cells depletion. 
A B 
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No differences were observed in the frequency of CD4+Granzyme B+ cells in the 
SI following Treg depletion or Apc deletion/Treg depletion when compared to non-
induced mice (Figure 4.9 A). In the LI (Figure 4.9), spleen and MLN (Figure S 9.5) 
particularly Treg depletion alone resulted in a significantly increased frequency of 
CD4+Granzyme+ cells. This effect was significantly attenuated in Apc deleted/Treg 
depleted mice suggesting that these cells do not participate in the anti-tumour immune 
response in the early stages of intestinal cancer. 
The frequency of CD8+Granzyme B+ cells is significantly increased in the SI IEL 
following Apc deletion/Treg depletion (Figure 4.9 C). There were no significant changes 
in the SI LPL, however the large spread in the data make a definitive conclusion difficult 
(Figure 4.9 C). In the LI (Figure 4.9 D), spleen and MLN (Figure S 9.6) an increased 
frequency of CD8+Granzyme B+ cells in both Treg depleted and Apc/Treg cells depleted 
group was observed, suggesting that Granzyme B secreted by CD8+ cells may have a 
role in the anti-tumour immune response. 
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(A)The frequency of CD4+ cells expressing Granzyme B was not altered in the SI following Treg 
depletion or Apc deletion/Treg depletion when compared to non-induced mice. (B) In the LI there 
Figure 4.9 Frequency of CD4+ and CD8+ cells expressing Granzyme B in the specified 
compartments of SI and LI following Treg cells depletion. 
A B 
C D 
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was an increased frequency of CD4+ cells expressing Granzyme B, especially following Treg 
depletion, as well as Apc deletion/Treg depletion. (C) The frequency of CD8+ cells expressing 
Granzyme B was increased following Apc deletion/Treg depletion in the SI IEL. There were no 
significant changes in the SI LPL. (D) In the LI both Treg depleted and Apc deleted/Treg depleted 
mice have an increased frequency of CD8+ cells expressing Granzyme B. Data represent a single 
experiment, n ≥ 4 mice per group. Data for the non-induced and Lgr5CreERT2Apcfl/fl groups are 
repeated in figure 3.7. (*) P value ˂ 0.0.5, (**) P value ≤ 0.01, (***) P value ≤ 0.001, (****) P value 
≤ 0.0001, two-tailed Mann Whitney U test. 
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There were no significant alterations in the frequency of CD4+IL-17A+ cells in 
both SI (Figure 4.10 A) and LI (Figure 4.10 B) in any of the experimental groups. Contrary 
to the intestines, CD4+IL-17A cell frequency was significantly increased in both spleen 
and MLN (Figure S 9.7) particularly in Treg depleted and Apc deleted/Treg depleted 
mice, suggesting that a systemic immune response that is not mirrored in the intestine, 
thereby implying that this cytokine does not participate in initiation of intestinal cancer 
and/or in the anti-tumour immune response. 
 The frequency of CD8+IL-17A+ cells was significantly increased in the SI in Apc 
deleted/Treg depleted mice (Figure 4.10 C). In the LI IEL, only Treg depletion resulted in 
an increase in the frequency of IL-17A, with no alterations in the LPL compartment 
(Figure 4.10 D). Similar to CD4+IL-17A+ cells, the frequency of CD8+IL-17A+ cells was 
significantly increased in the spleen and MLN (Figure S 9.8) with both Treg depletion 
and Apc deletion/Treg depletion, however in both situations the frequency of IL-17A was 
very low, suggesting again that IL-17A does not have an important role in the early stages 
of intestinal cancer. 
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(A), (B) There were no significant changes in the frequency of CD4+ cells expressing IL-17A in 
both SI and LI. (C) The frequency of CD8+ cells expressing IL-17A was significantly increased in 
Apc deleted/Treg depleted mice. In the SI LPL, CD8+IL-17A+ cells frequency was significantly 
Figure 4.10 Frequency of CD4+ and CD8+ cells expressing IL-17A in the specified compartments 
of SI and LI following Treg depletion. 
A 
C 
B 
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increased in Treg depleted and Apc deleted/Treg depleted mice. (D) The frequency of CD8+ cells 
expressing IL-17A was significantly increased in Apc deleted/Treg depleted, but particularly in 
Treg depleted mice. Data represent a single experiment done, n ≥ 4 mice per group. Data for the 
non-induced and Lgr5CreERT2Apcfl/fl groups are repeated in figure 3.8. (*) P value ˂ 0.0.5, (***) P 
value ≤ 0.001, two-tailed Mann Whitney U test. 
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Finally, I analysed the frequency of IFNγ in the different cell compartments. The 
frequency of CD4+IFNγ+ cells was significantly increased in the SI LPL (Figure 4.11 A), 
LI (4.11 B), spleen and MLN (Figure S 9.9) following Treg depletion. The effect of Treg 
depletion was attenuated in Apc deleted/Treg depleted mice, however it was still 
significantly increased in LI (4.11 B), spleen and MLN (Figure S 9.9) when compared to 
non-induced and Apc deleted mice. 
Treg depletion significantly increased the frequency of CD8+IFNγ+ cells in SI 
(Figure 4.11 C), LI (Figure 4.11 D), spleen and MLN (Figure S 9.10). Again, we observed 
an attenuation of the effect of Treg depletion in Apc deleted mice, particularly in the SI 
LPL (Figure 4.11 C) and LI (Figure 4.11 D), suggesting that CD8+IFNγ+ cells may have 
an important role in the anti-tumour immune response in the early stages of intestinal 
cancer. 
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(A) Treg depletion did not alter the frequency of CD4+ cells expressing IFNγ in the SI IEL. There 
is an increased frequency of IFNγ in the SI LPL in Treg depleted mice. (B) Both Treg depletion 
and Apc deletion/Treg cells depletion increased the frequency of CD4+ cells expressing IFNγ. (C) 
The frequency of CD8+ cells expressing IFNγ is increased particularly with Apc deletion/Treg 
Figure 4.11 Frequency of CD4+ and CD8+ cells expressing IFNγ in the specified compartments 
of SI and LI following Treg depletion. 
A B 
C D 
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depletion in the SI IEL. In the SI LPL Treg depletion showed increased frequency of IFNγ. (D) In 
the LI both Treg cells depleted and Apc deleted/Treg depleted mice had increased frequency of 
CD8+ cells expressing IFNγ. Data represent a single experiment, n ≥ 4 mice per group. Data for 
the non-induced and Lgr5CreERT2Apcfl/fl groups are repeated in figure 3.9. (*) P value ˂ 0.0.5, (**) 
P value ≤ 0.01, (***) P value ≤ 0.001, (****) P value ≤ 0.0001, two-tailed Mann Whitney U test. 
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4.3 Discussion 
 
Treg cells play an important role in maintaining peripheral tolerance and preventing 
autoimmunity. Studies have shown that Tregs are increased in cancer patients, including 
in CRC. These studies led to divergent correlations between increased Tregs and 
disease outcome, which emphasized the interest of studying the role of these cells in 
tumour initiation and progression. 
There is accumulating evidence that by depleting Tregs, an anti-tumour immune 
response is unleashed. In the recent years, studies performed in mouse models have 
shown that depletion of Tregs improved the anti-tumour immune response with a strong 
activation and amplification of CD4+ and CD8+ T-cells and the control of tumour growth 
(Chaput et al. 2007; Goudin et al. 2016).  
A few clinical trials have tested the efficacy of depleting Tregs in cancer patients. 
Dannull and colleagues have shown that depletion of these cells in patients with 
metastatic renal cancer improved the stimulation of tumour-specific T-cell responses 
(Dannull et al. 2005). Another example is a randomized study from our group where 
patients with inoperable metastatic CRC were treated with a vaccine to improve serologic 
and T-cell responses against 5T4, an oncofoetal antigen expressed in more than 90% of 
CRCs, in combination with a low dose of cyclophosphamide, to deplete Tregs. Prior 
depletion of Tregs did not increase the immune responses generated by the vaccination, 
however each treatment, independently, improved the survival outcome of the patients 
without toxic effects (Scurr et al. 2017a; Scurr et al. 2017b). 
The different approaches to deplete Tregs in clinical trials were mainly applied to 
patients with advanced disease and the studies in mouse models were done using a 
variety of cancer cell lines including ones derived from ovarian (Chen et al. 2012) and 
melanoma (Shabaneh et al. 2018). Fewer studies have been conducted, however it is 
essential in the context of colorectal cancer. There is a need to clarify the effects of Treg 
depletion in the initiation of intestinal cancer  
By deleting the Apc gene in the ISCs, it is possible to mimic the early stages of 
intestinal cancer, with the formation of aberrant crypt foci and micro-adenomas. I also 
observed increased Treg cells numbers and frequencies in the intestines, spleen and 
MLN. The effects of Treg depletion were analysed for the first time in the genetically 
modified mouse model Lgr5CreERT2Apcfl/flFoxp3DTR, giving new insights about what 
happens to the early stages of intestinal tumourigenesis in the absence of the immune 
suppressive Treg cell population. Here, it was hypothesized that by depleting the Treg 
cells the tumour burden would be reduced. Indeed, as expected, the number of aberrant 
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crypts was significantly reduced in the large intestine and there was a trend to be reduced 
in the small intestine, however not significant.  
It was showed that in the Treg depleted mice there was an increased apoptotic 
index when compared to Treg replete mice indicating that Treg depletion affects directly 
the homeostasis of the intestinal crypts. However, when the number of apoptotic bodies 
was compared between normal and aberrant crypts of Apc deleted/Treg depleted mice, 
I observed that apoptosis was significantly increased in the aberrant crypts. These data 
suggest that by depleting Tregs, in the context of cancer, there is a specific effect in pro-
tumorigenic but not in the normal tissue. A possible explanation by which Treg depletion 
increased apoptosis is that, as observed by flow cytometry analysis, Treg depletion led 
to increased secretion of IFNγ. This cytokine is known to promote apoptosis in malignant 
cells, being this one of the mechanisms responsible for the anti-tumour responses 
promoted by IFNγ (Liu et al. 2011; Kotredes and Gamero 2013; Ni and Lu 2018).The 
apoptotic index was calculated based on the identification of apoptotic bodies present in 
H&E stained sections. For this analysis other experiments were performed, such as IHC 
for cleaved caspase 3, a specific marker of apoptosis. However, because of unknown 
circumstances, the method did not work. In the future this experiment should be repeated 
and added to the analysis.  
Accordingly, we demonstrated that Treg depletion, following Apc deletion, reduced 
the relative gene expression of the Wnt markers Axin2 and cMyc, when compared to Apc 
deletion alone, indicative of reduced tumour burden. The same was observed with the 
ISCs markers Lgr5, Olfm4 and Ascl2. Gene expression data confirmed that in Treg 
depleted mice there was a significant increased frequency of IFNγ, a cytokine that, as 
previously described, participates in anti-tumour immune responses (Wang et al. 2015a; 
Katlinski et al. 2017; Liu et al. 2017). Although the gene expression of Foxp3 was 
significantly reduced in the Lgr5CreERT2Apcfl/flFoxp3DTR group, the same was not 
observed in the group treated with DT (Foxp3DTR) to achieve Treg depletion alone where 
the reduced gene expression of Foxp3 was not significant. This could have happened 
because the depletion was not efficient in this particular group. Depletion efficiency 
should be tested by flow cytometry and/or ELISA. Altogether, these data indicate that, in 
this mouse model, Treg depletion, in the early stages of intestinal cancer, had a positive 
effect in promoting an anti-tumour immune response, particularly in the large intestine. 
Future experiments should include gene expression analysis in large intestine. 
After analysing the effect of Treg depletion on tumour burden, we characterized 
the frequency of the previously described T-cell populations. In this analysis there was a 
high variability of some markers limiting the interpretation of the data. Intra-epithelial 
lymphocytes provide the first defence against infections, being essential in the regulation 
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of intestinal homeostasis (Sheridan and Lefrançois 2010). The frequency of CD3+ cells 
was significantly increased in the IEL compartment of both SI and LI, following Treg 
depletion in Apc deleted mice, with no significant alterations in the LPL compartment. 
This suggests that in the absence of Tregs, the inflammatory T-cell populations infiltrate 
particularly in the intra-epithelial compartment where they may exert an anti-tumour 
immune response.  
As expected, we observed an increased frequency of CD4+ T-cells in the 
intestines, but decreased in the spleen and MLN of Treg depleted mice, providing 
evidence, again, that in the absence of the immune suppressive Treg cells, Foxp3- CD4+ 
T-cells can expand and exert their anti-tumour immune responses supporting the data 
from other groups in different mouse models (Wing et al. 2014; Goudin et al. 2016). 
Infiltration of CD8+ T-cells has been associated with better survival in cancer 
patients, including the in early stages of CRC (Pages et al. 2009; Ziai et al. 2018). Our 
data shows that most significant changes in the frequency of CD8+ T-cells were 
observed in the LI where there was an increased frequency of this marker following Treg 
depletion and Apc deletion/Treg depletion. Surprisingly, no differences were observed in 
the SI. One possible explanation if that the whole SI and LI were analysed even though 
the highest recombination of the Apc gene and, as a consequence, the formation of 
micro-adenomas happens in the first 5 cm of the SI.  It is possible that, by analysing only 
the first 5 cm of the SI, similar differences would have been observed. 
The frequency of CD4+Granzyme B+ cells was increased in the intestines of Treg 
depleted mice, particularly in the LI. Treg depletion in Apc deleted mice attenuated the 
increased frequency of Granzyme B+ cells. Similar to CD4+Granzyme B+ cells, the 
frequency of CD8+Granzyme B+ cells was significantly increased in the LI following Treg 
depletion and, with equivalent frequency, in Apc deleted/Treg depleted mice. The fact 
that most significant changes occur in the LI may explain why, in this model, a significant 
decrease in the number of aberrant crypts observed in in the LI, whereas only a trend is 
observed in the SI it is only observed a trend for a decreased number of aberrant crypts 
as the expression of Granzyme B has been associated to improved survival in CRC 
(Prizment et al. 2017).  
As previously described, the role of IL-17A in tumorigenesis is controversial 
(Murugaiyan and Saha 2009; Yang et al. 2016).  Our data does not show significant 
changes in both SI and LI following either Treg depletion or Apc deletion/Treg depletion 
for frequencies of CD4+IL-17A+ cells, indicating that these cells may not be relevant in 
the anti-tumour immune response in the early stages of intestinal cancer.  On the other 
hand, CD8+IL-17A+ cells were significantly increase in the SI following Apc deletion/Treg 
depletion, suggesting a role of CD8+ cells. Further experiments, such as IL-17A 
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neutralization, should help understanding the role of IL-17A in the initiation of intestinal 
cancer in this mouse model. 
The frequency of CD4+IFNγ+ cells in the SI was only increased in the LPL 
compartment following Treg depletion, indicating that in the early stages of intestinal 
cancer the secretion of IFNγ by CD4+ T-cells does not play a relevant role in the anti-
tumour immune responses in the SI. There was a significantly increased frequency of 
CD4+IFNγ+ cells in the LI, and CD8+IFNγ+ cells in both SI and LI following Treg 
depletion, however this was attenuated in Apc deleted/Treg depleted mice, with the 
exception of CD8+IFNγ+ cells in the SI IEL. Our data suggest that IFNγ may play an 
important role in the anti-tumour immune responses in the early stages of intestinal 
cancer, similarly to what was previously published where it was demonstrated the anti-
tumour role of IFNγ+ in CRC (Wang et al. 2015a; Katlinski et al. 2017; Liu et al. 2017).  
In the distant compartments, in both spleen and MLN, there was an increased 
frequency of Granzyme, IL-17A and IFNγ – producing cells after Treg depletion 
demonstrating that depletion of these cells unleashes a peripheral immune response. 
The higher increased frequencies in the cytokine-producing cells were mainly observed 
in CD8+ T-cells, which indicates that, these cells may participate the anti-tumour immune 
responses in the initiation of intestinal cancer. 
In summary, it was demonstrated that Treg depletion in an Apc deleted mouse 
decreases the tumour burden in the early stages of intestinal cancer, particularly in the 
large intestine. This may be explained by the increased apoptotic index in the intestine, 
particularly in the aberrant crypts, possibly caused by the increased secretion of IFNγ by 
CD8+ cells; inactivation of Wnt signalling pathway and increased frequency of cells 
producing Granzyme B and IFNγ, particularly CD8+ cells. Future experiments, to further 
understand the immune cell populations that participate in the anti-tumour immune 
responses, will include the depletion of CD4+ and CD8+ T-cells, and neutralisation of 
IFNγ. 
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5 Cellular subsets responsible for the anti-tumour immune 
response 
5.1 Introduction 
 
The progression of tumourigenesis in CRC and other solid tumours involves 
interactions between the tumour and the host immune environment, that comprise a 
variety of cell types, including CD4+ and CD8+ cells (Szabo et al. 2003; Corthay 2009; 
Zhu and Paul 2010; Tripathi and Lahesmaa 2014; Kaplan et al. 2015; Vlad et al. 2015).  
Previously I demonstrated, using the Lgr5CreERT2Apcfl/flFoxp3DTR model, that 15 
days following ISC Apc deletion there was an expansion of Tregs in the intestine, spleen 
and MLN. Depleting the Tregs in this model, led to a reduction in intestinal 
tumourigenesis. Treg depletion led to an expansion of CD8+ and CD4+ cells that 
expressed either granzyme B or IFNγ in the intestine.  This increase in CD8+ cells, while 
indicative of an anti-tumour response, was mainly due to the absence of Tregs. 
The aim of this chapter was to identify whether the immune changes associated 
with Treg depletion play an anti-tumour role in the early stages of intestinal cancer. 
I hypothesised that depletion of CD8+ cells and neutralisation of IFNγ would 
increase the intestinal tumour burden in these mice as they have been considered 
responsible for the anti-tumour immune responses in a variability of cancers, including 
CRC (Pages et al. 2009; Ziai et al. 2018). CD4+ cells include in their population 
conventional T-cells that promote inflammation, but also Tregs, characterized by their 
immune-suppressor activity. By depleting CD4+ cells I sought to verify whether 
conventional T-cells play a key role in the early stages of intestinal tumourigenesis. I 
hypothesised that if CD4+ cell depletion increased the tumour burden, conventional T- 
cells play an important role in the anti-tumour immune responses. On the other side, if 
there was a decreased tumour burden with CD4+ cell depletion, this would suggest that 
Tregs are the sub-population of CD4+ cells with a more relevant role in the early stages 
of intestinal cancer. 
To determine the importance of the CD4+, CD8+ cells and the cytokine IFNγ in the 
reduction of tumour burden observed in the Lgr5CreERT2Apcfl/flFoxp3DTR model, these 
mice were treated with antibodies to either deplete the immune cells or neutralise the 
cytokine. For each experimental group tumour burden was analysed in the first 5 cm of 
the small intestine, as well as the relative gene expression of Wnt signalling, ISCs and 
immune markers. Relative expression of mRNA was calculated using the ΔΔCt method 
and ACT B was used as an internal control. Finally, I quantified the number of CD4+ and 
CD8+ cells and analysed their localization in the small intestinal crypts.  
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5.2 Results 
 
5.2.1 Analysing the effect of CD4+ T-cells depletion in an Apc deleted mice 
 
5.2.1.1 Examining the partial tumour burden following CD4+ cell depletion 
 
To analyse the role of CD4+ cells in the initiation of intestinal cancer, the 
Lgr5CreERT2Apcfl/flFoxp3DTR mouse model was injected with two different depleting 
antibodies (clones YTS-191 & YTS-3) (section 2.4.2.2). Here, I compared four 
experimental groups: the previously described Lgr5CreERT2Apcfl/fl and 
Lgr5CreERT2Apcfl/flFoxp3DTR groups, as well as following CD4+ cell depletion, 
(Lgr5CreERT2Apcfl/fl, Anti-CD4 and Lgr5CreERT2Apcfl/flFoxp3DTR, Anti-CD4).  
To determine the impact of CD4+ cell depletion on the intestine I analysed the 
tumour burden by quantifying number of Apc deficient aberrant crypts in the first 5 cm of 
the small intestine (section 2.7.2). Nuclear β-catenin was used as a surrogate marker of 
Apc loss to identify aberrant crypts (section 2.6.3). Depletion of CD4+ cells significantly 
reduced the tumour burden when compared to Apc deletion alone (Figure 5.1). 
Fifteen days following Apc deletion in the ISCs there was a non-significant 
decrease in the number of aberrant crypts in the Apc deleted/Treg depleted mice, as 
shown previously. This reduction in aberrant crypts became significant in the Apc 
deleted/CD4+ cells depleted animals, in which all CD4+ cells, including Tregs, would be 
depleted. This indicates that, while Tregs play a role in the tumour burden, other CD4+ 
cells are also relevant. However, this effect was lost when CD4+ cells were depleted in 
combination with Apc deletion/Treg depletion, resulting in a non-significant decrease in 
aberrant crypts (Figure 5.1). 
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(A) Representative images of β-catenin (grey) and CD8+ cells (brown) IHC staining in the small 
intestine. Black arrows indicate aberrant crypts and brown arrows indicate CD8+ cells. (B) CD4+ 
cells depletion resulted in a significantly decreased the number of aberrant crypts in the small 
intestine of the Apc deleted mice. CD4+ cells depletion in Apc deleted/Treg depleted mice 
resulted in a trend for a decreased number of aberrant crypts. Data represent a single experiment, 
n ≥ 4 mice per group. (*) P value ˂ 0.05, two-tailed Mann Whitney U test. Error bars represent 
Standard Deviation (SD). Scale bars represent 50 µm.  
 
B 
Figure 5.1  Tumour burden analysis in the small intestine of CD4+ cells depleted mice. 
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5.2.1.2 Evaluating the gene expression of Wnt, ISC and immune markers following 
CD4+ depletion 
 
While CD4+ cells and Treg depletion reduced the number of aberrant crypts in 
the proximal 5cm of the Lgr5CreERT2Apcfl/fl small intestine (based on serial sections for 
the last group) it was only significant for CD4+ cells depletion. To identify whether this 
reduction was a significant feature for the whole intestine I examined Wnt signalling 
activation by analysing the relative gene expression of Axin2 and c-Myc. A reduction in 
the expression level of these genes would support a reduction in the number of crypts 
with nuclear β-catenin. Relative gene expression was analysed in the intra-epithelial cells 
from the small intestine of Apc deleted/CD4+ cells depleted and Apc deleted/Treg and 
CD4+ cells depleted groups by qRT-PCR, and compared to the previously analysed 
experimental groups. 
 Depletion of CD4+ cells in Apc deleted mice resulted in a significantly reduced 
expression of the Wnt signalling markers Axin2 and cMyc supporting the reduction in the 
number of aberrant crypts (Figure 5.2). 
These aberrant crypts are supported by ISCs, so I looked at the expression of 
ISCs markers in mice where CD4+ cells were depleted. Depletion of CD4+ cells and 
Tregs in Apc deleted mice resulted in a significantly decreased relative gene expression 
of Lgr5, when compared to Apc deleted mice (Figure 5.3). There were no significant 
changes in the gene expression of Olfm4 and Ascl2 following CD4+ cell depletion (Figure 
5.3), indicating that CD4+ cell depletion affects particularly Lgr5, also a Wnt target, 
suggesting again that the reduction of the number of crypts is supported by a reduction 
in the Wnt activation. 
Depletion of CD4+ cells resulted in a significantly reduced relative gene 
expression of Foxp3. As previously explained, Foxp3 is a transcription factor expressed 
by Tregs, and these cells also express the CD4 marker (Figure 5.4). IFNγ gene 
expression was significantly decreased following Apc deletion/CD4+ cells depletion 
when compared to Apc deletion and the other groups where Tregs were depleted (Figure 
5.4). IFNγ can be secreted by a variety of immune cells, including CD4+ cells, which 
explains its reduction when these cells are depleted. 
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Depletion of CD4+ cells, in both Apc deleted and Apc deleted/Treg cells depleted mice resulted in a decreased relative gene expression of Axin2 and cMyc 
when compared to Apc deletion alone. Data represent a single experiment, n ≥ 3 mice per group. Data for the non-induced, Lgr5CreERT2Apcfl/fl, Foxp3DTR, 
Lgr5CreERT2Apcfl/flFoxp3DTR groups are repeated in figure 4.3. (*) P value ˂ 0.05, one-tailed Mann Whitney U test
Figure 5.2 Relative gene expression of Wnt signalling markers in the small intestinal epithelium, following CD4+ cell depletion. 
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Depletion of CD4+ cells in both Apc deleted and Apc deleted/Treg depleted mice resulted in a decreased relative gene expression of Lgr5 when compared to 
Apc deleted mice. There were no significant changes in the relative gene expressions of Olfm4 and Ascl2 following CD4+ cells depletion. Data represent a 
single experiment, n ≥ 3 mice per group. Data for the non-induced, Lgr5CreERT2Apcfl/fl, Foxp3DTR, Lgr5CreERT2Apcfl/flFoxp3DTR groups are repeated in figure 4.4.  
(*) P value ˂ 0.05, (**) P value ≤ 0.01, one-tailed Mann Whitney U test.  
Figure 5.3 Relative gene expression of ISC markers in the small intestinal epithelium, following CD4+ cells depletion. 
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Figure 5.4 Relative gene expression of Foxp3 and IFNγ in the small intestinal epithelium, following CD4+ cells depletion. 
 
Relative gene expression of Foxp3 was significantly reduced following CD4+ cells depletion in Apc deleted and Apc deleted/Treg depleted mice. CD4+ cells 
depletion significantly decreased the gene expression of IFNγ particularly in Apc deleted mice when compared to Apc deleted, Treg depleted and Apc 
deleted/Treg depleted mice. Data represent a single experiment, n ≥ 3 mice per group. Data for the non-induced, Lgr5CreERT2Apcfl/fl, Foxp3DTR, 
Lgr5CreERT2Apcfl/flFoxp3DTR groups are repeated in figure 4.5. (*) P value ˂ 0.05, (**) P value ≤ 0.01, one-tailed Mann Whitney U test
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5.2.1.3 Evaluating the number of T-cells following CD4+ depletion 
 
The number of CD4+ and CD8+ cells was quantified in slides stained with the 
respective antibodies. The experimental groups analysed were the previously described 
Lgr5CreERT2Apcfl/fl and Lgr5CreERT2Apcfl/flFoxp3DTR groups, as well as following CD4+ cell 
depletion, (Lgr5CreERT2Apcfl/fl, Anti-CD4 and Lgr5CreERT2Apcfl/flFoxp3DTR, Anti-CD4). A 
group of non-induced mice and another with Tregs depletion alone (Foxp3DTR) were also 
included in the analysis. For each experimental group, the number of either CD4+ or 
CD8+ cells were quantified in both normal crypts (NC) and aberrant crypts (AC). Here, I 
wanted to analyse whether these immune cells would have a different localization 
between normal and aberrant tissue that is characterized by the positive β-catenin 
nuclear staining. 
Injection with the Anti-CD4 antibody nearly depleted completely the CD4+ cells 
in the mice small intestine (Figure 5.5). 
As expected, Treg depletion alone significantly increased the number of CD4+ 
cells when compared to crypts from non-induced mice (Figure 5.5), suggesting that 
without the immunosuppressive activity of Tregs the other conventional T-cells could 
expand. In both Apc deleted and Apc deleted/Treg depleted mice CD4+ cells cluster 
around the newly formed lesions, where there is a significantly higher number of CD4+ 
cells when compared to normal adjacent tissue (Figure 5.5), suggesting a role of these 
cells in the initiation of intestinal cancer, supported by the reduction in the tumour burden 
upon their depletion (Figure 5.1). 
Similar to CD4+ cells, CD8+ cells are significantly increased when Tregs are 
absent, suggesting again that upon Treg depletion the immune response is unleashed. 
Apart from Apc deleted/Treg depleted mice, that show a high number of CD8+ cells in 
both normal and aberrant crypts, in all the other experimental groups there is a 
significantly increased number of CD8+ cells in aberrant crypts (Figure 5.6). CD4+ cell 
depletion in Apc deleted mice significantly increased the number of CD8+ cells in the 
aberrant crypts. This effect might be explained by the fact that Tregs are a sub-population 
of the CD4+ cells and, as a consequence of CD4+ cell depletion, Tregs will be also 
depleted and will not exert their immune suppressive activity, explaining the increased 
number of CD8+ cells (Figure 5.6). 
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Figure 5.5 Quantification of CD4+ cells in the small intestine following CD4+ cells depletion. 
 
(A) Representative images of β-catenin (grey) and CD4+ cells (brown) IHC staining in the small 
intestine. Black arrows indicate aberrant crypts (AC) and brown arrows indicate CD4+ cells. (B) 
CD4+ cells were significantly increased in Treg depleted mice. In both Apc deleted and Apc 
deleted/Treg depleted mice CD4+ cells were increased in the aberrant crypts when compared to 
normal crypts (NC). Data represent a single experiment, n ≥ 4 mice per group. (*) P value ˂ 0.05, 
two-tailed Mann Whitney U test. Error bars represent Standard Deviation (SD). Scale bars 
represent 50 µm. 
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Figure 5.6 Quantification of CD8+ T-cells in the small intestine following CD4+ cells depletion. 
 
(A) Representative images of β-catenin (grey) and CD8+ cells (brown) IHC staining in the small 
intestine. Black arrows indicate aberrant crypts and brown arrows indicate CD8+ cells. (B) CD8+ 
cells numbers were significantly increased in Treg depleted mice. Apart from Apc deleted/Treg 
depleted mice, there was a significantly increased number of CD8+ cells in aberrant crypts (AC), 
when comparing to normal crypts (NC). Data represent a single experiment, n ≥ 4 mice per group. 
(*) P value ˂ 0.05, (**) P value ≤ 0.01. Two-tailed Mann Whitney U test. Error bars represent 
Standard Deviation (SD). Scale bars represent 50 µm. 
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5.2.2 Analysing the effect of CD8+ T-cells depletion in an Apc deleted mice 
 
5.2.2.1 Examining the partial tumour burden following CD8+ depletion 
 
To analyse the role of CD8+ cells in the initiation of intestinal cancer, mice were 
injected with a monoclonal antibody (clone YTS 169) to selectively deplete CD8+ cells 
(see section 2.4.2.3). Four experimental groups were compared: the previously 
described Lgr5CreERT2Apcfl/fl and Lgr5CreERT2Apcfl/flFoxp3DTR groups, as well as following 
CD8+ cell depletion, (Lgr5CreERT2Apcfl/fl, Anti-CD8 and Lgr5CreERT2Apcfl/flFoxp3DTR, Anti-
CD8). The tumour burden was analysed as previously described in the first 5 cm of the 
small intestine. Contradicting the proposed hypothesis, that CD8+ cell depletion would 
increase the number of aberrant crypts, it was observed that CD8+ cell depletion in Apc 
deleted mice significantly decreased the tumour burden in the small intestine (Figure 
5.7). There is a trend for a decreased tumour burden in Apc deleted mice were both 
CD8+ T-cells and Tregs were depleted (Figure 5.8), suggesting that in the early stages 
of intestinal cancer CD8+ cells play a pro-tumoral role.  
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A) Representative images of β-catenin (grey) and CD8+ cells (brown) IHC staining in the small 
intestine. Black arrows indicate aberrant crypts and brown arrows indicate CD8+ cells. (B) CD8+ 
cells depletion resulted in a significantly decreased number of aberrant crypts in the small 
intestine of the Apc deleted mice. Apc deleted/Treg and CD8+ cells depleted mice had a trend for 
a decreased number of aberrant crypts. Data for the Lgr5CreERT2Apcfl/fl and 
Lgr5CreERT2Apcfl/flFoxp3DTR groups are repeated in figure 5.1. Data represent a single experiment, 
n ≥ 4 mice. (*) P value ˂ 0.05, two-tailed Mann Whitney U test. Error bars represent Standard 
Deviation (SD). Scale bars represent 50 µm. 
 
 
 
 
 
 
 
 
 
 
Figure 5.7 Tumour burden analysis in the small intestine following CD8+ cells depletion.  
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5.2.2.2 Evaluating the gene expression of Wnt, ISC and immune markers following 
CD8+ depletion 
 
To analyse whether the effects of CD8+ depletion were a feature of the whole 
intestine, the expression of Wnt markers were analysed. It was hypothesised that the 
observed reduction in the tumour burden would be reflected in the non-activation of the 
Wnt pathway. As expected, the decreased tumour burden observed in Apc deleted/CD8+ 
cell depleted mice were reflected in the reduction of the relative gene expression of the 
Wnt signalling markers, Axin2 and c-Myc, when compared to Apc deletion alone (Figure 
5.8). Interestingly, CD8+ cell depletion alone resulted in a significantly reduced relative 
gene expression of Wnt targets (Figure 5.8), suggesting that these immune cells play a 
role in the Wnt signalling activation.  
As the aberrant crypts are supported by ISCs, next I analysed the gene 
expression of ISCs markers. CD8+ cell depletion significantly reduced the relative gene 
expression of Lgr5 in Apc deleted and Apc deleted/Treg depleted mice when compared 
to Apc deletion alone (Figure 5.9). There were no significant changes, following CD8+ 
cell depletion, in Olfm4 and Ascl2 was significantly decreased in Apc deleted mice 
(Figure 5.9). Taken together, these data show that, depletion of CD8+ cells resulted in a 
reduced gene expression of the Wnt markers Axin2 and c-Myc, as well as the ISC marker 
Lgr5, itself a Wnt marker, suggesting that the reduction in the number of aberrant crypts 
is supported by the reduced Wnt signalling, 
To verify whether depletion of CD8+ cells had an impact in the gene expression 
of Tregs and the cytokine IFNγ, the relative gene expression of Foxp3 and IFNγ were 
analysed.  CD8+ cell depletion alone significantly reduced the relative gene expression 
of Foxp3, however this effect was rescued when CD8+ cells were depleted in Apc 
deleted mice (Figure 5.10). This might be a consequence of Apc deletion that, as 
previously shown, significantly increases the expression of Foxp3. As previously 
explained, IFNγ can be secreted by a variety of immune cell populations, including CD8+ 
cells. As expected, CD8+ cell depletion, alone or in Apc deleted mice, significantly 
decreased the gene expression of IFNγ. However, this effect was rescued in Apc 
deleted/Treg depleted mice in the absence of CD8+ cells, where a significantly increased 
gene expression of IFNγ was observed that might be explained by Treg depletion (Figure 
5.10). 
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CD8+ cells depletion alone and in combination with Apc deletion and Apc deletion/Treg depletion resulted in a significantly decreased relative gene expression 
of Axin2 and c-Myc when compared to Apc deleted mice. Data represent a single experiment, n ≥ 3 mice per group. Data for the non-induced, Lgr5CreERT2Apcfl/fl, 
Foxp3DTR, Lgr5CreERT2Apcfl/flFoxp3DTR groups are repeated in figures 4.3 and 5.2. (*) P value ˂ 0.05, one-tailed Mann Whitney U test. 
 
 
Figure 5.8 Relative gene expression of Wnt signalling markers in the small intestinal epithelium, following CD8+ cells depletion. 
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Figure 5.9 Relative gene expression of ISC markers in the small intestinal epithelium, following CD8+ cells depletion. 
 
CD8+ cells depletion resulted in a decreased the relative gene expression of Lgr5, particularly in Apc deleted/Treg depleted mice. There were no changes in 
the Olfm4. Ascl2 was significantly decreased in Apc deleted/CD8+ cells depleted mice when compared to Apc deletion alone. Data represent a single experiment, 
n ≥ 3 mice per group. Data for the non-induced, Lgr5CreERT2Apcfl/fl, Foxp3DTR, Lgr5CreERT2Apcfl/flFoxp3DTR groups are repeated in figures 4.4 and 5.3. (*) P value 
˂ 0.05, (**) P value ≤ 0.01, one-tailed Mann Whitney U test. 
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CD8+ cells depletion resulted in a significantly reduced expression of Foxp3 and IFNγ, however in the last one the relative gene expression was rescued in Apc 
deleted/Treg depleted mice. Data represent a single experiment, n ≥ 3 mice per group. Data for the non-induced, Lgr5CreERT2Apcfl/fl, Foxp3DTR, 
Lgr5CreERT2Apcfl/flFoxp3DTR groups are repeated in figures 4.5 and 5.4. (*) P value ˂ 0.05, (**) P value ≤ 0.01, one-tailed Mann Whitney U test.
Figure 5.10 Relative gene expression of Foxp3 and IFNγ in the small intestinal epithelium, following CD8+ cells depletion 
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5.2.2.3 Evaluating the number of T-cells following CD8+ cell depletion 
 
The number of CD4+ and CD8+ cells was quantified in CD8+ cell depleted mice, 
as previously described, in both normal (NC) and aberrant crypts (AC). Similar to the 
analysis performed for the T-cell quantification in the CD4+ cell depleted mice, here I 
included the following groups: non-induced, Foxp3DTR, Lgr5CreERT2Apcfl/fl and 
Lgr5CreERT2Apcfl/flFoxp3DTR groups. The groups where CD8+ cells were depleted were: 
Lgr5CreERT2Apcfl/fl, Anti-CD8; Lgr5CreERT2Apcfl/flFoxp3DTR, Anti-CD8; and CD8 depletion 
alone (Anti-CD8). CD8+ cell depletion alone did not alter significantly the number of 
CD4+ cells in the small intestinal crypts, suggesting that in the absence of CD8+ cells 
there are no alterations in the infiltration of CD4+ cells (Figure 5.11). However, CD4+ 
cells were significantly increased following CD8+ cells depletion in Apc deleted and Apc 
deleted/Treg depleted mice, particularly in the aberrant crypts (Figure 5.11). There were 
no differences in the number of CD4+ cells between Apc deleted and Apc deleted/CD8+ 
cell depleted mice (Figure 5.11), suggesting that CD8+ cell depletion does not have an 
impact in the infiltration of CD4+ cells in the intestine in the early stages of intestinal 
cancer. 
As expected, mice injected with the antibody to achieve CD8+ cell depletion, had 
a significantly decreased number of CD8+ cells in the small intestinal crypts, when 
compared to non-induced mice (Figure 5.12). In Apc deleted/CD8+ cell depleted mice 
significant increase in the number of CD8+ cells around the newly formed lesions was 
observed, suggesting that in the context of Apc deletion there is a recruitment of these 
cells to the pro-tumoral tissue even when mice are injected with a depleting antibody to 
eliminate CD8+ cells. These data suggest a role of these cells in the initiation of intestinal 
cancer. CD8+ cell depletion in Apc deleted/Treg depleted mice had a significantly 
increased number of CD8+ cells, possibly due to Tregs depletion that, itself, resulted in 
a significantly increased number of CD8+ cells (Figure 5.12) 
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(A) Representative images of β-catenin (grey) and CD4+ cells (brown) IHC staining in the small 
intestine. Black arrows indicate aberrant crypts and brown arrows indicate CD4+ cells. (B) CD4+ 
cells were significantly increased in the aberrant crypts (AC) of Apc deleted/CD8+ cells depleted 
mice when compared to normal crypts (NC). CD8+ cells depletion in Apc deleted/Treg depleted 
mice significantly increased the number of CD4+ cells, but with no differences between normal 
and aberrant crypts. Data represent a single experiment, n ≥ 4 mice per group. Data for the non-
induced, Foxp3DTR, Lgr5CreERT2Apcfl/fl and Lgr5CreERT2Apcfl/flFoxp3DTR groups are repeated in 
figure 5.5. (*) P value ˂ 0.05, (**) P value ≤ 0.01. Two-tailed Mann Whitney U test. Error bars 
represent Standard Deviation (SD). Scale bars represent 50 µm. 
 
Figure 5.11 Quantification of CD4+ cells in the small intestine following CD8+ cells depletion. 
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(A) Representative images of β-catenin (grey) and CD8+ cells (brown) IHC staining in the small 
intestine. Black arrows indicate aberrant crypts and brown arrows indicate CD8+ cells. (B) CD8+ 
cells depletion resulted in a significantly decreased number of CD8+ cells in the crypts when 
compared to non-induced mice. Apc deleted and Apc deleted/Treg depleted mice, even following 
CD8+ cells depletion, had a significant increased number of CD8+ cells in the aberrant crypts. 
Data represent a single experiment, n ≥ 4 mice per group. Data for the non-induced, Foxp3DTR, 
Lgr5CreERT2Apcfl/fl and Lgr5CreERT2Apcfl/flFoxp3DTR groups are repeated in figure 5.6. (*) P value ˂ 
0.05, (**) P value ≤ 0.01, two-tailed Mann Whitney U test. Error bars represent Standard Deviation 
(SD). Scale bars represent 50 µm. 
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Figure 5.12 Quantification of CD8+ cells in the small intestine following their depletion. 
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5.2.3 Analysing the effect of IFNγ neutralisation in an Apc deleted mice 
 
5.2.3.1 Examining the partial tumour burden following IFNγ neutralisation 
 
Finally, I analysed the effects of IFNγ in the early stages of intestinal 
tumourigenesis. Mice were injected with an antibody to specifically neutralise IFNγ (clone 
XMG 1.2) (section 2.4.2.4). 
 As previously, I started by quantifying the tumour burden in the first 5 cm of the 
small intestine of mice following IFNγ neutralisation. Similar to the analysis performed 
for the CD4+ and CD8+ cell depletion experiments, I included the Lgr5CreERT2Apcfl/fl and 
Lgr5CreERT2Apcfl/flFoxp3DTR groups. The groups where IFNγ was neutralised were: 
Lgr5CreERT2Apcfl/fl, Anti-IFNγ and Lgr5CreERT2Apcfl/flFoxp3DTR, Anti-IFNγ.  Considering 
that IFNγ has been associated to play a role in the anti-tumour immune responses, I 
hypothesised that the neutralisation of this cytokine would significantly increase the 
tumour burden. Contrary to what it was expected, IFNγ neutralisation did not have a 
significant effect in the tumour burden of Apc deleted and Apc deleted/Treg depleted 
mice (Figure 5.13), suggesting that it does not play a key role in the early stages of 
intestinal cancer.
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(A) Representative images of β-catenin (grey) and CD8+ cells (brown) IHC staining in the small 
intestine. Black arrows indicate aberrant crypts and brown arrows indicate CD8+ cells. (B) IFNγ 
neutralisation did not alter the tumour burden in Apc deleted and Apc deleted/Treg depleted mice. 
Data for the Lgr5CreERT2Apcfl/fl and Lgr5CreERT2Apcfl/flFoxp3DTR groups are repeated in figures 5.1 
and 5.7. Data represent a single experiment, n ≥ 4 mice per group. Two-tailed Mann Whitney U 
test. Error bars represent Standard Deviation (SD). Scale bars represent 50 µm. 
  
Figure 5.13  Tumour burden analysis in the small intestine following IFNγ neutralisation. 
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5.2.3.2 Evaluating the gene expression of Wnt and ISC markers following IFNγ 
neutralisation 
 
 
Considering that IFNγ did not alter the tumour burden in the small intestine when 
compared to Apc deleted mice, I hypothesised that relative gene expression of Wnt 
signalling markers would be similar to the one observed in Apc deletion alone. 
Interestingly, IFNγ neutralisation attenuated the effect of Wnt targets upregulation when 
compared to Apc deletion alone or Apc deletion /Treg depletion, suggesting that there 
was less Wnt signalling in these mice (Figure 5.14).  
Next, I looked at the expression of ISCs, responsible for the support of aberrant 
crypts, and observed that Lgr5 gene expression, also known as a Wnt marker, was 
significantly reduced following IFNγ neutralisation, when compared to Apc deleted or Apc 
deleted/Treg depleted mice (Figure 5.14), suggesting again that there was a lower 
activation of the Wnt signalling pathway. Both Ascl2 and Olfm4 had a significantly 
reduced gene expression following IFNγ neutralisation in Apc deleted/Treg depleted 
mice, when compared to Apc deletion alone, suggesting a possible reduction in the 
malignant ISC population (Figure 5.15). 
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IFNγ neutralisation resulted significantly increased relative gene expression of the Wnt markers Axin2 and c-Myc when compared to non-induced mice, but it 
was significantly decreased in comparison to Apc deleted mice. IFNγ neutralisation in Apc deleted/Treg depleted mice resulted in a significantly decreased 
expression of c-Myc when compared to Apc deleted/IFNγ neutralised mice. Data represent a single experiment, n ≥ 3 mice per group. Data for the non-induced, 
Lgr5CreERT2Apcfl/fl, Foxp3DTR, Lgr5CreERT2Apcfl/flFoxp3DTR groups are repeated in figures 4.3, 5.2 and 5.8. (*) P value ˂ 0.05, (**) P value ≤ 0.01, one-tailed Mann 
Whitney U test. 
 
 
Figure 5.14 Relative gene expression of Wnt signalling markers in the small intestinal epithelium, following IFNγ neutralisation. 
146 
 
 
 
 
 
 
 
 
 
 
 
 
Relative gene expression of the ISC markers, following IFNγ neutralisation, was not altered when compared to non-induced mice. Lgr5 was significantly 
downregulated when compared to Apc deleted mice. Treg depletion in Apc deleted/IFNγ neutralised mice resulted in a significantly reduced relative gene 
expression of Lgr5 and Ascl2 when compared to Apc deleted/IFNγ neutralised mice. Data represent a single experiment, n ≥ 3 mice per group. Data for the 
non-induced, Lgr5CreERT2Apcfl/fl, Foxp3DTR, Lgr5CreERT2Apcfl/flFoxp3DTR groups are repeated in figures 4.4, 5.3 and 5.9. (*) P value ˂ 0.05, (**) P value ≤ 0.01, 
one-tailed Mann Whitney U test
Figure 5.15 Relative gene expression of ISC markers in the small intestinal epithelium, following IFNγ neutralisation. 
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5.2.3.3 Evaluating the number of T-cells following IFNγ neutralisation 
 
The number of T-cells was quantified as previously described for the other 
groups. Similar to the analysis performed for the T-cell quantification in the CD4+ and 
CD8+ cell depleted mice, the following groups were included: non-induced, Foxp3DTR, 
Lgr5CreERT2Apcfl/fl and Lgr5CreERT2Apcfl/flFoxp3DTR groups. The groups where IFNγ was 
neutralised were: Lgr5CreERT2Apcfl/fl, Anti-IFNγ and Lgr5CreERT2Apcfl/flFoxp3DTR, Anti-
IFNγ. 
  IFNγ neutralisation resulted in a significantly increased number of CD4+ cells in 
the aberrant crypts of Apc deleted and Apc deleted/Treg depleted mice, when compared 
to normal crypts (Figure 5.17). Interestingly, IFNγ neutralisation in Apc deleted and Apc 
deleted/Treg depleted mice significantly increased the number of CD4+ cells in both 
normal and aberrant crypts when compared to same group, but without neutralisation of 
this cytokine, possibly suggesting that a higher infiltration of CD4+ cells was happening 
so the secretion of IFNγ could be increased back to normal and that this process was 
facilitated by the absence of Tregs.  
IFNγ neutralisation significantly increased the number of CD8+ cells in the 
aberrant crypts of Apc deleted, but particularly in Apc deleted/Treg depleted mice (Figure 
5.18). There were no differences in the numbers of CD8+ cells between Apc deleted or 
Apc deleted/Treg depleted and the same groups but following IFNγ neutralisation (Figure 
5.18), suggesting that IFNγ neutralisation did not have an impact in the infiltration of 
CD8+ cells and that, possibly, CD4+ cells are the main responsible cell population for 
the secretion of IFNγ in the intestine. 
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(A) Representative images of β-catenin (grey) and CD4+ cells (brown) IHC staining in the small 
intestine. Black arrows indicate aberrant crypts and brown arrows indicate CD4+ cells. (B) IFNγ 
neutralisation resulted in a significantly increased number of CD4+ cells in the aberrant crypts in 
both Apc deleted, but particularly Apc deleted/Treg depleted mice, when compared to normal 
surrounding tissue. Data represent a single experiment, n ≥ 4 mice per group. Data for the non-
induced, Foxp3DTR, Lgr5CreERT2Apcfl/fl and Lgr5CreERT2Apcfl/flFoxp3DTR groups are repeated in 
figures 5.5 and 5.11. (*) P value ˂ 0.05, (**) P value ≤ 0.01, two-tailed Mann Whitney U test. Error 
bars represent Standard Deviation (SD). Scale bars represent 50 µm. 
 
Figure 5.16 Quantification of CD4+ cells in the small intestine following IFNγ neutralisation. 
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(A) Representative images of β-catenin (grey) and CD8+ cells (brown) IHC staining in the small 
intestine. Black arrows indicate aberrant crypts and brown arrows indicate CD8+ cells. (B) IFNγ 
neutralisation resulted in a significantly increased number of CD8+ cells in the aberrant crypts of 
Apc deleted and Apc deleted/Treg depleted mice when compared to normal crypts. Data 
represent a single experiment, n ≥ 4 mice per group. Data for the non-induced, Foxp3DTR, 
Lgr5CreERT2Apcfl/fl and Lgr5CreERT2Apcfl/flFoxp3DTR groups are repeated in figures 5.6 and 5.12. (*) 
P value ˂ 0.05, (**) P value ≤ 0.01, two-tailed Mann Whitney U test. Error bars represent Standard 
Deviation (SD). Scale bars represent 50 µm. 
  
Figure 5.17 Quantification of CD8+ cells in the small intestine following IFNγ neutralisation. 
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5.3 Discussion 
 
The immune system has a complex role in cancer as immune cells can act both 
as suppressors of tumour initiation and progression (Dunn et al. 2004), but also as 
promoters of the disease (Balkwill and Coussens 2004). Recently, infiltration of tumours 
with high numbers of lymphocytes has been associated with a better prognosis and 
improved survival of cancer patients, not only in CRC (Galon et al. 2006; Mei et al. 2014; 
Braha et al. 2016), but also other tumour types such as breast (Menegaz et al. 2008) 
and lung cancer (Al-Shibli et al. 2008; Dieu-Nosjean et al. 2008). Previously, I have 
shown that Treg depletion increased both frequency and number of CD4+ and CD8+ 
cells regardless whether Apc is deleted. The frequency of IFNγ was also increased upon 
Tregs depletion. In this chapter, I wanted to evaluate whether these alterations in the T-
cells and IFNγ play a role in reducing the number of aberrant crypts in the small intestine.  
 
5.3.1 Evaluating the role of CD4+ cells in intestinal homeostasis 
 
CD4+ cells are a very heterogeneous population that includes a variety of sub-
populations that have been described as pro- and anti-tumoral. These sub-populations 
comprise, for example Tregs, Th1 and Th17 cells. Tosolini and colleagues have 
analysed, in CRC patients, the balance between different populations of T-lymphocytes 
and how they correlate with disease-free survival. They have shown that increased 
frequencies of Th17 cells were associated with a poor prognosis, whereas increased 
numbers of Th1 cells was linked to a prolonged disease-free survival (Tosolini et al. 
2011). I have previously shown that Treg depletion results in a decreased tumour burden 
in the intestine. In this chapter, I demonstrated that depletion of CD4+ cells significantly 
reduced the small intestinal tumour burden. Taken together, these data indicate that in 
the early stages of tumour initiation, CD4+ T cells are more likely to promote than prevent 
tumour growth. A more in-depth analysis of the T cell subsets involved is now needed.   
Interestingly, CD4+ cell depletion in Apc deleted and Apc deleted/Treg cells 
depleted mice resulted in a significantly reduced gene expression of the Wnt markers 
Axin2 and c-Myc, when compared to Apc deletion alone, suggesting again that depletion 
of CD4+ cells was beneficial in the early stages of intestinal cancer. CD4+ cell depletion 
was associated with reduced the gene expression of the ISC and Wnt marker Lgr5, in 
Apc deleted mice, but had no effects in the other ISC markers Olfm4 and Ascl2, 
suggesting that the ISC population was not altered.  
 In a recently published study, it was demonstrated  that CRC suppress CD4+ T-
cells immunity through canonical Wnt signalling (Sun et al. 2017). Sun and colleagues 
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demonstrated that β-catenin was elevated in intra-tumoral T-cells, which correlated with 
decreased  IFNγ expression and increased IL-17A expression in activated CD4+ cells 
(Sun et al. 2017). Here, CD4+ cells depletion, in Apc deleted mice, significantly reduced 
the relative gene expression of IFNγ when compared to Apc deleted mice.  
 Analysis of CD8+ cells number, in CD4+ cells depleted mice, showed an 
accumulation of these cells around the newly formed lesions compared to normal 
surrounding tissue. The same was observed in Apc deleted mice, suggesting that CD8+ 
T-cells play a key role in the anti-tumour immune responses in the early stages of 
intestinal cancer.  
 
5.3.2 Evaluating the role CD8+ cells in the intestinal homeostasis 
 
CD8+ cells have long been considered a key population in anti-tumour immunity 
and infiltration by these cells has been associated to a better prognosis in a number of 
malignancies such as breast (Liu et al. 2012; Ziai et al. 2018), melanoma (van Oijen et 
al. 2004), ovarian (Hamanishi et al. 2007), pancreatic (Fukunaga et al. 2004) as well as 
CRC (Galon et al. 2006; Pages et al. 2009; Mlecnik et al. 2011; Ziai et al. 2018).  
It is therefore surprising that the data herein demonstrate that CD8+ cells depletion 
in Apc deleted mice significantly reduces the tumour burden in the small intestine. In 
accordance with this, Wnt signalling markers were significantly reduced in CD8+ cell 
depleted mice when comparing to Apc deleted mice, indicating a reduction in Wnt 
activation and supporting the decreased number of aberrant crypts. The same was 
observed for the ISC markers Lgr5 and Ascl2, possibly indicating a reduction in the ISC 
pool and, as a consequence, a reduction in the number of Apc deficient ISC, resulting in 
a decreased number of aberrant crypts. The increased gene expression of Foxp3 was 
attenuated following CD8+ cell depletion in Apc deleted mice, when compared to Apc 
deletion alone, suggesting again a beneficial effect of CD8+ cell depletion in this model. 
CD8+ cell depletion significantly reduced the gene expression of IFNγ. CD8+ cell 
depletion alone did not alter the number of CD4+ cells in the small intestinal crypts, 
however CD8+ cell depletion in Apc deleted mice significantly increased the number of 
CD4+ cells in the aberrant crypts, possibly suggesting that CD4+ cells may be having a 
beneficial effect in controlling tumour growth.  
Treatment with the depleting antibody, as expected, significantly reduced the 
number of CD8+ cells, however not completely. Interestingly, CD8+ T-cells accumulated 
in the aberrant crypts of Apc deleted, but particularly Apc deleted/Treg depleted mice, 
suggesting that these cells are attracted to the pro-tumorigenic tissue in the absence of 
Tregs even when a depleting antibody is applied. Another possible explanation is that is 
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this experimental group (Lgr5CreERT2Apcfl/flFoxp3DTR, Anti-CD8) CD8+ cell depletion was 
not efficient. In the future, a higher dose of depleting antibody or injection with another 
clone (YTS-156) together with YTS-169 could be tested in order to improve CD8+ 
depletion (Jones et al. 2002). To further understand the effects of T-cell depletion in the 
reduction of the number of aberrant crypts, other experiments should be included, such 
as cleaved caspase 3 IHC to analyse the intestinal apoptotic index, as this may be a 
possible mechanism by which there is a reduction in the tumour burden. 
 Taken together, these data suggest that CD8+ cell depletion had a beneficial 
effect in the early stages of intestinal cancer, contradicting the initial hypothesis that 
CD8+ cells depletion would promote tumourigenesis. 
 
5.3.3 Evaluating the role of IFNγ in the intestinal homeostasis 
 
Finally, I analysed the effect of IFNγ neutralisation in the initiation of intestinal 
cancer. The interaction between the tumour and the immune cells is a controlled process 
in all stages of tumour progression, in which IFNγ plays a key role. Studies have shown 
that genetic variations in IFNγ are associated with a lower survival following CRC 
diagnosis (Slattery et al. 2011; Bondurant et al. 2013; Di Franco et al. 2017; Kosmidis et 
al. 2018).  Wang and colleagues investigated the role of IFNγ deficiency in Apcmin mice. 
IFNγ deficient mice had an increased number and size of adenomas with increased Wnt 
signalling (Wang et al. 2015a). Moreover, administration of IFNγ inhibited the 
proliferation of Apc mutated colon cancer cell line but not wild-type cell lines in vitro. In 
vitro knockdown of IFNγ increased cell proliferation and colony formation, suggesting 
that IFNγ participates in the anti-tumour immune responses (Wang et al. 2015a).  
Surprisingly, IFNγ neutralisation did not increase the tumour burden in the small 
intestine of the treated mice. IFNγ neutralisation significantly increased the expression 
of the Wnt markers Axin2 and c-Myc, however this effect was attenuated when compared 
to Apc deletion alone, suggesting a beneficial effect of IFNγ neutralisation in this mouse 
model. Relative gene expression of the ISC markers were only significantly reduced 
following IFNγ neutralisation in Apc deleted/Treg depleted mice when compared to Apc 
deleted mice. This was similar to what was observed in Apc deleted/Treg depleted mice, 
possibly indicating that this effect is mainly due to Treg depletion and not IFNγ 
neutralisation. IFNγ neutralised mice had an increased number of both CD4+ and CD8+ 
cells around the newly formed lesions. A limitation in this study was the fact that IFNγ 
neutralization was not confirmed by IHC and/or flow cytometry. This is clearly necessary 
before any firm conclusions can be drawn. Importantly, for the immune cell depletion and 
cytokine neutralisation, the tumour burden was only quantified in the first 5 cm of the 
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small intestine due to experimental limitations, particularly the concentration of 
antibodies available for the injections. Further experiments should include the 
quantification of the total tumour burden in serial sections of the whole small and large 
intestines in order to confirm these findings. Considering that it was not possible to 
include a group with CD4+ depletion and IFNγ neutralisation alone, in the next 
experiments these should be included. Future experiments should also include 
confirmation of T-cell depletion and IFNγ neutralisation by IHC, flow cytometry and/or 
ELISA.  
In summary, in this chapter it was shown that both CD4+ and CD8+ cell depletion 
significantly decreased the small intestinal tumour burden. IFNγ neutralisation had no 
effect on the number of aberrant crypts. The changes in the intestine, as a consequence 
of the altered immune system in the Lgr5CreERT2Apcfl/flFoxp3DTR following T-cell depletion 
and IFNγ neutralisation, gave unexpected results, such as the decreased tumour burden 
following CD8+ cell depletion.  
One possible explanation is that CD8-depleting antibodies might impact on the ISC 
pool thereby reducing the targets for Apc deletion and, as a consequence, reducing the 
intestinal tumour burden. Further experiments should include CD8+ cell depletion 
following Apc deletion in the ISCs in order to clarify whether the reduced tumour burden 
observed is a consequence of eliminating CD8+ cells and not because ISCs number was 
altered by the antibody treatment. In addition, changes in the Lgr5 ISC stem cells could 
be analysed in situ by RNAscope. This will provide information about the changes in Lgr5 
transcripts, not only their number, but also localization in the intestine, possibly giving 
new insights into how the immune system impacts intestinal homeostasis. Part of this 
analysis will be presented in the following chapter.
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6 RNAscope analysis of Lgr5 transcripts in the early stages 
of intestinal cancer 
 
6.1 Introduction 
 
In the previous chapter it was demonstrated that depletion of CD4+ and CD8+ T-
cells significantly reduced the tumour burden in the mice small intestine. This was 
particularly surprising with CD8+ T-cells depletion, where it was expected an increased 
number of aberrant crypts, as these cells have been considered responsible for the anti-
tumour immune response in a variability of cancers (van Oijen et al. 2004; Liu et al. 2012; 
Ziai et al. 2018), including CRC, but the opposite was observed. 
Depletion of CD8+ cells was done prior to Apc deletion in the ISCs. It is possible 
that this altered the stem cell pool. If that was the case, a lower number of ISCs would 
be transformed explaining the reduced number of aberrant crypts. It was, then, 
hypothesised that depletion of T-cells would impact in the homeostasis of the ISCs and 
that it would have a direct effect in the initiation of intestinal cancer. To start testing it, 
the number of Lgr5 transcripts was analysed by RNAscope in the small intestine of the 
previously described groups. This method allows the visualization of the transcripts in 
the tissue providing quantitative data on expression of Lgr5, the number of cells which 
express it and their localisation.
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6.2 Results 
 
The previously described groups were used in the analysis of Lgr5 transcripts by 
RNAscope staining. Lgr5 transcripts were identified by the brown strained dots, 
independently of the intensity of the staining. As expected, the number of Lgr5 transcripts 
was significantly increased in the crypts of Apc deleted mice (Figure 6.1), when 
compared to non-induced mice, reflecting the increase that was previously observed in 
the gene expression analysis by qRT-PCR (Figure 4.4). Interestingly, Treg depletion in 
Apc deleted mice resulted in a reduced number of Lgr5 transcripts when compared to 
Apc deletion alone (Figure 6.1), suggesting that the reduced tumour burden in Apc 
deleted/Treg depleted mice (Figure 4.1) can be explained by a reduced number of 
transformed ISC. The same is observed in mice where CD4+ cells were depleted (Figure 
6.1), possibly explaining again the reduced tumour burden observed (Figure 5.1). 
Interestingly, Treg depletion alone did not alter significantly the number of Lgr5 
transcripts, however altered the re-distribution of the transcripts, possibly suggesting that 
Tregs play a role in the homeostasis of ISCs (Figure 6.1). 
Depletion of CD8+ T-cells did not alter the number of Lgr5 transcripts when 
compared to non-induced mice, however there was a re-distribution of the transcripts 
from the bottom to other parts of the crypts (Figure 6.2). The same was observed in Apc 
deleted/CD8+ cell depleted mice (Figure 6.2). Taken together these data suggest that 
depletion of CD8+ cells alter the homeostasis of the ISCs and that is might be the reason 
why CD8+ cell depletion in Apc deleted mice resulted in a reduced tumour burden (Figure 
5.7). 
IFNγ neutralisation resulted in a significantly decreased the number of Lgr5 
transcripts in Apc deleted mice and altered their re-distribution in the crypts (Figure 6.3), 
however, in this case, the reduced number of Lgr5 transcripts was not reflected in a 
reduced tumour burden (Figure 5.13). 
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(A) Representative images of Lgr5 (brown) RNAscope staining in the small intestine. Black arrow 
indicated an example of a brown dot representing an Lgr5 transcript. (B) Apc deletion significantly 
increased the number of Lgr5 transcripts in the crypts. Depletion of CD4+ T-cells in Apc deleted 
mice significantly reduced the number of Lgr5 transcripts. Data represent a single experiment, n 
≥ 4 mice per group. (*) P value ˂ 0.05, two-tailed Mann Whitney U test. Error bars represent 
Standard Deviation (SD). Scale bars represent 20 µm.
Figure 6.1 Lgr5 expression analysis in the small intestinal crypts following CD4+ T-cells depletion. 
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(A) Representative images of Lgr5 (brown) RNAscope staining in the small intestine. (B) Depletion 
of CD8+ T-cells did alter significantly the number of Lgr5 transcripts and, in Apc deleted mice, 
had a trend for an increased number of Lgr5 transcripts in in the crypts. CD8+ T-cells depletion 
in Apc deleted/Treg cells depleted mice significantly increased the number of Lgr5 transcripts in 
the crypts. Data represent a single experiment, n ≥ 4 mice per group. Data for the non-induced, 
Foxp3DTR, Lgr5CreERT2Apcfl/fl and Lgr5CreERT2Apcfl/flFoxp3DTR groups are repeated in figure 6.1. (*) 
P value ˂ 0.05, two-tailed Mann Whitney U test. Error bars represent Standard Deviation (SD). 
Scale bars represent 20 µm. 
 
Figure 6.2 Lgr5 expression analysis in the small intestinal crypts following CD8+ T-cells depletion. 
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(A) Representative images of Lgr5 (brown) RNAscope staining in the small intestine. (B) IFNγ 
neutralisation in Apc deleted mice significantly reduced the number of Lgr5 transcripts in the 
crypts. There were no significant changes following IFNγ neutralisation in Apc deleted/Treg cells 
depleted mice. Data represent a single experiment, n ≥ 4 mice per group. Data for the non-
induced, Foxp3DTR, Lgr5CreERT2Apcfl/fl and Lgr5CreERT2Apcfl/flFoxp3DTR groups are repeated in 
figures 6.1 and 6.2. (*) P value ˂ 0.05, two-tailed Mann Whitney U test. Error bars represent 
Standard Deviation (SD). Scale bars represent 20 µm. 
 
Figure 6.3 Lgr5 expression analysis in the small intestinal crypts following IFNγ neutralisation. 
B 
164 
 
To further evaluate the how the immune changes affected the homeostasis of the 
ISCs, the number of Lgr5 transcripts was quantified in the villi of the previously analysed 
mice.  As expected, the number of Lgr5 transcripts was significantly increased in the villi 
of Apc deleted mice (Figure 6.4). Depletion of CD4+ cells in Apc deleted mice had no 
effect in the number of Lgr5 transcripts in the villi, however increased in Apc deleted/Treg 
depleted mice, suggesting again that the immune cell populations may play a role in the 
homeostasis of ISCs (Figure 6.4). 
Interestingly, CD8+ T-cells depletion, alone and in combination with Apc deletion, 
significantly increased the number of Lgr5 transcripts in the villi, however this effect was 
significantly attenuated in Apc deleted/Treg cells depleted mice (Figure 6.5), suggesting 
once again a role of the immune system in the regulation of ISCs homeostasis. 
The number of Lgr5 transcripts was not altered following IFNγ neutralisation in 
Apc deleted mice, however it was significantly increased in Apc deleted/Treg cells 
depleted mice (Figure 6.6). 
Taken together, these data show that either depletion of T-cells or neutralization 
of IFNγ result in an altered distribution of Lgr5 transcripts from the bottom of the crypts 
to other parts, including the villi, suggesting a role of these cells in the ISCs homeostasis. 
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(A) & (B) Representative images of Lgr5 (brown) RNAscope staining in the small intestine. (C) 
Apc deletion significantly increased the number of Lgr5 transcripts in the villi. Depletion of CD4+ 
T-cells in Apc deleted did not alter the number of Lgr5 transcripts, however increased in the villi 
of Apc deleted/Treg cells depleted mice. Data represent a single experiment, n ≥ 4 mice per 
group. (*) P value ˂  0.05, two-tailed Mann Whitney U test. Error bars represent Standard Deviation 
(SD). Scale bars represent 20 µm. 
Figure 6.4 Lgr5 expression analysis in the small intestinal villi following CD4+ T-cells depletion. 
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(A) Representative images of Lgr5 (brown) RNAscope staining in the small intestine. (B) Depletion 
of CD8+ T-cells alone, and in Apc deleted mice, significantly increased the number of Lgr5 
transcripts in the villi. Data represent a single experiment, n ≥ 4 mice per group. Data for the non-
induced, Foxp3DTR, Lgr5CreERT2Apcfl/fl and Lgr5CreERT2Apcfl/flFoxp3DTR groups are repeated in 
figure 6.4. (*) P value ˂ 0.05, two-tailed Mann Whitney U test. Error bars represent Standard 
Deviation (SD). Scale bars represent 20 µm.  
Figure 6.5 Lgr5 expression analysis in the small intestinal villi following CD8+ T-cells depletion. 
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(A) Representative images of Lgr5 (brown) RNAscope staining in the small intestine. (B) IFNγ 
neutralisation in Apc deleted mice did not alter significantly the number of Lgr5 transcripts in the 
villi. IFNγ neutralisation in Apc deleted/Treg depleted mice significantly increased the number of 
Lgr5 transcripts in the small intestinal villi. Data represent a single experiment, n ≥ 4 mice per 
group. Data for the non-induced, Foxp3DTR, Lgr5CreERT2Apcfl/fl and Lgr5CreERT2Apcfl/flFoxp3DTR 
groups are repeated in figures 6.4 and 6.5. (*) P value ˂ 0.05, two-tailed Mann Whitney U test. 
Error bars represent Standard Deviation (SD). Scale bars represent 20 µm. 
  
Figure 6.6 Lgr5 expression analysis in the small intestinal villi following IFNγ neutralisation. 
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6.3 Discussion 
 
The ISCs are essential in the maintenance of the intestinal homeostasis (Peterson 
and Artis 2014), where they give rise to the progenitors that, later differentiate to specific 
intra-epithelial cells (Munoz et al. 2012; Tetteh et al. 2016). It is well established that 
canonical signal pathways, such as Wnt and Notch are essential in the ISCs dynamics 
(Tian et al. 2015), however it is less known how immune cells and the adjacent ISCs 
interact. 
I have previously demonstrated that depletion of T-cells has a direct effect in the 
number of aberrant crypts and I hypothesised that these immune cells had a direct effect 
in the ISCs homeostasis. Here, the number of Lgr5 transcripts was quantified in the small 
intestines of non-induced, Apc deleted, T-cells depleted and IFNγ neutralized mice. 
The expression of Lgr5, in normal intestinal homeostasis, is restricted to the bottom 
of the crypts in both small and large intestines and it is lost upon cell differentiation 
(Barker et al. 2007; Barker et al. 2013). As expected, Apc deletion significantly increased 
the number of Lgr5 transcripts in the small intestinal crypts and villi. Other studies have 
shown an increased expression of Lgr5 in CRC cells relative to normal adjacent tissue 
(Fan et al. 2010; Wu et al. 2012; Baker et al. 2015; Wang et al. 2015b; Morgan et al. 
2018).  
So far, the interactions between immune cells and the ISCs were not fully studied, 
and this is reflected by the lack of literature in this field. Previous studies have suggested 
a role for the immune cells in tissue homeostasis of the intestine by showing that tissue-
resident innate immune cells such as macrophages and type 3 innate lymphoid cells 
(ILC3s) rescue ISCs and promote their regeneration (Lindemans et al. 2015; Saha et al. 
2016). Treg cells have been associated to tissue regeneration within muscles, lungs and 
the central nervous system (Burzyn et al. 2013; Arpaia et al. 2015; Dombrowski et al. 
2017). Recently, Biton and colleagues have shown that CD4+ T-helper (Th) cells 
communicate with ISCs and affect their differentiation (Biton et al. 2017). The authors 
used single-cell RNA-sequencing of intestinal epithelial cells in order to identify possible 
mechanisms for interactions between ISCs and immune cells (Biton et al. 2017). They 
have shown that MHC class II (MHC II) is enriched in subsets of Lgr5 ISCs that are highly 
proliferative and that knockout of MHC II in the intestinal epithelial cells would promote 
the expansion of the ISCs pool (Biton et al. 2017). Moreover, the authors have shown 
that mice lacking T-cells had also expanded ISCs pools and that specific Treg cells 
depletion in vivo caused a reduction in the ISCs numbers (Biton et al. 2017). Contrary to 
this work, I have shown that Treg cells depleted mice had a trend for an increased 
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number of Lgr5 transcripts in both crypts and villi suggesting an alteration in the 
homeostasis of Lgr5 in the absence of Treg cells. Depletion of CD4+ T-cells in Apc 
deleted mice significantly decreased the number of Lgr5 transcripts the crypts and had 
no significant changes in the villi. It is possible that, in the context of cancer, depletion of 
the immune cells will have a different effect when compared to T-cells depleted WT mice. 
CD8+ T-cells depletion alone did not alter the number of Lgr5 transcripts in the 
crypts, but resulted in a re-distribution from the bottom of the crypt to other parts. CD8+ 
depletion resulted in a significantly increased in the villi, suggesting again that depletion 
of immune cells have a direct impact in the ISCs. On the other hand, CD8+ T-cells 
depletion in Apc deleted mice had a trend for an increased number of Lgr5 transcripts in 
crypts, but significantly increased in the villi. IFNγ neutralisation significantly decreased 
the number of Lgr5 transcripts in the crypts of Apc deleted mice and increased in the villi 
of Apc deleted/Treg cells depleted, suggesting one more time an interaction between the 
immune system and regulation of ISCs. 
The quantification of the number of transcripts does not explain itself the reduction 
of aberrant crypts following the depletion of Treg cells, CD4+ and CD8+ T-cells. An 
important study would be quantifying the localization of the stem cells in the crypts in the 
different experimental groups. Alteration in the position of the stem cells could mean that 
they would not function as they usually do and that, following induction with tamoxifen, 
less stem cells would be transformed, being a possible reason for the reduced number 
of aberrant crypts following T-cells depletion. Barker and colleagues have demonstrated 
that only the cells located in the bottom of the crypt can initiate tumours (Barker et al. 
2009).The presence of more transcripts does not exactly mean more Lgr5 stem cells as 
it is possible that the homeostasis is interrupted and that these cells do not function 
anymore as normal ISCs. To verify the capacity of the ISCs, crypt and villus cells from 
the T-cell depleted mice could be isolated and their stemness evaluated by their capacity 
of developing organoids.  
In summary, it was shown that depletion of T-cells and IFNγ neutralisation affected 
the number and distribution of Lgr5 transcripts, suggesting that there is a crosstalk 
between the immune system and the ISCs and that it must be further analysed. 
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7 General Discussion/Conclusion 
 
Foxp3+ Tregs are enriched in mouse (Akeus et al. 2014) and human tumours 
(Clarke et al. 2006; Betts et al. 2012; Syed Khaja et al. 2017), however it is still unclear 
whether these cells limit or promote the anti-tumour immune responses. Most of the 
studies were done in patients with advanced disease. There is a need to understand the 
role of these cells in the early stages of tumourigenesis.  
The first aim of this project was to understand how Tregs were affected in the early 
stages of intestinal cancer. Using the Lgr5CreERT2Apcfl/flFoxp3DTR mouse model it was 
possible to delete the Apc gene in the Lgr5 ISCs mimicking an early event of the intestinal 
tumourigenesis initiation. It was hypothesised that the number and frequency of Tregs 
would increase 15 days following Apc deletion. It was shown for the first time, in this 
model, that Tregs accumulate in both small and large intestines, but also spleen and 
MLN indicating that the suppressive immune response is also enhanced in the distant 
sites. As previously discussed in chapter 3, the mechanism responsible for the 
accumulation of Tregs upon ISCs Apc deletion is still not clarified. Possibly there is a 
disruption of the epithelial barrier, promoting infiltration of bacteria and, as a 
consequence, activation of the immune system leading to the attraction of Tregs to the 
lesions sites. Another possibility is that ISCs can function as non-conventional antigen-
presenting cells, attracting and activating Tregs (Figure 7.1).  
Little changes were detected in other immune markers following Apc deletion. One 
possible reason for this observation was that at this early time point where the analysis 
was performed, large scale changes in the immune activation were not detectable. 
Another possible explanation is that as the analysis was performed using the whole small 
and large intestines potentially local changes were masked.  
The second aim was to investigate whether Tregs play a pro- or anti-tumoral role in 
the Lgr5CreERT2Apcfl/flFoxp3DTR mouse model. Depletion of Tregs have been previously 
reported as having a beneficial effect in both mouse models (Chaput et al. 2007; Goudin 
et al. 2016) and cancer patients. This was tested in few clinical trials in patients with 
metastatic disease (Dannull et al. 2005), including patients with inoperable metastatic 
CRC (Scurr et al. 2017a; Scurr et al. 2017b), where it was observed an unleashed 
immune response and, as a consequence, an improved survival outcome. 
It was hypothesised that Treg depletion would enhance the anti-tumour immune 
responses and limit tumour initiation and progression. As expected, Treg depletion in 
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Apc deleted mice resulted in a decreased tumour burden in the mice intestines, 
particularly in the large intestine. 
The reduced tumour burden following Treg depletion was also supported by the 
reduced gene expression of Wnt and ISCs markers, considering that their high 
expression is associated with tumour progression (2012; Polakis 2012). Treg depletion 
also resulted in an increase frequency of CD8+ producing Granzyme B and IFNγ cells. 
These cells have been demonstrated to participate in the anti-tumour immune 
responses, suggesting that they play an important role since the early stages of 
tumourigenesis. Taken together, these data suggest that Tregs play key role in the early 
stages of tumour initiation. 
Controversial data about the role of Tregs can be attributed to various reasons. In 
the case where cancer development is inflammation-driven Tregs may limit cancer 
growth by suppressing inflammation (Erdman 2010). Another explanation is that the 
populations of Tregs that where analysed may be heterogeneous in terms of their 
functional state and/or stability, possibly affecting whether they would promote or limit 
tumour progression.   
It is possible that by giving to the Lgr5CreERT2Apcfl/flFoxp3DTR mice dextran sodium 
sulphate (DSS) to induce chronic inflammation, possibly Tregs would play a key role but 
in the anti-tumoral immune responses. It has also been suggested a beneficial effect of 
a high fibre diet in the prevention of CRC (Burkitt 1971). A high fibre diet is known to 
have anti-inflammatory properties (Kunzmann et al. 2015). This is due to an increase in 
the metabolite butyrate produced as a consequence of fibre fermentation by the 
microbiota present in the large intestine (Cushing et al. 2015). Studies have shown that 
butyrate promotes differentiation of naïve CD4+ cells into Tregs, limiting inflammatory 
challenges (Zeng and Chi 2015). 
Considering that the data in this project suggested that Tregs play a key role in the 
early stages of intestinal cancer by limiting the anti-tumour immune responses, the next 
aim was the identification of immune cell populations and cytokines that were possibly 
responsible for the anti-tumour immune responses following Tregs depletion. Previous 
data from this project showed increased frequency of CD4+ and CD8+ cells following 
Treg depletion in the early stages of intestinal cancer. The same was observed with the 
cytokine IFNγ. Infiltration of tumours with high numbers of lymphocytes has been 
associated with a better prognosis and improved survival in CRC cancer patients (Galon 
et al. 2006; Mei et al. 2014; Braha et al. 2016) and in other cancer types (Al-Shibli et al. 
2008; Dieu-Nosjean et al. 2008; Menegaz et al. 2008).  
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To analyse the role of T-cells and IFNγ in the early stages of intestinal cancer, mice 
were injected with monoclonal antibodies to selectively deplete separately CD4+ and 
CD8+ cells and neutralise IFNγ. Depletion of CD4+ cells, in Apc deleted mice, resulted 
in a decreased number of aberrant crypts in the first 5 cm of the small intestine. Further 
studies are needed to analyse the role of the different T-cell subsets involved in the early 
tumourigenesis. Depletion of Th1 or Th17 cells, or neutralisation of the cytokines 
secreted by these cells, would give new insights about the role of different CD4+ cell 
subpopulations, clarifying how which one could be targeted to stop tumour progression. 
The previous findings that suggested an important role of CD8+ cells in the anti-
tumour immune responses in the early stages of intestinal cancer were, surprisingly, 
contradicted by the reduction of the number of aberrant crypts in the first 5 cm of Apc 
deleted/CD8+ cells depleted mice. The reduction in the tumour burden was associated 
with a decreased gene expression of the Wnt markers. It was also shown a decreased 
gene expression of the ISCs markers Lgr5 and Ascl2, possibly indicating a reduction in 
the ISC pool and, as a consequence, a reduction in the number of Apc deficient ISC, 
resulting in a decreased number of aberrant crypts. Considering that in this project CD8+ 
cells were depleted prior Apc deletion, there is the possibility that the stem cell pool was 
altered, resulting in a lower number of aberrant crypts, and not as a direct consequence 
of CD8+ cell depletion. RNAscope analysis showed an increased number of Lgr5 
transcripts in the villi when comparing to non-induced mice. Depletion of CD8+ cells in 
Apc deleted mice resulted in a re-distribution of the Lgr5 transcripts from the bottom to 
the other areas of the crypt. Interestingly it was demonstrated an increased number of 
transcripts in the villi, suggesting an alteration in the homeostasis of the ISCs. This can, 
possibly explain the reduced number of lesions following CD8+ cell depletion in Apc 
deleted mice. It has been shown that stem cells are located in the bottom of the crypts 
and only these cells can initiate tumours (Barker et al. 2009). Barker and colleagues 
have shown that Apc deletion in the non-stem cell compartment led to the production of 
small lesions that were retained within the intestinal epithelium, however these lesions 
did not form tumours (Barker et al. 2009). 
A recent study published by Biton and colleagues gave new insights into the effect 
of adaptive immune cells on ISCs fate (Biton et al. 2018). The authors showed that 
intestinal organoids supplemented with Tregs or their suppressive cytokine IL-10 had an 
expansion in the ISC pool. On the other side, organoids supplemented with T-helper 
subsets showed lower numbers of ISCs associated with increased cell differentiation 
(Biton et al. 2018). Next, the authors analysed the effect of MHC-II deficiency in vivo. 
Mice deficient in MHC-II, compared to control mice, had an increased proportion of ISCs 
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and reduced numbers of CD4+ T-cells in the intestines (Biton et al. 2018). These data 
suggests that MHC-II expression is essential for the support of ISCs. Similar to these 
results, mice deficient in T-cells had an increased expansion of ISCs, indicating again 
that T-cell interactions are essential for the ISCs differentiation. Finally, the authors 
showed that Treg depletion in Foxp3DTR mice resulted in aberrant ISC differentiations 
and reduction of the ISC pool. Treg depleted mice, as expected had an increased 
frequency of Th cells that may contribute for ICs differentiation (Biton et al. 2018). 
Altogether, these data provide new insights into the response of Lgr5+ ISCs to pro- and 
anti-inflammatory signals and how important these interactions are to maintain a balance 
between stem cell renewal and differentiation. 
Further studies are needed to test the hypothesis that the different distribution of the 
Lgr5 transcripts resulted in a reduced stemness and that, as a consequence, less stem 
cells would be recombined, giving origin to a reduced number of aberrant crypts. A way 
to test this would be by the isolation of cells from the crypt and villus to examine 
stemness. Another was the induction of Apc deletion by gavage so only villi cells would 
recombine, testing whether the population of cells expressing Lgr5 in the villi could form 
tumours (Barker et al. 2009).  
Another surprising result was the fact that IFNγ neutralisation did not have an impact 
in the tumour burden as it has been demonstrated that this cytokine plays a key role in 
the anti-tumour immune responses in the early stages of intestinal cancer (Wang et al. 
2015a). It is therefore important to mention that IFNγ neutralisation was not validated by 
any other method such as IHC or flow cytometry, being possible that neutralisation was 
not successfully achieved. Importantly, the analysis of the groups where T-cell were 
depleted and IFNγ was neutralised, to access tumour burden, were only done performed 
in the first 5 cm of the small intestine. A more complete analysis would include the 
quantification of the aberrant crypts in serial sections of the whole small and large 
intestines, possibly giving new insights about the role of IFNγ in the early stages of 
intestinal cancer. 
In conclusion, it was shown that Tregs are increased 15 days following Apc deletion. 
Depletion of Tregs significantly decrease the tumour burden, particularly in the large 
intestine, suggesting a key role of Tregs in the early stages of intestinal cancer (Figure 
7.1). It is important, however, to analyse the role of Tregs in different disease contexts 
as they are a possible target for prevention of CRC impeding its progression to a more 
aggressive disease. 
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Apc deletion leads to the increased expression of Wnt and ISCs markers. Apc deleted mice have 
an increased number of Tregs that are responsible for the suppression of the anti-tumour immune 
response. Two mechanisms are proposed to explain the increased infiltration of Tregs. It is 
possible that the intestinal epithelial barrier is disrupted, leading to the infiltration of bacteria and 
activation of the immune system. Another possible mechanism is that ISCs can function as 
antigen-presenting cells, being able to interact and activate Tregs. Following Treg depletion, in 
Apc deleted mice, there is a reduction of Wnt and ISCs markers, and a reduction of the tumour 
burden, particularly in the mice’s large intestine. 
Figure 7.1 Representative model of the effects of Treg depletion in Apc deleted mice. 
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9 Supplementary Material 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The frequency of CD4+ cells expressing Foxp3 increased after Apc deletion in both spleen and MLN. 
The treatment with diphtheria toxin (DTR) resulted in a significantly decreased frequency of the Foxp3 
marker as expected in both spleen and MLN. Data represent a single experiment, n ≥ 7 mice per group.  
(*) P value ˂ 0.05, (**) P value ≤ 0.01, (***) P value ≤ 0.001, two-tailed Mann Whitney U test. 
  
Figure S 9.1 Frequency of CD4+ cells expressing Foxp3 in the spleen and MLN. 
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Apc deletion did not alter the frequency of CD3+ cells in the spleen. The frequency of CD3+ cells 
increased with Treg depletion alone and in Apc deleted/Treg depleted mice. The frequency of CD3+ 
cells was decreased in the MLN following Treg depletion when comparing to Apc deletion alone. There 
was a trend for a decreased frequency of CD3+ cells when Tregs were depleted together with Apc 
deletion although was is not significant. Data represent a single experiment, n ≥ 7 mice per group. (*) 
P value ˂ 0.05, (**) P value ≤ 0.01, (***) P value ≤ 0.001, two-tailed Mann Whitney U test. 
  
Figure S 9.2 Frequency of CD3+ T-cells in the spleen and MLN. 
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The frequency of CD4+ cells was significantly with in Treg depleted and Apc deleted/Treg depleted 
mice. There was a trend for a decreased frequency of CD4+ cells following Apc deletion. In the MLN 
the frequency of CD4+ cells was significantly decreased with Apc deletion, Treg depletion and both 
treatments together. Data represent a single experiment, n ≥ 7 mice per group. (*) P value ˂ 0.05, (**) 
P value ≤ 0.01, (***) P value ≤ 0.001, (****) P value ≤ 0.0001, two-tailed Mann Whitney U test. 
  
Figure S 9.3 Frequency of CD3+ cells expressing CD4 in the spleen and MLN. 
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The frequency of CD8+ cells, in the spleen, was increased in Apc deleted/Treg depleted mice. The 
frequency of CD8+ cells was significantly increased with Apc deletion, Treg depletion and both 
treatments together in the MLN. Data represent a single experiment, n ≥ 7 mice per group. (*) P value 
˂ 0.05, (**) P value ≤ 0.01, (***) P value ≤ 0.001, (****) P value ≤ 0.0001, two-tailed Mann Whitney U 
test. 
  
Figure S 9.4 Frequency of CD3+ cells expressing CD8 in the spleen and MLN. 
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The frequency of CD4+ expressing Granzyme B was not changed after Apc deletion. Treg depletion 
alone and together with Apc deletion resulted in a significantly increased expression of Granzyme B. 
The frequency of Granzyme was significantly increased in the MLN with Apc deletion, Treg depletion 
and both treatments together. Data represent a single experiment, n ≥ 7 mice per group. (*) P value ˂ 
0.05, (**) P value ≤ 0.01, (***) P value ≤ 0.001, (****) P value ≤ 0.0001, two-tailed Mann Whitney U test. 
  
Figure S 9.5 Frequency of CD4+ expressing Granzyme B in the spleen and MLN. 
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The frequency of CD8+ cells expressing Granzyme B is significantly increased with Tregs depletion 
alone and Apc deleted/Treg depleted mice in both spleen and MLN. Data represent a single experiment, 
n ≥ 7 mice per group. (***) P value ≤ 0.001, (****) P value ≤ 0.0001, two-tailed Mann Whitney U test. 
  
Figure S 9.6 Frequency of CD8+ cells expressing Granzyme B in the spleen and MLN. 
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The frequency of CD4+ cells expressing IL-17A was significantly increased in the spleen with Apc 
deletion, Treg depletion and both treatments together. In the MLN the frequency of CD4+ expressing 
IL-17A was increased with Treg depletion alone and Apc deletion with Treg depletion together. Data 
represent a single experiment, n ≥ 7 mice per group. (**) P value ≤ 0.01, (***) P value ≤ 0.001, (****) P 
value ≤ 0.0001, two-tailed Mann Whitney U test. 
  
Figure S 9.7 Frequency of CD4+ cells expressing IL-17A in the spleen and MLN. 
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The frequency of CD8+ cells expressing IL-17A was significantly increased with Treg depletion alone 
and Apc deletion/Treg depletion in both spleen and MLN. Data represent a single experiment, n ≥ 7 
mice per group. (**) P value ≤ 0.01, (***) P value ≤ 0.001, two-tailed Mann Whitney U test. 
  
Figure S 9.8 Frequency of CD8+ cells expressing IL-17A in the spleen and MLN. 
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The frequency of CD4+ cells expressing IFNγ was significantly increased in the spleen with Apc 
deletion, Treg depletion and Apc deletion/Treg depletion. In the MLN the frequency of CD4+ cells 
expressing IFNγ was significantly increased with Treg depletion alone and Apc deletion/Treg depletion. 
Data represent a single experiment, n ≥ 7 mice per group. (*) P value ˂ 0.05, (***) P value ≤ 0.001, (****) 
P value ≤ 0.0001, two-tailed Mann Whitney U test. 
  
Figure S 9.9 Frequency of CD4+ cells expressing IFNγ in the spleen and MLN. 
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The frequency of CD8+ cells expressing IFNγ was significantly increased with Treg depletion alone and 
Apc deletion/Treg depletion in both spleen and MLN. Data represent a single experiment, n ≥ 6 mice 
per group. (**) P value ≤ 0.01, (***) P value ≤ 0.001, two-tailed Mann Whitney U test. 
 
 
Figure S 9.10 Frequency of CD8+ cells expressing IFNγ in the spleen and MLN. 
